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Abstract 
 
Background: Non-adherence to treatment poses a challenge to tuberculosis (TB) 
treatment since it increases the risk of drug resistance, death, relapse and prolonged 
infectiousness. TB patients co-infected with human immunodeficiency virus (HIV) 
constitute a large proportion of TB patients in Ethiopia. How being co-infected with HIV 
as well as concomitant treatment with anti-retroviral therapy (ART) among other things 
affect adherence to TB treatment has not been studied in Ethiopia, and we did a study to 
explore this.   
 
Objectives: To assess magnitude of default and factors associated with defaulting from 
TB treatment in patients with TB/HIV co-infection who received concomitant treatment, 
and to assess co-infected patients’ and health professionals’ perspectives of barriers and 
facilitators of TB treatment 
 
Methods: Through a review of records, we retrospectively assessed the TB treatment 
outcomes in a cohort of TB patients co-infected with HIV who were initiated on TB 
treatment in the period July 2006-September 2007 and who concomitantly received ART 
in three Health Centers in Addis-Abeba. We conducted in-depth interviews with 15 
purposefully selected patients and 9 health professionals involved in their management. 
We also conducted two focus group discussions in patients with TB/HIV co-infection 
receiving concomitant treatment. 
 
Results: We found that, from the 248 patients included, 148(59.7%) completed treatment, 
32(12.9%) were cured, 31(12.5%) died, twenty six patients (10.5%) defaulted treatment, 
3(1.2%) failed and 8 patients (3.2%) were transferred out. Multiple regression analysis 
showed that male sex (AOR= 2.66(95%CI: 1.05- 6.71), P=0.038), lower education 
(AOR= 3.81(95% CI: 1.38- 10.52), P= 0.009), and timing of ART initiation were 
associated with defaulting from TB treatment, with those started on ART in the intensive 
phase having the highest risk of defaulting (AOR= 9.68(95%CI: 2.71- 34.57), P= <0.001, 
as compared to those initiated on ART in the continuation phase), followed by those 
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initiated on ART before anti-TB initiation (AOR= 4.83(95% CI:1.19- 19.83), P= 0.025, 
as compared to those initiated on ART in the continuation phase) . The qualitative study 
further showed that many misperceptions exist among patients about TB/HIV, and that 
adverse perception of prognosis of TB in the presence of HIV with an eagerness to 
survive, support from families and health professionals were positively influencing 
treatment, whereas side effects, pill burden, economic constraints, lack of food, stigma, 
lack of adequate communication with health professionals and poorly organized TB/HIV 
collaborative activities were acting as barriers to treatment.  
 
Conclusion: The default rate from TB treatment among patients who are TB/HIV co-
infected and who received concomitant treatment is still higher than the World Health 
Organization recommended rate, and many of those who finish treatment seem to face 
many difficulties. Health professionals and policy makers should be aware of factors 
influencing TB treatment in these patients and act accordingly, since many of these 
factors are amenable to change.       
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Chapter one: Introduction 
  
1.1. Ethiopia: country profile 
    1.1.1. Demography  
  Ethiopia is located in the Horn of Africa, at the cross roads between Africa and the 
Middle East. The total area of the country is about 1.1 million square kilometers and it is 
bordered by Djibouti, Eritrea, Sudan, Kenya and Somalia. It is a country with high 
geographical diversity, and the climate also varies with the topography with temperatures 
as high as 47 degree Celsius in the Afar depression and as low as 10 degree Celsius in the 
highlands (1).  
  
   Ethiopia’s population was estimated to be around 81 million in 2006, with a population 
annual growth rate of 2.5%. Only 16% of the population lives in urban areas, making 
Ethiopia one of the least urbanized countries in the world. Ethiopia is the third most 
populous country in Africa, following Egypt and Nigeria.  Ethiopia is comprised of a 
complex variety of nations, nationalities and peoples and linguistic groups with over 80 
different languages constituting 12 Semitic, 22 Cushitic, 18 Omotic and 18 Nilo-Saharan 
languages being spoken in the country. The majority of the population resides in the 
highland areas of the country. The main occupation of the settled population is farming, 
whereas the population in the lowland areas is mostly pastoral, moving from place to 
place with their livestock, in search for water and grass. The major religions are 
Christianity and Islam (1).  
 
  After ruling by successive emperors and kings until 1974, a military government took 
over the reign of rule until 1991. Currently, a federal system of government exists and the 
country is administratively structured into nine regional states (Amhara, Affar, Tigray, 
Oromiya, Somali, Benishangul Gumuz, Southern Nations Nationalities and Peoples, 
Harari and Gambela) and two city administrations (Addis-Ababa and Dire Dawa 
administration council) (1). 
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   1.1.2. Economy 
  Ethiopia is an agrarian country. Agriculture accounts for 54% of the gross domestic 
product and accounts for about 90% of the exports. Agriculture also employs 80% of the 
population. Coffee remains the main export of the country, although other agricultural 
products are being introduced into the export market.  
      
  Ethiopia remains one of the least developed countries in the world. The per capita gross 
national income was estimated to be US$110.The Ethiopian currency is the birr, and 
currently, one US dollar is equivalent to about 11 birrs. Between 1974 and 1991, the 
country operated a central command economy under the socialist banner of the Derg 
regime. Since the overthrow of that regime, the country has moved toward a market 
oriented economy. Economic growth averaged about 5 percent per annum during the 
period 2000-2005; adjusting for population growth, the average per capita income rose by 
about 2.1% per annum (1). 
 
    1.1.3. Health profile 
   The health system in Ethiopia remains underdeveloped. The majority of the   
population resides in the rural areas and has limited access to modern health facilities. 
The health service coverage remains low and the quality of services available, especially 
in rural areas, is variable, aggravated by poor transportation (1). 
 
    There is a heavy burden of disease with a growing prevalence of communicable 
infections in the country. Many Ethiopians face disease morbidity and mortality largely 
attributable to potentially preventable infectious diseases and nutritional deficiencies (2). 
       
    No elaborate health policy existed up through the 1950s, but a health policy initiated 
by the WHO was adopted in the early 1960s. In the mid 1970s, a thorough health policy 
with emphasis on disease prevention and control was adopted, prioritizing rural areas and 
advocating community involvement. Under the current administration, another health 
policy has been set, and to realize the objectives of this policy, the government has 
established the Health Sector Development Programme (HSDP), incorporating a 20 year 
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health development strategy, through a series of five year development programs. The 
program calls for the democratization and decentralization of health services; 
development of preventive health care; capacity building within the health service system; 
equitable access to health services; self-reliance; promotion of intersectoral activities; and 
participation of the private sector including non-governmental organizations(NGOs); and 
cooperation and collaboration with all countries in general and neighboring countries in 
particular and between regional and international organizations. Currently, the HSDPIII 
covering the period 2005/06-2009/10 is in its third year of implementation and thousands 
of Health Extension Workers have been trained for this purpose (1, 2).   
          
Table 1 Basic health indicators for Ethiopia, Ethiopian Ministry of Health (2) 
Total fertility rate: 5.4 children per women in life during her 
reproductive ages. 
Infant mortality rate : 77/ 1000 live birth 
Maternal mortality rate: 766 per 100.000 live births 
Life expectancy at birth: 50 and 48 years for females and males 
respectively. 
Neonatal mortality rate 41/1000 live births 
Under 5 mortality rate 123/1000 live births 
Percentage of children 
under 5 underweight 
35 
ANC coverage  52.1 % 
EPI *coverage 72.6% 
Contraceptive Prevalence 
Rate 
15% 
Attended Delivery 16.4% 
 
* Expanded program for immunization  
 
    1.1.4. Traditional medicine in Ethiopia 
   Traditional medicine was the only system of health care until the advent of modern 
medicine. Even today, a large majority of the population relies on traditional medicine( in 
1991, it was estimated that 80% of the population was using traditional medicine); due to 
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shortage and inequitable distribution of health services but also due to the persistence of 
traditional beliefs and practices among the public, and in particular in rural areas (3).  
      
   Diverse traditional medicinal practices exist, and  traditional medicine is concerned not 
only with the curing of diseases but also with the protection and promotion of human 
physical, spiritual, social, mental and material wellbeing. The many categories of 
traditional medicinal practices dealing with these different aspects of health include: 
spiritual healing, prevention, as well as curative and surgical practices. The health and 
drug policies of the Ethiopian Ministry of Health recognize the important role traditional 
health systems play in health care (4).    
 
   1.2. Study area: Addis-Abeba  
  Addis-Abeba, the Capital City of Ethiopia, is located in the heartland of the 
Country. It has a population of around 3.6 million. It is divided into 10 administrative sub 
cities and 99 Kebeles (5). 
       
 Addis-Abeba Health Bureau is responsible for both curative and preventive health care 
of the city under which there are 5 hospitals, 1 public health laboratory and 1 nursing 
school. There are also 10 sub-city health departments, which are directly accountable to 
their respective sub-city administration (6). 
         
  Totally there are 27 hospitals in the city of which 5 are owned by AAHB, 5 by federal 
ministry of health, 2 by NGOs, 3 by defense and police and 12 by private owners. There 
are 24 health centers of which 21 are owned by the city administration, 2 by NGOs and 1 
by the public. There are also 456 clinics of which 6 are run by the City Administration, 
28 by NGOs and 56 by other government organizations, 46 by factories and 320 by 
private owners. In addition to these, there are about 180 retail drug outlets and 46 health 
posts. Moreover, there are about 40 NGOs working in Addis-Abeba on different health 
activities. Regarding health professionals, there are currently a total of 3,216 
professionals out of which 1, 710 are practicing in the public sector under the City 
Administration and 1,506 in the private sector (6). 
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  The potential health service coverage (the population covered in percentage based on 
the existing health centers and health stations in catchment’s area) in Addis-Ababa with 
regard to geographical accessibility is 100%, while the primary health care unit coverage 
is 68 % (6).  
 
   The main causes of morbidity and deaths in the City are communicable & nutritional 
diseases that could be prevented through primary health care activities; HIV/AIDS, TB, 
and nutritional problems are assuming greater importance. In addition, one of the major 
problems in the City has now become high rate of accident, i.e. the first in the ten top 
diseases of Hospital morbidity in the past few years (6). 
 
 
 Table 2 Basic health indicators for Addis-Ababa, Addis-Abeba Health Bureau (6) 
Total fertility rate: 2.24 children per women in life during her 
reproductive ages. 
Infant mortality rate : 61/ 1000 live birth 
Maternal mortality rate: 566 per 100.000 live births 
Life expectancy at birth: 64.1 & 60.3 years for females and males 
respectively. 
ANC coverage  80.4 % 
Contraceptive Prevalence 
Rate 
37.8% 
Attended Delivery 32.9% 
DPT 3 73% 
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 1.3. TB, HIV, TB/HIV: pathogenesis, global and national burden 
   1.3.1. Tuberculosis  
      1.3.1.1. Pathogenesis 
   Tuberculosis is an ancient disease. It has affected humans throughout known history 
and even human prehistory .Robert Koch discovered its causative agent in 1882 and in 
1944, the first anti-TB drug, Streptomycin, was discovered. (7) TB is a disease associated 
with poverty and is responsible for the loss of more years of healthy life than any 
communicable disease except HIV/AIDS (8). It is the leading cause of death from a 
curable infectious disease (9).  
 
  Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis and 
occasionally by Mycobacterium bovis and Mycobacterium africanum. It is transmitted via 
the respiratory route, with the most important source of infection being the patient with 
TB of the lung, who is coughing, releasing infectious droplet nuclei, which can also be 
spread into the air through talking, sneezing, spitting and singing, and can remain in the 
air for long periods, especially in the absence of direct sunlight (10).  
         
   After penetrating the respiratory tract, the bacteria (bacilli) infect macrophages, while 
CD4+ T-lymphocytes and other lymphocytes produce interferon gamma, interleukin 2, 
tumor necrosis factor alpha, and macrophage colony stimulating factor, which activate 
macrophages and cytotoxic cells to inhibit the growth of the bacilli. TB appears when 
limiting the growth of the bacteria has been impossible for the immune system with 
insufficient induction of granuloma formation. Interferon gamma formation plays a 
critical role at this stage (11).  
 
  The risk of infection for a person depends on two factors: the extent of exposure to the 
bacilli and the person’s susceptibility to infection. The risk is higher with prolonged and 
close exposure to an infectious person and in a person with decreased immune function. 
Of those infected, 90% of people without HIV infection will not develop the disease. Of 
those with the disease, if untreated, 50% will be dead, 25% will be self cured and 25% 
will remain ill with chronic infectious TB (10).  
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   1.3.1.2 Global burden  
   Globally, in 2006, 9.2 million new cases of TB and 1.7 million deaths occurred, of 
which 0.7 million cases and 0.2 million deaths were in HIV positive people. Mortality 
due to TB as well as incidence of TB have been decreasing or stabilizing in all regions of 
the world except Sub-Saharan Africa and, to some extent, Europe (8). In some areas, the 
factors influencing TB trends remain the traditional ones such as poverty, failures in the 
treatment system and immigration. In others, and increasingly, the HIV epidemic is 
playing a major role (12). The 22 high burden countries account for approximately 80% 
of the estimated number of new TB cases arising worldwide each year, and in developing 
countries, TB comprises 25% of all avoidable adult deaths (13). Without the 
implementation of proper control measures, WHO estimates that between 2000 and 2020, 
nearly one billion people will be newly affected, 200 million will get sick and 35 million 
will die from TB (14). Tuberculosis affects mainly the economically productive age 
group with 75% of cases occurring in the age group 15-54 (13). 
 
   1.3.1.3. National burden 
  Ethiopia is one of the 22 high burden countries for tuberculosis, standing 7th place in the 
global rank by estimated number of cases. The incidence of TB in Ethiopia is estimated 
to be 379 per 100 000 populations for all cases and the prevalence 643 per 100 000 
populations (15). According to the MOH hospital statistics data, TB is the leading cause 
of morbidity, the third cause of hospital admission and the second cause of death in 
Ethiopia, after malaria (13). 
 
   1.3.2. HIV 
      1.3.2.1 Pathogenesis     
   The first case of HIV was diagnosed in 1981 and since that period, researchers have 
identified two serotypes of HIV: HIV-1, the commonest type of HIV worldwide, and 
HIV-2, most common in West Africa. Both have the same routes of transmission, but 
HIV-2 is believed to be more easily transmitted, and progression to AIDS might be 
slower in those infected with HIV-2(10). 
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 The main route of transmission worldwide remains sexual intercourse although the 
routes of transmission vary greatly between regions. In Sub-Saharan Africa, sexual 
intercourse, contaminated blood and mother to child transmission play the major role in 
transmission whereas in the fast growing epidemics in Russian federation and the 
Ukraine, the commonest cause of transmission is injecting drug use (10). 
 
  HIV infects cells which have the CD4 antigen on their surface that is principally the 
helper T-lymphocytes, which are critical for cell mediated immunity. Thus the principal 
abnormality in patients with HIV infection results from the fact that the number of CD4+ 
T-lymphocytes is decreased and the remaining lymphocytes also have an alteration in 
function, resulting in progressive immune suppression, which will result in increased 
susceptibility to infections in those infected.  
 
   1.3.2.2 Global burden  
  In 2007, 33 million people were living with HIV, with 2.7 million new infections and 2 
million deaths in that same year. Of these, 22 million were estimated to be living in Sub-
Saharan Africa and 4.2 million in South and South-East Asia. Of the 7400 infections 
occurring every day, more than 96% are in low and middle income countries. Among 
infections occurring in the age group of 15 and older, 45% occur among young people 
(15-24), hence affecting largely the economically productive group (16). In the most 
affected countries, HIV has decreased life expectancy by more than 29 years, has 
aggravated household poverty and slowed economic growth (17).  
 
     1.3.2.3 National burden  
   In 2008, the adult HIV prevalence in Ethiopia was estimated to be 2.2%.The prevalence 
in that same period was estimated to be 1,037,267 among adults and 68,136 among 
children (18). Significant rural urban discrepancies remain with urban prevalence of 
10.5% in 2006, according to the MOH (19). Unpublished data from the Addis-Abeba 
Health Bureau indicate that the prevalence of HIV was 7.2% in Addis-Abeba in 2008, 
with an all age prevalence of 156,577 and  with 41,433 people in need for ART in 2008 
(5). 
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   1.3.3 TB/HIV co-infection 
      1.3.3.1. Pathogenesis 
 The lifetime risk of developing TB from an infection with Mycobacterium Tuberculosis 
is 5-10% in an HIV negative person versus 50% in an HIV positive individual. The 
production of interferon gamma is decreased dramatically in parallel with the decrease in 
CD4+ T-lymphocytes associated with HIV infection. This leads to a significantly 
increased risk of developing reactivation or reinfection in HIV infected individuals. (11) 
HIV leads to progression to active TB both in people with recent and with latent infection. 
It is the most important factor in the reactivation of latent disease into active disease. It 
also increases the occurrence of recurrent TB, due to either reactivation or reinfection 
(20). HIV also leads to atypical presentations of TB as well as higher rates of smear 
negative and extra pulmonary TB (8,10).  
             
 Similarly, TB might also alter the course of HIV infection. Proinflammatory cytokine 
production by tuberculous granulomas has been associated with increased HIV viraemia, 
accelerating disease progression. The risk of death in a patient with HIV who has TB is 
twice that of an HIV patient without TB, adjusted for CD4 count, the death resulting not 
from TB but from HIV disease progression (11). 
 
    1.3.3.2 Global burden         
  Worldwide, about 11.1 million adults are estimated to be infected with TB and HIV. 
Seventy percent of these live in Sub-Saharan Africa, 20% in South East Asia and 4% in 
Latin America and the Caribbean (18). Over the past decade, some parts of Sub Saharan 
Africa have seen a 3-5 fold increase in the number of TB case notifications. It is also 
estimated that, in Sub Saharan Africa, one third or more of HIV infected may develop TB. 
In some areas of this region, rates of co-infection as high as 60%-70% have been reported 
(21). 
 
   1.3.3.3 National burden      
   In Ethiopia, data on TB/HIV co-infection is limited. Routine data from 44 sites in 
2005/6 showed that the co-infection rate was 41% whereas another routine data in 2006/7 
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showed a rate of co-infection of 31 % (18). Hospital based studies have indicated rates of 
50% and even higher (22). The WHO Global Report 2008 estimates that in Ethiopia, 40% 
of patients treated for TB are HIV positive (13).  
  
  1.4. Global and national measures to control TB and TB/HIV 
    1.4.1. Global response to TB and TB/HIV 
   In 1993, WHO declared TB a global emergency, a reflection of the magnitude of the 
problem. Different targets for TB control have also been set. In 1991, the World Health 
Assembly set a target to detect 70% of new smear positive cases in DOTS programmes 
and to successfully treat 85% of the detected cases, recognizing TB as a major global 
public health problem. The Millennium Development Goals (MDG) also set a target for 
TB control: MDG 6 Target 6C is to halt and reverse incidence by 2015. Two additional 
target impacts have been set by the Stop TB Partnership, which are to half prevalence and 
death rates by 2015 as compared to 1990 (15).Whether these goals are met depends on 
several factors. Different control strategies have been adopted to fight against TB and to 
meet the above mentioned targets.   
 
   One such strategy is the Directly Observed Treatment, Short Course (DOTS) strategy, 
launched by WHO in 1994. After further subsequent expansion and clarification, the 
framework has been implemented in 182 countries. Major progress in TB control has 
been achieved with the expansion of DOTS which has also helped national TB 
programmes, although the targets for TB control have not yet been met in every corner of 
the world. The five major components of this Strategy are: 
• political commitment with increased and sustained financing  
• case detection through quality assured bacteriology 
• standardized treatment with supervision and patient support 
• effective drug supply and management system 
•  monitoring and evaluation system and impact measurement  
 
   One of the most important components of the DOTS strategy is the direct observation 
of treatment (DOT), which implies that the patient should be supervised while taking 
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treatment, most often by a health worker. DOT’s purpose is to ensure that patients take 
the correct treatment regularly (to achieve cure and prevent development of drug 
resistance); to find out quickly when a dose has been missed by a patient, in order to find 
out why that happened and to try and solve it; and to monitor any disease or treatment 
associated problem e.g. side effects. It is necessary to ensure that supervision is done in a 
patient sensitive and contextualized manner and that it is aimed to enhance adherence 
among both patients and providers. In addition, identifying physical, financial, social and 
cultural barriers to TB treatment is very important to ensure proper patient support (8, 13).  
DOT is surrounded by many controversies related to its effect compared to self 
supervision which we will come to in the literature review. The HIV epidemic has 
challenged DOTS as the sole strategy for TB control in Africa, because of the rising 
incidence of TB related to high HIV prevalence (23).    
 
   The Stop TB Strategy was launched in 2006 to achieve the 2015 impact targets and the 
targets for case detection and treatment success. It has six major components: DOTS 
expansion and enhancement; addressing TB/HIV, MDR-TB and other challenges; 
contributing to health system strengthening; engaging all care providers; empowering 
patients and communities; enabling and promoting research. In addressing TB/HIV, 
WHO’s policy on TB/HIV collaborative activities is to be followed. This policy 
recommends twelve collaborative activities between TB and HIV/AIDS control 
programmes, classified in three broad categories:  
• establishing the mechanisms for collaboration 
•  reducing the burden of TB in people living with HIV 
•  reducing the burden of HIV in people living with TB (8). 
      
   The need for TB/HIV collaboration is justified because the two diseases commonly 
occur together and impact each other; both TB and HIV patients will benefit from 
collaborative activities, and it would allow efficient use of resources, especially in view 
of the fact that health systems are overburdened by the high rates of TB infections related 
to HIV infections.  
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  The Global Plan to Stop TB 2006-2015, fully adopts the Stop TB Strategy and its 
implementation is intended to bring various achievements in terms of expansion of 
equitable access for all of TB diagnosis and treatment; treatment and cure of millions of 
people; and sets forwards goals for introduction and improvement of drugs, vaccines and 
diagnostic tests (13).  
 
 1.4.2. National response to TB and TB/HIV 
  The recognition of TB as a major public health problem in Ethiopia dates to more than 
half a century ago. In the early 1960s, TB centers and sanatoriums were established in 
three major urban areas in the country, as an effort to control TB. In 1976, the Central 
Office (CO) of the National Tuberculosis Control Programme was established. In 1992, a 
standardized TB prevention and control programme, incorporating DOTS, was initiated 
as a pilot programme in Arsi and Bale zone, Oromia region. DOTS has been 
subsequently scaled up and implemented nationally, with a geographic coverage reaching 
90%, whereas the Health Facility coverage is 75%. In June 2000, the previous 
Epidemiology / AIDS department of the MOH was restructured and named Disease 
Prevention and Control Department, and the TB and Leprosy Control Programme was 
incorporated into that department (13). 
              
  As any TB control programme, the general objectives of TB control programme in 
Ethiopia are to interrupt transmission of the infections; to reduce morbidity, mortality and 
disability; to prevent emergence and spread of drug resistance; to reduce the burden of 
TB among people living with HIV; to reduce HIV burden among TB patients, and the 
programme is aligned with the globally recommended Stop TB strategy and follows its 
strategies. The basic strategies in reaching the objectives are through early case detection, 
adequate chemotherapy, provision of comprehensive and standard patient care, enhanced 
case management, accurate monitoring and evaluation of programme performance and 
community participation. Community participation is intended to bring the health 
services as close as possible to the community, and to increase the demand and the 
awareness for the services. In addition, it can also enhance support to patients throughout 
treatment until cure, and it can also help in raising awareness about TB at patient, family 
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and community level. Community based DOTS introduced in the Oromia region in 2006, 
with Community DOTS supporters providing health education to the community, as well 
as tracing suspected patients and directly observing patients, has shown encouraging 
results with increased case detection rates although the effects on treatment outcomes 
were unknown. In addition, Public Private Mix (PPM) DOTS has also been started in 
2006 as a pilot project in Addis-Ababa and Oromia involving for-profit health providers 
and is intended to improve the DOTS coverage and to increase case detection rates. The 
contribution of these private facilities is becoming apparent in that they already reported 
1,266 cases (13). 
 
  The national response to the TB/HIV co-epidemics began in 2001, after WHO’s call for 
implementation of TB/HIV collaborative activities for four countries in SSA including 
Ethiopia, which had high burdens of both TB and HIV. In 2002, a TB advisory 
committee was established. As part of expansion, TB/HIV collaborative activities are 
being implemented in 138 hospitals and 280 health centers and private clinics with ART 
services as of June 2007. Since then, key collaborative TB/HIV activities have taken 
place and have included: capacity building including training for regional TB and 
HIV/AIDS control programme managers and health workers; procurement and 
distribution of TB/HIV supplies; HIV testing of TB patients; provision of cotrimoxazole 
preventive therapy for HIV infected TB patients; referral to HIV related care, TB 
screening and referral among HIV infected patients; supportive supervision/mentoring 
and review meetings. In addition, Advocacy, Communication and Social Mobilization 
(ACSM) was advocated in order to create awareness about TB/HIV among the 
community in general and in those at risk in particular; in order to educate individuals, 
families and communities about transmission, prevention and treatment of TB and HIV; 
to ensure treatment adherence and to promote awareness about the dangers of defaulting 
treatment. Similarly, community involvement is also advocated, making both community 
based HIV and community based TB prevention activities work together (18). To what 
extent these strategies are being implemented and what their impact in the control of the 
dual epidemics is remains to be seen.        
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   In addition, Ethiopia was among the first few African countries to introduce ART in 
selected health facilities in 2000, following the introduction of ART in resource-limited 
settings. The free ART service was launched in 2005(18). The ART program has been 
expanded since then to cover more regions and facilities (19).  
 
  1.5. Why is TB increasing globally?         
   The question then is why, despite the many efforts that have been put both globally and 
nationally to combat TB both prior to and after the HIV epidemics and the increase in 
both international and national commitment to fight TB, it  continues to be a major 
problem, and might continue to be so.  
 
   Many factors might play a role in the increase of TB worldwide. These include socio-
demographic factors such as the increase in population worldwide, which occurs to a 
higher extent in populations where the prevalence of TB is already high; an increase in 
poverty worldwide, which results in overcrowding, under nutrition…, factors 
contributing to increased susceptibility and transmission of TB; and the HIV epidemic, 
again occurring mainly in areas already most affected by TB, and resulting in a 
significant increase in case rates (24). An increase in life expectancy, mainly in 
developed countries, also contributes to an increase in cases. The other problem is the 
emergence of multi drug resistant TB (MDR TB), and, according to WHO, 500 000 
cases of MDR TB were reported worldwide in 2006, and, with the available laboratory 
and treatment facilities to date, countries project that they will only be able to treat 10% 
of the cases of MDR TB in 2008. In addition, shortage in funding also threatens to affect 
TB control with a funding shortfall of US$1 billion for the 90 countries in which 91% of 
the world’s TB cases occur, if they are to meet the 2008 Targets of the Global Plan to 
Stop TB (15). In addition, in less developed countries, two issues most common to the 
majority of locations are delayed presentation for treatment and defaulting from treatment, 
which threaten TB control programs (25).   
 
    All these factors also threaten the TB control in Ethiopia, a poor country with a rapidly 
increasing population; highly affected by the HIV epidemic and which is seeing an 
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increase in MDR TB; where diagnostic and treatment facilities remain poor and where 
donor funding is mandatory to sustain TB and TB/HIV programmes, especially in view 
of the increase in TB cases fuelled by the HIV epidemic. In addition, treatment delay and 
defaulting form treatment have also been described as problems that TB programs face in 
Ethiopia (26-33). 
 
  1.6. Adherence 
      1.6.1. Definition 
  Adherence is defined by WHO as “the extent to which a person’s behavior- taking 
medication, following a diet, and or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (34). It is important to note here the 
difference from the concept of compliance. In compliance, the guidelines given by 
physicians are assumed to be accurate and patient responses to treatment are measured 
according to these guidelines and hence it contains a value statement and a bias, allowing 
the issue of blame in the picture. As Farmer explains, the term also exaggerates patient 
agency, as it suggests that all patients possess the ability to comply- or refuse to comply- 
with anti-TB treatment, which he explains is far from true (35). According to Farmer, the 
poor are victims of “structural violence”, which includes factors such as poverty, racism, 
gender inequality…which affects them from the time of exposure to the disease all the 
way up to their access to health care (35).But the use of the concept of adherence is 
important in that it conveys a partnership between patient and physician. It also allows 
for a more comprehensive assessment of factors related to adherence such as 
characteristics of the regimen; attitudes of the providers; socio-economic, cultural and 
environmental factors (36). Therefore while addressing adherence we should not only 
address factors directly related to the patient but also the aforementioned factors, since, as 
Farmer notes, although adopting a patient centered approach is important, it is 
nevertheless insufficient: “The challenge to researchers is to acknowledge that adherence 
is influenced by a complex array of factors, many of which are beyond the patient’s 
control, and to begin identifying and describing these factors.”(35). The differentiation 
between the two terminologies is therefore of critical importance, although, in the 
literature, the two terms are sometimes used interchangeably.  
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  1.6.2. Why study adherence? 
   “Because the magnitude of non-adherence and the scope of its sequelae are so alarming, 
more health benefits worldwide would result from improving adherence to existing 
treatments than by developing new medical treatments.” 
                                                                                                       (WHO 2003) 
   Adherence to long term therapy for chronic illnesses in developed countries averages 
50%, with rates possibly being lower in developing countries (34). The impacts of non-
adherence are many, including poor treatment outcomes and increased health-related 
costs. Additional consequences, of public health importance, occur with infectious 
diseases such as TB. Non-adherence to TB treatment might lead to an increased risk of 
drug resistance and a prolonged infectiousness, in addition to relapse and death. This in 
turn will have implications not only for the patient but also for the community at large. 
Further discussion on this topic will be presented in the literature review. 
 
   1.6.3 How do we measure adherence? 
   There are different ways of assessing adherence to treatment, and many methods are 
currently used. But there is no gold standard in the measurement of adherence (37, 38). 
One of the means of measurement of adherence is to ask patients and providers to 
subjectively rate their adherence or to use standardized patient administered 
questionnaires. This method might be liable to over or under estimation of adherence 
both from the side of the provider or the patient. The second method is the pill count, 
whereby remaining pills are counted when the patients come at treatment facilities, and 
with this strategy, in addition to counting inaccuracies, it is difficult to assess the timing 
of dosage and the patterns of missed dosages. A third approach is to do biochemical 
measurements in urine or blood of non toxic biological markers added to medications, but 
the results can be misleading and are liable to influence by factors such as diet, 
absorption and rate of excretion(34). Other methods such as assessment of pharmacy 
refills, electronic monitoring are also being employed and similarly display their own 
advantages and disadvantages.   
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   In the case of TB, outcome oriented assessment of adherence is often made. The 
success of treatment, that is, the sum of the patients who are cured and those who have 
successfully completed treatment under the DOTS strategy being a proxy indicator of 
 treatment adherence (34). 
1.7. Literature review 
   The literature on treatment outcomes/adherence to TB treatment is vast. Many studies, 
both quantitative and qualitative have explored the issue in different geographical 
contexts. But the study on adherence in TB/HIV co-infected patients, and in those on 
concomitant treatment, is scarce, as is the literature on the experiences of treatment and 
of illness perception in co-infected patients. The studies in co-infected patients and of 
those on concomitant treatment focus usually on the mortality of the patients studied. 
Some of those studies will be discussed because it is possible to make some assessment 
of adherence or because they reflect the problems that patients with co-infection on 
concomitant treatment face with regards to for e.g. complications of treatment. Thus, 
much of the literature review would be on patients with TB only, and I believe that many 
of the challenges or opportunities that patients with co-infection face with their TB 
treatment would be similar to those of patients without co-infection. I will begin with 
comprehensive reviews on TB/HIV and concomitant TB/HIV treatment and in addition 
discuss shortly about adherence to chronic treatment in general. In addition, a short 
review of the literature on adherence to HIV treatment will be made, since, in patients 
with co-infection receiving concomitant treatment, factors affecting adherence to ART 
could also potentially affect adherence to TB treatment. Review articles have been a large 
part of my literature review, since, as I mentioned above, the literature I’m exploring is 
vast and these articles provided a good summary. 
 
   In addition to review articles, I chose to discuss largely individual studies instead of 
grouping the findings into categories because I believed that it is important to see how 
different factors interact in a specific set up to affect adherence to treatment. Grouping 
findings into categories would overshadow the findings of studies, because, in most 
instances, multiple factors are associated with adherence in a specific study context. 
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   1.7.1. Overview of co-infection and concomitant treatment 
   I will start by discussing three review articles which provide an overview of the 
epidemiological and clinical aspects of co-infection. The pathophysiology and the burden 
of co-infection which are also discussed in these articles have been described above in the 
background section. In addition, these articles highlight the difficulties associated with 
concomitant treatment as well as the benefits associated with it. They point to the fact 
that concomitant HAART during TB treatment is complicated by high pill burden, 
overlapping drug toxicities, concerns about drug-drug interactions and paradoxical 
immune reconstitution reactions, and non-adherence to treatment. Because of this, there 
is an argument to delay or defer initiation of HAART during TB treatment. In addition, 
other barriers exist in the management of co-infection including the different ways in 
which TB and HIV are perceived, and their control systems set. In every case, the priority 
is to treat TB because of public health issues. The studies also discuss the effect of 
HAART on TB epidemiology. The case fatality rates of TB are 16-35% in patients not 
receiving HAART as compared to 4-9% in those who are HIV negative. The case fatality 
rates can be significantly decreased with the use of HAART as it shown by the example 
from England where mortality fell by 72% in TB patients with the introduction of 
HAART. There were mixed reports about discontinuation of treatment in patients on 
concomitant treatment. Drug toxicities were found to have led to discontinuation of either 
or both TB/HIV treatment in one study, and TB drug intolerance was also described in 
another study resulting in discontinuation of anti-TB treatment in 6% of patients. All 
three articles also discuss the Immune Reconstitution Inflammatory Syndrome (IRIS), 
most common in patients who start ART early in their TB treatment, and which presents 
as a worsening of TB signs and symptoms, and with frequencies of as high as 35-36% 
presented in some studies. The effects of IRIS on treatment adherence were not discussed. 
The optimal timing of ART during TB treatment is also discussed. That has been very 
difficult to determine because of the aforementioned factors. Experts’ opinion on 
adherence when multiple medications are started at the same time is used in determining 
timing of ART in some guidelines, and not actual findings from studies, which are 
lacking. The studies also point that in Africa, TB is the leading cause of death among 
HIV infected patients; and often the first manifestation of HIV infection (11, 23, 39).  
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  1.7.2. Medication regimen factors and their impact on adherence to 
chronic treatment 
   A review of literature conducted in 2007 to assess the impact of medication regimen 
factors on adherence to chronic treatment, gave the following findings, although the 
authors underline the fact that it was difficult to get quality studies conducted within the 
area. The authors mention that several factors have been identified as correlates of 
adherence to long term medication regimens and include patient factors such as 
depression, health literacy, and substance use disorders, environmental or contextual 
factors such as social support and socioeconomic status, clinician factors such as clear 
communication and the time spent explaining the disease and treatment, patient clinician 
relationship factors like trust, disease factors such as chronicity, symptom prominence, 
response to treatment, health care delivery factors such as waiting time, pharmacy and 
clinic convenience, and treatment regimen factors such as pill burden, regimen 
complexity, side effects, duration of needed treatment and dosing schedule. In addition, 
the review showed that in most areas of chronic illness study, there is some evidence that 
greater dosing frequency is associated with poorer adherence. In some areas such as 
diabetes, hypertension, HIV/AIDS, strong and consistent evidence exists that dose 
frequency and regimen complexity are related to poorer adherence. The authors 
recommend that regimens as simple as possible requiring the fewest doses per day would 
help improve adherence (40).   
 
   Similarly, a review of studies which used electronic monitoring to measure adherence 
published in 2001 also showed that the higher the number of doses prescribed per day, 
the lower the adherence, with less frequent dosing resulting in better compliance for a 
variety of therapies(41). 
     
   Another review article published in 2003 to see the health outcomes and health care 
costs of reduced dose frequency also supports the above findings with reductions in daily 
doses resulting in improvements in adherence. Advantages associated with fewer doses 
per day included the avoidance of social stigma of taking medications in public, the 
feeling of being less dependent on medications, the reduced chance of taking duplicate 
medications, and the convenience of the dosing schedule (42). 
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1.7.3. Studies in patients with co-infection 
   A study conducted in Portugal to assess determinants of an unfavorable TB treatment 
outcome (no cure or death) and to assess determinants of non-adherence in HIV positive 
TB patients on ART, showed that 32.9% of patients were non-adherent to treatment and 
that 22.9% had an unfavorable outcome. Non-adherence was found to be the only 
predictor of an unfavorable outcome and adherence was independently associated with 
I.V. drug use, treatment complications and use of methadone. In this study, the sample 
size was small (70 patients), and the timing of ART initiation was not mentioned (43).  
 
   A retrospective cohort study conducted in England to assess the risks and benefits of 
administering HAART during the treatment of TB in HIV infected patients showed that 
there was a significant decrease in viral load and AIDS defining illness in those who were 
initiated on ART, as well as a decrease in mortality. In addition, there was a significant 
association between the occurrences of adverse events and use of ART.10% of patients 
had paradoxical worsening, 90% of whom were on ART. The authors point out the fact 
that the occurrence of AE could potentially influence adherence to either disease but 
there was no evidence of it in the study (44). 
 
 A study conducted in Malawi to assess whether ART reduces case fatality among HIV-
positive patients with TB, in which patients who received ART in the continuation phase 
of TB treatment were compared to those who didn’t receive ART showed that ART 
started in the continuation phase didn’t have any effect in reducing case fatality (6 out of 
ten deaths occur in the intensive phase).Similarly, the other treatment outcomes were also 
similar in the two groups e.g. treatment success, loss to follow up…although that was not 
discussed by the authors. The limitation in this study is that the two groups compared 
were patients who accepted and those who refused ART, hence there might be 
differences in economic or social status between the groups which influenced treatment 
outcome (45). 
   Another study was also conducted in Malawi to compare 6-month and 12-month cohort 
treatment outcomes of HIV positive TB patients and HIV positive non TB patients 
treated with ART, and this study showed that those patients with TB had a significantly 
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lower default rate and the authors discussed that it was possibly due to the fact that these 
patients had time to stabilize and prepare for their ART since they were started on ART 
only in the continuation phase of TB treatment, whereas the other patients were started on 
ART in a short time (46). Thus, this can indicate that adherence to either treatment (anti-
TB or ART) might be a challenge for those patients who start the ART drugs in the 
intensive phase of anti-TB treatment.  
 
   A study conducted in Nigeria to compare the treatment outcomes of TB/HIV positive 
and TB/HIV negative patients showed that default rate, which was 17% overall was not 
significantly related to HIV status, although more HIV positive than HIV negative 
patients defaulted from treatment. It was also found that reasons for default to TB 
treatment in the HIV positive patients included: severely ill patients going back their 
home town to receive support from their extended families; patients leaving the area to 
consult healers that advertised that they would cure HIV; seriously ill patients not being 
able to come to collect their drugs personally; stigma and discrimination forcing some 
HIV positive patients to relocate, mainly those with HIV wasting and other obvious HIV 
related symptoms. The study showed a significant difference in mortality (15.5%in HIV 
positives VS 3.1% in HIV negatives.)The HIV positive patients were not on ART in this 
study (47).   
 
   Two studies conducted in England also showed that paradoxical reactions during TB 
treatment were more common in co-infected patients receiving ART, mainly when 
introduced early (48); adverse events also occurred more frequently in HIV positive 
patients in one study comparing HIV negative patients with HIV positive patients (of 
whom 70% received ART).But despite a greater rate of serious adverse events such as 
hepatotoxicity, peripheral neuropathy, rash, persistent vomiting, in the HIV positive 
individuals, TB treatment discontinuation was similar in the two groups (49). 
 
  Two studies on adherence to TB preventive therapy in HIV positive patients showed 
high rates of default. 26.5% of patients defaulted from preventive treatment in Thailand, 
with migration for job search, denial of HIV status, perceived drug side effects, and 
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confusion about the duration of treatment being associated with defaulting. Married 
people, women, outpatients, surviving spouses, the self-employed, and those with no 
history of physical symptoms were more likely to be adherent to the treatment (50). 
Similarly in South Africa, more than half of HIV patients initiated on TB preventive 
treatment interrupted it, with fear of stigmatization, lack of money for food and transport, 
the belief that TB is incurable, competition between western and traditional medicine, 
and reluctance to take medications in the absence of symptoms being barriers to 
adherence and disclosure of HIV status, social and family support, a supportive clinic 
environment positively influencing adherence (51).  
   1.7.4. Studies on adherence to TB treatment and on perceptions 
about TB and its treatment 
   Hereunder, I will present selected articles on adherence to TB treatment in different 
settings and studies which focused on understanding/perception about TB. 
 
   First, I will discuss a recent systematic review of qualitative research on adherence to 
TB treatment. The aim of the review was to understand factors considered as important 
by patients, caregivers and health care providers for TB medication adherence. Eight 
major themes came out; organization of treatment and care for TB patients, with 
factors such as distance from institutions, availability of transport, long waiting times, 
inconvenient appointment times, maltreatment by providers, rigidity of DOT… affecting 
adherence; interpretation of illness and wellness with patients discontinuing treatment 
once they felt well, others continuing treatment because they felt encouraged by 
improvement, others discontinuing treatment when they saw no improvement in their 
condition...; financial burden of TB treatment with loss of job associated with TB 
diagnosis, difficulty to obtain sick leave, difficult choice between the need to attend 
clinics or earn a living, excessive costs of treatment…affecting adherence; knowledge, 
attitudes and beliefs about TB treatment with understanding about the treatment, its 
duration, beliefs in treatment efficacy, fear and denial of diagnosis…  affecting adherence. 
Law and immigration with legal and immigration requirements in certain set ups 
influencing patients’ adherence; Personal characteristics and adherence behavior with 
substance abuse, mental illness, particular ethnic groups, age, sex, religion, literacy… 
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affecting adherence; Side effects and adherence with side effects resulting in 
discontinuation of treatment and at times being given cultural meanings by patients; 
family, community and household influence with the strong influence of stigma on 
adherence, and the contribution of family support be it financial, emotional influencing 
treatment. The study also indicates a lack of evidence on the experiences of patients 
living with HIV/AIDS and taking treatment for TB or for both illnesses (52).  
    
   Another recent review of qualitative research which reported on experiences and 
perception of TB and its treatment of people with or at risk of TB, health service 
providers, policymakers, also came up across similar themes which were classified into 
five themes: Socio-economic circumstances, material resources and individual 
agency:  poverty and disadvantage played a negative role in the delay as well as in the 
treatment of patients (and some groups such as drug and alcohol users, refugees and 
migrants were particularly vulnerable in some set ups). This through an inability to give 
up work or risk losing their income though attending treatment; and dealing with costs 
including transportation costs, drug costs and costs related to food. In many instances, 
patient struggled to overcome these barriers as far as their finances and other 
circumstances allow. Explanatory models and knowledge systems in relation to TB 
and its treatment: diverse patient beliefs about TB and its treatment were found to shape 
their decisions regarding treatment. For example, patients who believed that TB is a 
punishment from god were found to revert to non medical healers. The experience of 
stigma and public discourses around TB: across many cultures, widespread TB related 
stigma exists, articulated by public discourses around TB, resulting in people being 
reluctant to seek diagnosis or to be seen taking treatment and studies focusing on gender 
indicate that women suffer from stigma more than men. Sanctions, incentives and 
support: punitive sanctions such as threats of deportation, imprisonment were adversely 
affecting treatment while incentives such as provision of food and transport money and 
detoxification programs were found to be positively influencing adherence. Financial and 
social support from families and friends were also found to be of critical importance for 
adherence. The social organization and social relationships of care: services were 
found to be rarely designed taking the patients’ needs into consideration. Inconvenient 
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treatment schedules, distance to health facilities, as well as inpatient management were 
found to be difficult for patients. In addition, lack of health education, poor quality 
services mainly in governmental centers, and poor relationship between providers and 
patients, as well as misunderstanding and miscommunication between patients and health 
providers were found to adversely affect adherence (53).  
 
  Individual studies from different countries that I reviewed were in line with the findings 
of the two above review articles. Different factors were found to play a role with regard 
to adherence in many settings.  Findings from selected studies are discussed below. 
 
  A case control study from Nepal showed that longer travel to health facility, not being 
informed about the consequences of defaulting by health professionals, side effects such 
as vomiting, stomach problems and itching which patients were not informed about, 
health care workers’ behavior, health service failure were associated with defaulting 
whereas desire for cure and knowledge that TB is curable were most important for 
completing treatment among those who successfully completed treatment (54).  
 
  A case control conducted in Madagascar showed that long transportation time, male sex, 
poor information given to the patient by health professionals, poor communication 
between patients and health providers were significantly associated with default. Males 
were thought to default more than females because they have to reconcile work with 
treatment, males having paid work more frequently then females (55).  
 
   In Uganda, a retrospective cohort study showed that treating patients at one unit, 
treating patients near their homes, training and supervision of health workers and 
progressive use of short course chemotherapy were associated with high treatment 
completion, with significant increase in the rates of treatment completion in the set up; 
with a default rate of 8.8% among survivors (56).  
 
   In Malaysia, a default rate of 28.8% was found in a prospective cohort study which 
showed that patients had misconceptions about TB and its treatment, with many getting 
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the information from friends or relatives. Patients who thought about disappearance of 
symptoms as cure tended to have a higher default. Patient characteristics such as age, sex, 
education did not affect adherence (57). 
 
   In a cross sectional study conducted in Zambia, a default rate of 29.8% was found, and 
it was also found that beginning to feel better, lack of knowledge on the benefits of 
completing a course, running out of drugs at home, TB drugs being too strong were 
associated with non compliance, whereas there was no association between age, marital 
status, educational level and compliance (58).  
    
   In Nigeria, a default rate of 23% was found in a retrospective study. The study showed 
that the important risk factor associated with compliance was male sex, which was 
explained by the authors as resulting from the fact that males were usually the 
breadwinners in the society, and had difficulty to comply with treatment, mainly the daily 
attendances at the clinics. Defaulting was highest in the continuation phase of treatment, 
with 78% of defaults occurring in the continuation phase with HIV positive patients 
having twice the risk of default during the intensive phase as HIV negative patients. HIV 
status was not associated with defaulting (59). 
 
    In the United States, two studies showed that increasing incentives is related with 
higher treatment adherence in different population groups where increase of preexisting 
incentives at treatment centers resulted in improved adherence to TB treatment (60) and 
to prophylactic treatment among intravenous drug users (61). Previous TB, resistance to 
rifampicin, human immunodeficiency virus infection, psychiatric illness, homelessness, 
smoking and drug use were related to non-adherence in the first study. A review of 11 
randomized controlled trials on the effects of financial incentives (cash, vouchers, lottery 
tickets, or gifts) on compliance to different treatments has similarly shown that incentives 
increased compliance in 10 of the 11 trials, with all trials being conducted in the United 
States (62).   
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   In Ghana, a default rate of 13.9% was found in a study combining focus groups with 
cross sectional survey which showed that a good relationship between patients and health 
staff was the main facilitator of adherence while financial difficulty was the main barrier 
to adherence. Monthly income, lack of social support and problems relating with others 
while on treatment were also significantly associated with default. Stigma attached to TB 
made patients deny diagnosis or hide their illness (63). 
 
   In Burkina Faso, a qualitative study (observation, FGDs, in-depth interviews) showed 
that patients resort to traditional healers or self treatment before seeking medical help 
because of financial and cultural reasons; those starting anti-TB treatment faced problems 
to get to the health services (long distance, poor transportation, expenses related to 
transportation) and problems while at the health services (health provider attitude, 
waiting time) (64). 
 
   In Pakistan, a focus group study showed that TB was perceived as a dangerous and 
incurable illness, which leads to stigmatization and social isolation of TB patients as well 
as their families; the problems being worse for females, who risked divorce and low 
chance of marriage. Patients often deny diagnosis or refuse treatment because of fear of 
the negative impacts of having TB. Pregnancy was also found to be a reason for stopping 
treatment. Patients were found to face diverse socio-economical problems, worse on 
women because of their economic dependence on males (65). 
 
   In India, a qualitative study (in-depth interviews, observation) showed that convenient 
clinic timings, arrangements for the provision for treatment in the event of a family 
emergency and provision for complicated cases like alcoholics were needs of patients that 
were not met by the health system. Lack of attention and support at the clinic, long 
distance to the clinic, difficulty of reentering system after missing treatment because of 
labeling by health professionals, equating well being with cure also affected treatment 
(66). 
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   In South Africa, a qualitative study (interviews, FGDs) showed that there were 
misconceptions about the origin of TB and its treatment. TB was thought by 60% of 
patients to result from the breaking of cultural rules and that it can only be treated by 
traditional healers. TB was also thought to be due to mine work, malnutrition, infected 
food, smoking, alcohol and sexual contact. The stigma of TB (due to the fact that people 
with TB were thought to have broken cultural rules as well as its association with heavy 
drinking and poverty), the belief that there should be abstinence from sex while on 
treatment, difficulties to access health services, long waiting time and health worker 
attitudes were found to influence adherence to treatment (67). 
 
   In Kenya, a qualitative study (FGDs) showed that TB is perceived as a contagious 
disease difficult to treat. TB treatment is perceived as long, agonizing and rough. 
Misperceptions exist as to its origin i.e. alcohol, smoking, exposure to cold, hard work, 
hereditary. Prolonged self treatment until symptoms become severe, alternative treatment 
(traditional), the stigma associated with the disease (with patients and their families being 
isolated by the community) lead to treatment delay and these factors can also influence 
adherence (68).  
    
   A recent systematic review on the timing of default from TB treatment showed that, in 
the 15 studies included, many patients default in the later stages of treatment, with 
majority of patients completing the intensive phase of treatment (69). 
     
   A review of interventions to promote adherence to TB treatment showed that, in the 14 
trials included, reminder cards sent to defaulters, a combination package of a monetary 
incentive and health education and more supervision of clinic staff increased the number 
of people completing their tuberculosis treatment. One trial showed that intensive 
counseling/education did not help improve adherence. DOT was associated with better 
outcomes in one study, showed no difference in another study (70). 
 
  A review of trials comparing DOT with self supervision of treatment conducted in low, 
middle and high income countries showed that there was no difference in cure or 
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treatment completion in the two groups. Similarly, there was no difference in cure or 
treatment completion between patients supervised by different people (health 
professional, lay health worker, family/community member) (71). 
 
   In Thailand, a focus group study conducted to see the effect of high AIDS awareness on 
TB management showed that there were many misperceptions about TB transmission; the 
participants had a better awareness about HIV as compared to TB. Both illnesses were 
stigmatized, although more stigma was attached to HIV. Symptoms of TB were perceived 
as being symptoms of HIV, leading to people being suspected of having HIV when they 
had TB. This lead to delay in seeking treatment and non-adherence to TB treatment in 
patients who suspected they had HIV and feared for it to be detected (72).  
 1.7.5. Adherence to ART 
   A review of literature on adherence to HAART regimen indicated that barriers of 
adherence to ART treatment are similar to barriers to chronic treatment in general: 
regimen complexity ,with pill burden but mainly dosing schedules and food restrictions 
affecting adherence, but regimen that best fits the daily schedules and patients’ attitude 
towards treatment being stronger predictors than dosing schedules ;side effects resulting 
in poor tolerability (with transient or long lasting side effects at times resulting in 
treatment discontinuation), studies showed that adherence is optimal when symptoms are 
controlled and declines with the occurrence of side effects;  patient related factors such 
as forgetfulness which happens mainly when symptoms have improved,  and difficulty in 
understanding treatment schedules; psychosocial issues such as depression, stress, 
hopelessness, substance abuse adversely affecting adherence whereas support from 
families, friends, treatment buddies and peer counseling were found to facilitate 
adherence; patient belief system with greater adherence found in those who believe that 
HAART is effective, and patient provider relationship, with the pivotal role of 
adherence counseling .A good patient provider relationship assists adherence whereas 
miscommunications and unmanaged side effects frustrate patients and lead to non 
adherence(73).  
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   A study conducted in Uganda, Tanzania and Botswana and which used qualitative 
methods to identify context specific constraints to adherence showed that, despite a high 
motivation on the side of the patients to take drugs, some factors were challenging 
adherence .These included transport costs and user fees, and at times absence of adequate 
transportation; waiting times averaging as high as 5 hours in some set ups with patients 
having to miss their daily work for their drug refills; hunger, mainly when the body 
regains strength and weight, was a common problem for patients with some discontinuing 
treatment because of lack of food; HIV related stigma was found in all the countries, with 
loss of job, isolation by families and community members reported, and many patients 
chose not to tell about their HIV status to families, hence having to hide their medication 
intake which resulted at times in irregular intakes, but also patients resulted in patients 
not being able to get social support; side effects had lead to treatment discontinuation in 
patients, and patients in Tanzania and Uganda were not informed about side effects and 
that these could subside over time but patients in Botswana were given extensive 
information about side effects in pre-treatment counseling and few mentioned side effects 
as a reason for treatment discontinuation. The quality of counseling, which is a key 
requirement for successful ARV adherence, was found to be variable in different 
countries as well as within different parts of the same country, and patients in Uganda 
valued the support of community based volunteers who were HIV positive themselves. 
Heavy workloads at the clinics were also challenges noted in the three countries, since 
ART scale up was not followed by an increases in health personnel, but despite this 
workload, an absolute majority of patients reported being satisfied with the services 
provided at the health clinics (74).    
 1.7.6. The literature from Ethiopia 
   In Ethiopia, few studies have explored knowledge/perceptions about TB. Adherence to 
TB treatment has been studied better. Most of the studies conducted are quantitative 
studies. I will discuss each study below. In addition, I will discuss two articles on 
treatment delay, since factors affecting treatment delay might similarly affect adherence 
and I will also discuss one article on acceptability of HIV counseling and testing and 
three articles on ART treatment adherence.  
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    In 1989/90, a cross-sectional study was conducted in Addis-Abeba, consisting of 1206 
new TB patients with the aim of identifying the rate of defaulting from treatment and 
factors associated with it. A default rate of 82% was found, with rates of defaulting being 
higher in males, in the older age group and in those living near to the TB center. Most of 
the defaulting occurred in the third and fourth month, with feeling of improvement and 
social problems as the two top reasons for defaulting. In addition, comparison of 
defaulters and a control group of non-defaulters showed that inadequate knowledge, low 
educational level, nearer distance to the health center and negative attitude towards the 
TB center were significantly associated with defaulting (75).     
 
   An institution based cross sectional survey was conducted in 1996, in a rural health 
center in the South Gondar region with interview and respective review of medical 
records of 211 TB patients. It showed that social ostracism had affected TB patients and 
their families to a great extent, with patients and healthy family members excluded from 
social and religious ceremonies for fear of contagion. A divorce rate of 29.1% due to TB 
was reported. In addition, patients reported loss or threats to lose their job. Dietary 
misconceptions were also found to be very common, with patients avoiding millet, maize, 
sorghum, potatoes and onions fearing that these will decrease the potency of anti-TB 
drugs. Many patients similarly avoided sex during treatment since they thought that it 
will decrease the potency of the drug, which in turn impacted on their marriage. The 
study also showed that control activities were ineffective and poorly organized (76).  
 
   A community based cross sectional study was conducted in 1997 in the Northwest 
region to assess the perspective of the rural community towards TB and TB patients.1000 
heads of household were interviewed and information about the disease obtained for 5078 
family members. TB treatment defaulters were found in 10% of the households, with 
apparent clinical improvement after the intensive phase being the reason for defaulting in 
45% of the cases and far distance to the health institution contributing for 25.3% of the 
reason for defaulting. Evil spirit, contaminated food/water and sexual intercourse were 
thought to be causes for TB in 19.9%, 18.6% and 4.7% of respondents. It was also found 
that the community exhibited high ostracism towards TB patients, with a majority of 
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respondents not allowing attending social gatherings or festivities with a TB patient on 
treatment. With 76.2% of respondents having heard about HIV/AIDS, 19.4% also said 
that there could be an association between HIV/AIDS and TB (77).  
 
   Another cross sectional study was also conducted in the same year in the Harar region, 
and it included 418 pulmonary TB patients. In this study, comparison between HIV 
positive and HIV negative patients showed that HIV positive patients were more 
defaulters than the HIV negatives, although not significantly. In addition, that study 
showed that HIV positive patients had significantly higher levels of secondary drug 
resistance and that significantly higher numbers of them were cases of relapse and 
treatment failure (78). 
 
   In 1999, a case control study was conducted in the Oromia region, in which the records 
of 1367 patients were reviewed to determine the defaulting rate. A default rate of 11.3% 
was found. Defaulting was highest (81%) during the continuation phase of treatment. 
Comparison of cases (defaulters) and controls showed that medication side effects were 
significantly associated with defaulting while adequate knowledge and family support 
were protective against defaulting (29). 
 
  A cross-sectional study was conducted in 1999/2000 in the Jimma area among patients 
in the DOTS regimen to determine the rate of defaulting and associated factors. It showed 
an overall rate of defaulting of 6.7%. 52% of the defaulters were traced and their reasons 
for defaulting were sought. The major factors contributing for defaulting were 
socioeconomic factors including distance of patients’ residence from the health institution, 
lack of money for paying transportation and poor awareness about the disease (30). 
 
  A prospective cohort study was conducted in 2002-2004 in Southern Ethiopia with the 
aim of determining factors predicting treatment adherence in smear positive TB patients. 
It showed a default rate of 20% among the 404 patients involved. Most treatment 
interruptions (91%) occurred in the continuation phase of treatment. Again, distance from 
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home to treatment center was related to defaulting; as well as the necessity to use public 
transport to get to a treatment center and age>25 years (28).  
     
   Two studies have also been conducted to assess the effects of TB clubs on TB control. 
The first, a descriptive study conducted in the South Gonder region to assess the impact 
of “TB clubs” on the performance of the TB programme, showed that the introduction of 
the TB clubs helped to significantly increase the proportion of actual among expected 
attendances of tuberculosis patients for follow-up during treatment at health facilities. TB 
clubs together with other community members, also referred TB patients, promoted 
adherence and traced defaulters. TB clubs were also involved in the identification of the 
majority of new smear positive patients (79). 
 
   The effectiveness of TB clubs in improving compliance to TB treatment and in 
improving societal attitudes towards TB was also assessed by another study conducted in 
Northern Ethiopia. The study utilized a combination of a cohort study with focus groups 
and in-depth interview. A significantly higher treatment completion rate and a 
significantly lower default rate were found in the TB club group as compared to the 
comparison group. The qualitative study showed significant changes in patients’ 
understanding of TB, their reaction to initial diagnosis, misconceptions as to the cause 
and treatment of TB, the social isolation and compliance and belief in the modern health 
care in the TB club area (80). 
 
  A qualitative study consisting of in-depth interviews and focus groups was conducted in 
2001/2002 in Addis-Abeba to explore how symptoms of TB are perceived and managed 
from the onset of symptoms and during the course of treatment. It showed that TB was 
largely thought to be due to exposure to “bird” (cold), misperceptions existing even 
among health professionals. Early symptoms of TB were treated at home or in private 
clinics where patients were usually offered antibiotics to rule out pneumonia, resulting in 
treatment delay. Some patients related TB to supernatural forces; and many patients 
thought that TB could restart, leading to a non-curable type of TB, chronic type of TB or 
AIDS. AIDS was perceived as a second stage of TB. For many patients, cure would 
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necessitate proteinaceous foods in addition to the drugs, in addition to avoiding actions 
such as sex. It was also found that adequate information about the treatment was not 
provided to the patients by health professionals (81).   
      
  The same authors explored enablers and barriers in the management of TB treatment 
during the first five months of TB treatment in Addis-Abeba, and showed that many 
socio-economic factors affected patients’ adherence to treatment. These included loss of 
employment and the possibility to work, the difficulties associated with daily treatment 
and rigid routines existing in the health clinics, and financial problems faced by patients. 
In addition, the financial and practical help that patients received from relatives or 
communities would be lost over time, making them vulnerable to default in the later 
stages of treatment. Those mainly affected being those who were unable to regain their 
health early. In addition, the researchers noted that there was a strong association 
between TB and HIV/AIDS and that if the patient had a “curable disease”, he is expected 
to show improvement within a certain period of time and if that does not happen, he 
would be labeled as someone having an incurable disease (AIDS or a chronic type of TB), 
leading to additional stigma (31). 
    
   Two studies were also conducted to assess the effect of DOTS on treatment outcomes 
of TB patients. The first study, a register based analysis of 19971 patients registered 
between 1994 and 2001 in the Southern region of Hadiya, showed that, with a population 
coverage of DOTS reaching 75% in 2001 and 94% of patients being treated with short 
course chemotherapy, treatment success increased from 38% to 73% in 2000 in smear 
positives; default rate declined from 38% to 18%.Being a female patient, age 15-
24,smear positive pulmonary TB, treatment with short course chemotherapy, treatment at 
peripheral centers were associated with higher treatment success and lower default rates 
(32).  
     
    The second study explored the treatment outcomes of 136,572 patients treated between 
1995 and 2004 in the Southern region, and it was found that the decentralization of 
DOTS had significantly improved treatment outcomes with significant improvements in 
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the case detection rate, the case notification rate and the treatment success rate. The 
default rate decreased from 26% to 6% in that period (33).  
 
    Inadequate knowledge about TB and distance from home to health centers were found 
to be associated with delay before diagnosis, in a cross sectional study conducted in 1998 
in Addis-Abeba, which included 700 TB patients, and which showed a high delay (26). 
Another cross sectional study conducted in 2004 in the Amhara region, which included 
384 new smear positive patients, also showed an increased delay (both patient and 
provider), with a median total delay of 80 days. It also showed that self treatment and 
visit to non formal health providers were strongly associated with patients’ delays (27). 
 
  Three studies on adherence to ART treatment were also reviewed. The first, a recent 
cross-sectional study combined with in-depth interviews, conducted in Addis-Abeba 
among 431 HIV patients, showed a self reported adherence rate of 81.2%.Being too busy 
or simply forgot and being away from home were the major reasons for non-adherence 
whereas not being depressed, having no side effects, a regimen that fitted the daily 
routine and satisfaction with the relationship with doctors were found to be facilitators of 
adherence. Financial problems, medication side effects, lack of knowledge about the need 
for adherence emerged as major barriers in the interviews; and social support was 
reported as a facilitator of adherence (82). 
       
   A case control study conducted in the same region also showed that 13.6% of patients 
who had not come to the clinic had defaulted. Less than 40% of defaulters were traced 
because of incorrect address but, among those who were traced, loss of hope in 
medication, lack of food, mental illness, holy water, no money for transport, and other 
illnesses were given as reasons for defaulting. In addition, taking hard drugs (cocaine, 
cannabis and IV drugs), excessive alcohol consumption, being bedridden, living outside 
Jimma town and having an HIV negative or unknown HIV status partner were associated 
with defaulting ART (83).    
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   In addition, a cross sectional study conducted in Arba Minch Hospital in 2005 and 
which included 190 TB patients showed that women were more likely to be infected and 
that the acceptability rate of HIV testing was only 35%.Being unemployed was found to 
be the only factor associated with accepting the test (84). The implications of this study 
are that it might be difficult to scale up TB/HIV collaborative activities with such a low 
acceptability of HIV testing and that the reasons behind such a low acceptability of 
testing might also affect adherence to treatment in co-infected patients. 
 
   1.7.7. Summary of the review and gaps identified 
   The literature review shows that adherence to TB treatment has been studied across 
different settings. It shows that non adherence to TB treatment remains a problem in 
different parts of the world, although the magnitudes differ. Many factors seem to 
influence TB treatment adherence similarly in many settings. The studies on co-infection 
showed mixed results as to the impact of HIV infection on adherence to TB treatment, 
with some studies indicating an association between HIV status and TB treatment 
adherence and others showing no relationship. From the different studies reviewed, it is 
possible to see that personal characteristics such as age, marital status are unstable 
predictors of adherence, whereas other factors such as costs related to treatment, distance 
to health institution, patient-provider relationships… seem to have a uniform effect on 
adherence across studies. Needless to say that some of the barriers and facilitators of 
adherence are very much context specific for example reflecting specific illness 
perceptions in communities. In many instances, several factors are associated with non 
adherence to treatment in patients.  
     
  Studies exploring beliefs/attitudes about TB and its treatment are very important in 
understanding patterns of adherence in a community, but such studies are lacking 
compared to studies on adherence. 
     
  Similarly, despite the high rates of co-infection globally and in particular in Sub-
Saharan Africa, and despite fear of poor adherence in patients on concomitant treatment 
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among the medical community, few studies have focused on this subject, rather, the focus 
in co-infected patients has been to see prognosis and how prognosis is affected by the 
provision of ART to TB patients. 
 
  The studies from Ethiopia, largely quantitative and conducted mostly in rural areas have 
also identified socio-economic and structural barriers to adherence, and have also 
indicated that high TB related stigma exists within communities. Adherence rates in 
general seem to have shown improvement over the past decades (from 82% in 1989 to 
rates as low as 6.1% in recent years). In addition, a study conducted in Addis-Abeba in 
2001/2 indicates that there is a strong association between TB and HIV/AIDS and that 
AIDS is perceived as a second stage of TB which is thought to be incurable. This needs 
to be explored further and how these misperceptions and other factors act as barriers and 
facilitators of adherence to TB treatment in co-infected patients need to be studied. In 
addition, although the quantitative studies point to factors that can potentially affect 
adherence, they fail to show us how these factors actually interact to lead the patient to 
make a decision regarding his/her treatment and this is better explored through a 
qualitative approach, but qualitative studies are very few in Ethiopia.  
1.8. Objectives of the study 
    1.8.1. Overall objective 
• To provide knowledge for improvement of tuberculosis treatment outcomes 
in patients with TB/HIV co-infection receiving concomitant treatment 
    1.8.2. Specific objectives 
• To describe general clinical characteristics of tuberculosis in co-infected 
patients who received concomitant ART treatment 
• To describe magnitude of default and factors predicting tuberculosis 
treatment adherence in these patients  
• To compare TB treatment outcomes with a comparative group of HIV 
negative patients 
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• To explore  co-infected patients’ perspectives of facilitators and barriers to 
tuberculosis treatment adherence 
• To explore health workers’ perspectives of facilitators and barriers to 
tuberculosis treatment adherence  
1.9. Justification for the study 
   Ethiopia is one of the twenty two high burden countries for tuberculosis. The rate of 
TB/HIV co-infection is also high (30%-50%). 
  
  Concomitant treatment in co-infected patients is complicated by factors such as high pill 
burden, overlapping side effects, drug interactions, double stigma (TB and HIV 
related).How these factors affect adherence to TB treatment in co-infected patients on 
concomitant treatment together with other factors (socio-economic, structural…) has not 
been well studied, although expert opinions point to the fact that concomitant treatment 
might adversely affect treatment adherence, especially when ART is initiated in the 
intensive phase of TB treatment.   
    
   As to my knowledge, understanding of co-infection and how it impacts on adherence to 
TB treatment, and the experience of concomitant drug intake, as well as the effect of 
double stigma on adherence to anti-TB treatment among other things have not been 
explored in Ethiopia and I would like to explore this gap.    
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                        Chapter two: Subjects, materials and methods 
    2.1. Study area 
    The study was conducted in Addis-Abeba, in three health centers randomly chosen 
among 21 health centers. These health centers are administered by the Addis-Abeba 
Health Bureau and provide general medical services for the populations within their 
catchments areas. The health centers randomly selected were Bole Health Center, Arada 
Health Center and Woreda 7 Health Center. Although the TB clinics have been operating 
for many years in these health centers, the ART clinics have started working since 2006 
as part of the expansion of HAART provision program initially started in hospitals. The 
health centers offer free ART service and chronic HIV care for patients with HIV 
infection. In addition to diagnosis and treatment of patients with TB, the TB clinics 
located in these Health Centers also offer the Provider Induced Counseling and Treatment 
(PICT) service through which all patients coming to the TB clinics are offered screening 
for HIV. Both TB and ART treatment are offered for free in the health centers and the 
following regimens are used. 
     1. Regimens used for the treatment of TB: according to the guidelines of the National 
Tuberculosis and Leprosy control program, all new cases of TB are treated with short 
course chemotherapy, which is constituted of two months on RHZE (rifampicin, 
isoniazid, pyrazinamide, ethambutol), followed by a continuation phase of six months on 
EH. During the intensive phase, patients are supervised by health workers daily while 
taking treatment. In the continuation phase, drugs are self administered and collected on a 
monthly basis. Patients who are on retreatment because of default, relapse or treatment 
failure are treated with RHZE plus streptomycin (S) for two months, followed by one 
month treatment with RHZE, and five months treatment with RHE. Retreatment cases are 
to be supervised throughout treatment. Dosage is dependent on weight of the patient. 
Fixed dose combinations are used throughout. 
     2. ART regimens used: the following HAART regimens are available in the health 
centers: 
• Stavudine/lamivudine/nevirapine 
• Stavudine/lamivudine/efavirenz 
• Combivir/Nevirapine 
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• Combivir/Efavirenz 
      
   Fixed dose combinations (FDC) have recently been introduced in the health centers. 
Patients in our study have not used these FDCs during concomitant therapy. In addition, 
second line regimens are also being used, but in hospitals only.  
 
   When to initiate ART in the treatment of TB patients co-infected with HIV remains a 
controversy. In Ethiopia, the national recommendation is to start patients with CD4 of < 
50 on ART as early as possible; for those with CD4 between 50 and 200, initiation of 
ART should be within 2-8 weeks after anti-TB initiation and for those with CD4> 200 
(200-350), ART is to be initiated once the intensive phase of anti-TB is completed.  
          
  The different health centers in general do not have significant differences in terms of 
services they provide and in terms of health personnel and equipments available.         
    
   My initial plan was to conduct my studies in Hospitals providing ART services, since 
they were the ones where free ART treatment was first started in 2005.In addition, 
patients diagnosed in these hospitals were sent to nearby TB clinics for their TB 
treatment, so I wanted to explore the difficulties for patients of attending two treatment 
centers. But, when I got to Addis-Abeba and visited some hospitals, I found out that the 
TB treatment outcomes were not recorded for many patients at the ART clinics, and that 
it would be very difficult to trace the patients for whom the outcomes were unknown 
back to the health centers because the exact health center they were referred to was 
unknown in most of the cases. So, I decided to conduct my study in the health centers 
where both TB and ART services are provided.    
 
  2.2. Study design 
    The study adopted a combination of methods, quantitative and qualitative. The 
quantitative component was a register based retrospective cohort analysis of TB/HIV co-
infected patients aged 16 years and above registered for tuberculosis treatment in the 
period July 2006-August 2007 and who had been on ART treatment while on TB 
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treatment, irrespective of the timing of ART initiation in the course of TB treatment. We 
reviewed both the TB treatment registers and the HIV clinic charts of the patients to 
record information we wanted. We similarly collected the TB treatment outcomes of HIV 
negative TB patients, starting from the beginning of our inclusion period going onwards 
until we reached a similar sample size as the HIV positive patients, including all 
consecutive HIV negative patients, to minimize possible selection bias. This group was 
included in order to describe differences in treatment outcomes between the two groups. 
TB clinic registers were reviewed for the HIV negative patients. 
  
   Retrospective studies are cheap and non time consuming. But important information 
might be missing or otherwise unavailable while conducting retrospective studies (85). In 
my case, this was the study of choice, because, even though conducting a prospective 
study allows for careful control of the nature and quality of data recording (86), in my 
case allowing the recording of factors which could potentially affect adherence at the 
beginning of the study; it would nevertheless be impossible to conduct such a study 
within the time frame allocated for field work (six months).  
      
  The qualitative component consisted of in-depth interviews with purposefully selected 
patients and health professionals and focus group discussions with purposefully selected 
patients. In-depth interview is one form of qualitative interview. It is important in dealing 
with issues which involve private matters such as adherence, and is good to explore 
issues which involve complex phenomena. It allows us to see how the meaning making 
process unfolds in the interview, in addition to giving an answer to what is enquired. It 
allows us to see the interrelatedness of the whats and hows (87). Focus groups can be 
used to get an early impression of a target population, to develop interview guides, to 
validate and elaborate information gathered by other means (88). They are advantageous 
in that it is possible to involve 6-12 participants at the same time. The disadvantages are 
the difficulty to choose homogeneous groups, and the fact that it might be difficult to 
discuss personal and sensitive issues in groups (89).  
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    Mixed methods approach (combining qualitative and quantitative methods) can be 
used to either meet different needs at different stages of a project, to compensate for 
shortcomings of either method or for the purpose of triangulation. Triangulation involves 
the gaining of multiple perspectives through combining completed studies conducted on 
the same topic and that directly address each other’s findings. One method should either 
challenge (or clarify), illuminate (or add to the other) or verify (provide same conclusion 
to) the other .When used for triangulation, the methods are used either sequentially or in 
parallel. In this case, each study is conducted independently and is complete by itself and 
the results inform each other (90). In my case, I combined the methods for the purpose of 
triangulation. I wanted to see the clinical characteristics, treatment outcomes (in 
particular default vs successful treatment) and associated factors in patients with co-
infection on concomitant treatment, and I wanted to describe differences in these 
treatment outcomes with HIV negative patients. I used record review for this purpose. I 
further wanted to see what the barriers and facilitators of adherence to TB treatment in 
co-infected patients on concomitant treatment are from both patients’ and health workers’ 
perspectives, because it would not be possible to extract such information through 
reviewing records, and it would also help explain the findings of the quantitative study. In 
addition, by using in-depth interviews, I was able to address the multiple factors that 
might be involved in adherence to treatment, which were also contextualized. As I 
described above, assessing adherence would need assessing complex factors which 
include provider-related factors; social, cultural, economic factors; regimen related 
factors. Using the focus group discussions helped explore my objectives further and also 
helped me validate the results of the interviews. 
2.3. Inclusion criteria 
For the record review, records of all patients 16 years (cut off age for adult in treatment 
centers) and above registered for TB treatment during the inclusion period (July 2006- 
September 2007) and who concomitantly received ART while on TB treatment were 
reviewed. 
For the HIV negative group, records of consecutive patients 16 years and above and 
treated for TB were included, starting from the initial period of inclusion (July 2006). 
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The inclusion criteria for patients participating in the in-depth interviews were: 
• Age 18 years and above 
• Treated for TB and received ART while on anti-TB treatment  
• Treatment outcome known from TB register at the clinic 
For the focus group, the inclusion criteria were: 
• Age 18 years and above 
• On treatment for TB, has taken drug for at least two months  
• Is receiving concomitant ART 
In addition, health professionals in the three clinics who were actively involved in the 
management of co-infected patients were also included. 
 
  2.4. Exclusion criteria 
Records of patients below 16 years and charts of patients for whom the diagnosis of TB 
was changed before treatment completion were excluded. 
Patients who were less than eighteen years old, who were unwilling to participate, who 
were not mentally fit, and for whom the diagnosis of tuberculosis was changed before 
completion of treatment were excluded from the interviews and focus groups. 
 
  2.5. Study population 
  Our study population for the quantitative study was patients who had been registered for 
TB treatment in our period of inclusion and who concomitantly received ART in the three 
health centers we included. All co-infected patients on concomitant treatment in the 
period of inclusion were included if they fulfilled the inclusion criteria. We included all 
consecutive HIV negative patients registered for TB treatment starting from the period of 
inclusion onwards until the same sample size as the HIV negatives was reached.  
 
   The study population for the in-depth interviews and focus groups was also selected 
from the three health centers. Six patients from Bole Health Center, five from Arada 
Health Center and four from Woreda 7 Heath Center were recruited for the interviews. 
The numbers were determined by how many patients the health professionals were able 
to recruit for me from the respective health centers. For the focus group discussions, 
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patients were recruited from two health centers; the participants in the male group were 
selected from Arada Health Center and those in the female group from Bole Health 
Center. It was most convenient for patients to come to the health center where they were 
being treated and that was the reason why the focus groups were constituted of patients 
from the same health centers. The nine health professionals interviewed were recruited 
from all three health centers. The following tables (1-3) show the characteristics of the 
patients interviewed.  
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Table 1. Characteristics of patients interviewed 
Characteristic         No. 
Gender  
  Male 7 
  Female 8 
Age  
  < 25 3 
  26-35 4 
  > 35 8 
Education  
  Illiterate                                                                                                    3 
  Read and write 3 
  Primary school 4 
  Secondary school and above 5 
Occupation  
  Unemployed 4 
  Civil servant 1 
  Private 2 
  Other* 8 
Treatment outcome  
  Successful treatment completion 6 
  Default 6 
  Re-treatment 3 
* Includes patients with irregular jobs  
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Table 2. Characteristics of health professionals interviewed 
Characteristic         No. 
Gender  
  Male 3 
  Female 6 
Profession  
  Clinical nurse 6 
  Health officer 2 
  Doctor 1 
Work experience  
< 5 years 1 
5-10 years 2 
> 10 years 6 
 
 
Table 3. Characteristics of focus group participants 
Characteristic         No. 
Gender  
  Male 7 
  Female 7 
Age  
  < 25 years 2 
  25-35 years  7 
  > 35 years 6 
Occupation   
  Unemployed 3 
  Civil servant 2 
  Private 5 
  Other 4 
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   2.6. Data collection methods 
   The methods for data collection were both quantitative and qualitative. The use of this 
combination of methods allowed me to explore all my objectives in depth. Through the 
use of record reviews, I was able to see what proportion of patients defaulted treatment, 
as well as what proportion had the other different treatment outcomes. In addition, I was 
able to see whether some recorded variables from the patients chart could be predictors of 
adherence or non-adherence in these patients. In addition, I was able to describe 
differences in treatment outcomes with HIV negative patients. But many factors would be 
left unexplored if my study did not have the qualitative component, most importantly the 
experiences of drug intake of patients from their own perspective, including how 
concomitant illness, concomitant treatment, the health services provided etc are perceived 
and how they influence adherence. I used different groups of patients and I also included 
health professionals to get different perspectives and explore the different factors that 
could influence adherence.  
 
  2.7. Sample selection 
   I first contacted the Regional Health Bureau and I was able to determine all the health 
centers from which I could chose three health centers in which to conduct my study. I 
estimated roughly the total number of patients I could get from one health center in the 
inclusion period after contacting health professionals and I estimated that three health 
centers would be enough to reach my sample size, which ended up being the case. Then I 
selected the three health centers from the 21 health centers by using the lottery method, 
and Bole Health Center, Arada Health Center and Woreda 7 Health center were selected.   
     
   For the interviews, I used purposeful sampling. Sampling in qualitative methods is done 
to enhance and saturate theoretical sensitivity through strategic sampling, and not random 
sampling, as is the case with quantitative studies. This should result in adequate diversity 
and breadth of the matter that we want to analyze (51). Thus, I selected patients with 
different experiences (successful completion of treatment and default; as well as new 
patients and patients with previous history of treatment for TB, patients currently on 
treatment), different age groups, from both sexes and with differing socio-economic 
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status. In addition, I also tried to include patients for whom ART was started at different 
stages during TB treatment. (before anti-TB initiation, in intensive phase, in continuation 
phase).   
     
   It was quite difficult to get hold of defaulters because they totally disappeared from the 
health system, often abandoning simultaneously their ART treatment, hence, in the case 
of defaulters, I included those defaulters the health professionals could find for me 
without looking for the age, sex, socioeconomic etc. diversity I looked for in the other 
patients. 
        
   In addition, as my aim was to explore barriers and facilitators of treatment adherence, I 
did not limit my study to the study of defaulters or put particular emphasis on them. 
Rather, I believed that it was important to include the experience of both defaulters but 
also patients who had successfully completed treatment. Both defaulters and those with 
successful treatment completion might have their own barriers and facilitators, and what 
leads them in either direction (completing treatment or defaulting from treatment) might 
be the type of balance that is eventually reached and which factors are predominant; and I 
wanted to explore that.  Similarly, it is very important to explore the experience of new 
patients and those on re-treatment because patients on re-treatment constitute a large 
proportion of TB patients in the HIV era, and might have different experiences from that 
of the new patients. The literature on concomitant treatment also points to the fact that the 
timing of ART during the course of TB treatment can potentially affect adherence. Hence, 
I also wanted to explore the experiences of patients initiated on ART at different times.  
              
 When I first contacted the health professionals who did the patient recruitment for me, I 
explained to them that I wanted the above mentioned diversity in the patients, in addition 
to the inclusion criteria; I was also contacting them repeatedly to inform them of the 
patients I had interviewed in all three health centers and which patients I further wanted 
to interview.  
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   I conducted the focus group after I finished my in-depth interviews. My aim was to 
discuss factors that I felt needed further exploration but mainly to validate the results of 
my interviews by bringing forward issues discussed in the in-depth interviews. I selected 
patients who had been on treatment for TB for at least two months and were 
concomitantly on ART. I tried to create homogeneous groups as much as possible. I 
created groups with males only and with females only because I believed the cultural set 
up would restrain the females from talking if they were put together with men. 
Additionally, to make the groups as homogeneous as possible, I asked the health 
professionals to avoid extremes of age, again because, in the Ethiopian culture, age 
creates a certain hierarchy and younger people are usually supposed to listen when older 
people talk; but I was also afraid of the relationship between age and HIV infection and 
how it could affect the discussion. Although variations in other factors such as socio-
economic status, level of education etc could also be thought to influence the discussion, 
it would be quite difficult to create homogeneous groups with respect to all such factors, 
but I tried to create groups that are as homogeneous as possible.   
      
    I chose patients who were on treatment for the focus group for two reasons: the first is 
the fact that these patients will be sharing lived experiences of their illness and drug 
intake, share their day to day struggles while still experiencing them; it also offers the 
advantage of avoiding recall bias. In addition, it is easier to contact these patients as 
opposed to finding patients who have already left the health system, or are only coming 
infrequently to collect their ARV drugs.  
 
2.8. Sample size 
   For the quantitative study, the sample size was calculated using the formula used for 
determination of sample size for estimating single proportion: 
N= Z2P (1-P)/E2   
Where Z = 1.96 
P = rate of non-adherence (default) to anti-tuberculosis treatment 
E = allowable error 
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Hence, based on a previous study conducted in Ethiopia where they found a default rate 
of 18% (32), with confidence interval of 95% and taking a margin of error of 5%, I found 
a sample size of 227. And when 10% was added for exclusions from final analysis (death, 
failure, transfer out), the sample size was 249.  
     
   My eventual sample size was 248 patients, after including all the co-infected patients 
initiated on treatment within the inclusion period in the three health centers; I similarly 
included the same number of HIV negative TB patients.   
 
   For the in-depth interviews, I included fifteen patients and eight health professionals. I 
included fourteen patients in the focus group discussions, with seven patients in each 
focus group. This is the number of patients and health professionals I believed was 
sufficient in exploring my subject of interest in depth, with saturation reached.   
 
   2.9. Procedure for data collection   
   My first step after getting to Addis-Abeba was to go to hospitals providing free ART 
service to check whether the data I was looking for was available. I visited three hospitals 
and I found out that the treatment outcomes of TB were not recorded for many patients 
who had been treated in the ART clinic, although, for most patients, the TB treatment 
initiation was noted. These hospitals do not have TB clinics and the patients are sent to 
their closest health center for TB treatment. 
      
  Then, I started going to health centers where ART treatment was being provided           
and checked whether I could find the treatment outcomes. Although again the treatment 
outcomes for TB were not registered for all patients in the ART clinics, since the patients 
received their TB treatment in the same health center, I realized I would be able to trace 
the patients in the TB clinic based on the date of TB treatment start, the full name and the 
age of the patient present on the ART charts. I therefore decided to conduct my studies in 
the health centers. 
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  Thereafter, I contacted the Addis-Abeba Health Bureau for Ethical Clearance, and, after 
receiving my ethical clearance, I contacted the medical directors of the respective health 
centers I worked in, informed them of my study and asked for permission to work in their 
health center. After I got the permission from the health centers, I decided I would do the 
quantitative data collection in two of the health centers myself and that I would need one 
data collector in one of the health centers. I then found one clinical nurse with seventeen 
years of experience to collect the data in Bole Health Center where he works in the TB 
clinic. Together, we went through my recording form which we modified slightly from 
the initial version I had prepared based on the exact information we could extract from 
the ART charts and the TB charts. We filled five forms together and I also checked five 
forms that he filled at the beginning and then he continued working in Bole health center 
and I worked in the remaining two health centers.   
 
   After completing my quantitative data collection, I contacted the health personnel at the 
TB and ART clinic and asked them to invite patients for me, provided them with the 
invitation form and discussed with them about the contents of the invitation form, and 
mainly emphasized that they should make sure that the patients understood that the 
participation in the study is voluntary. When I met patients that had been invited by 
health professionals, at their time of convenience, I also further discussed the issue with 
them, explaining to them that participation is voluntary and will not affect their treatment; 
that confidentiality will be ensured; and I explained the purpose of the study and my role. 
 I invited the health professionals myself and similarly discussed the purpose of my study 
and the conditions for participation with them as well.  
       
  Then I pre tested my interview guide on two patients and modified it slightly from the 
original version because some questions were too vague and elicited   “what do you 
mean?” type of questions from the patients. After modifying my interview guide, I 
continued with my qualitative data collection.   
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2.10. Data description 
   We used a recording form as a data collection tool for the quantitative component and 
we used in-depth interviews and focus group interviews as tools for qualitative data 
collection. 
    
   The recording form for the HIV positive patients included socio-demographic variables, 
as well as clinical characteristics such as type of TB, bacilloscopy status, CD4 count at 
the time of anti-TB treatment initiation, WHO stage of HIV disease, ART regimen used, 
whether PCP prophylaxis was given, whether there was any documented side effect while 
the patient was on TB treatment, whether there was any concomitant illness (other than 
TB and HIV) during the TB treatment period. This information was gathered from the 
ART charts of the patients. For the HIV negative patients, the only variables that we 
could record were the age, sex of the patient, site of TB and bacilloscopy status for those 
with pulmonary TB since these are the only information available on the TB registers. 
         
   For both groups of patients, we also recorded the treatment outcomes of cured, 
completed treatment, died, defaulted, failed, transferred out, as defined in the TB 
clinics(as per the WHO criteria).  
         
   The in-depth interviews were conducted using an interview guide, which was semi-
structured with open-ended questions, and I tried to explore the knowledge of the patients 
about TB and about co-infection; the knowledge and attitude towards TB treatment as 
well as concomitant treatment and how these affect treatment; whether they have taken 
alternative treatment; the perceived barriers to treatment; the perceived facilitators of 
treatment; and I probed patients whenever necessary to explore factors that could 
potentially affect adherence for e.g. stigma, pill burden, attitude of health personnel… if 
they did not raise these points themselves. Although this was what I initially put in my 
interview guide, issues that came up in one interview were also explored in the following 
ones when necessary; hence, the interview guide was not strictly followed with some 
questions being left out and others added during the conduct of the study.  
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   For the focus groups, the questions/topics that were raised were similar but they were 
mainly based on my findings from the in-depth interviews, since I was trying to discuss 
further matters that I thought needed further exploration and I was at the same time trying 
to validate my findings from the in-depth interviews.  
 
   2.11. Quantitative data collection 
   I used a recording form to collect data from the patient charts. For the HIV positive 
cohort, I recorded information from the ART charts and the TB treatment register. Before 
leaving for field work, I had prepared my recording form which I had to transform 
slightly after revising the ART charts and looking at what information was exactly 
available in the charts. For the HIV negative group, I recorded information from the TB 
register only.  
 
    2.11.1. Definition of variables 
      2.11.1.1. Dependent variables (the definitions used are those used by WHO, also 
adopted by the Ethiopian TLCP) 
1. Cured: A initially smear positive patient who is sputum smear-negative at, or one 
month prior to, the completion of treatment and on at least one previous occasion (usually 
at the end of the 2nd or 5th month) 
2 .completed treatment: a patient who completed treatment but for whom smear results 
are not available at 7th month or one month prior to the completion of treatment. (This 
definition applies for pulmonary smear positive and smear negative patients and to 
patients with extra-pulmonary disease.) 
3. Died: a patient who died from any cause during treatment 
4. Failed: a patient who remains or becomes again smear positive at the end of five 
month or later during treatment. Or a patient who was PTB-negative at the beginning and 
turned out smear-positive at the end of the intensive phase. 
5. Defaulted: a patient who has been on treatment for at least four weeks and whose 
treatment was interrupted for 8 or more consecutive weeks. 
 61
6. Transferred out: a patient who started treatment and has been transferred to another 
reporting unit and for whom the treatment outcome is not known at the time of evaluation 
of treatment results. 
8. Successfully treated: a patient who was cured or who completed treatment (13). 
 
   2.11.1.2. Independent variables 
Age: in years 
Sex: male/female 
Marital status: classified into single/married/divorced/widowed 
Level of education: classified into illiterate /writes and reads/primary/secondary/higher 
education 
Stage of HIV: as per the WHO staging of HIV, patients with HIV diagnosed with 
pulmonary TB fall in stage III and would fall in stage IV in the presence of stage IV 
conditions; those with extra pulmonary TB are classified in stage IV. 
Site:  classified into pulmonary/extra-pulmonary  
• Pulmonary case: a patient with tuberculosis disease involving the lung 
parenchyma  
• Extra pulmonary case: a patient with tuberculosis of organs other than the lungs 
(pleura, lymph nodes, abdomen, genitourinary tract, skin, joints, bones, meninges) 
Diagnosis should be based on one culture positive specimen; or histological evidence 
from a biopsy; or strong clinical evidence consistent with active extra pulmonary disease, 
followed by a decision by a clinician to treat with a full course of anti tuberculosis 
therapy. A patient in whom both pulmonary and extra pulmonary tuberculosis had been 
diagnosed is classified as a pulmonary case (13). 
Bacilloscopy: classified into positive, negative 
• Smear positive pulmonary case: a patient with at least two initial sputum smear 
examinations positive for acid fast bacilli(AFB+) , or one sputum examination 
AFB+ and radiographic abnormalities consistent with active pulmonary TB as 
determined by a clinician , or one sputum specimen AFB+ and culture positive for 
MTB 
 62
• Smear negative pulmonary case: a patient with pulmonary tuberculosis not 
meeting the above criteria for smear positive disease. Diagnostic criteria should 
include: at least three sputum smear examinations negative for AFB, and 
radiographic abnormalities consistent with active pulmonary tuberculosis, and no 
response to a course of broad spectrum antibiotics, and a decision by a clinician to 
treat with a full course of anti tuberculosis therapy, or positive culture but three 
initial negative AFB sputum examinations (13). 
CD4 count at time of TB diagnosis: CD4 count in cells per cubic millimeter of blood  
ART regimen: regimens used for free ART service in the health centers 
PCP prophylaxis: whether patient received prophylaxis for PCP while on TB treatment 
or not 
Other concomitant illness: any illness other than TB and HIV that the patient had during 
the treatment of TB 
Side effect: documented side effect to either anti-TB or ART 
 
    2.11.2. Quantitative data analysis 
  Data was cleaned, entered into a computer and analyzed using SPSS version 15. I first 
calculated the proportion of co-infected patients with different socio-demographic 
characteristics (age group, sex, level of education, marital status), site of tuberculosis, 
smear status, ART regimen used, presence or absence of concomitant illness, presence or 
absence of PCP prophylaxis and I calculated the proportion of the different treatment 
outcomes in these patients. I also calculated the rate of defaulting and the rate of 
treatment success. Similarly, I calculated the mean age, and the proportions of HIV 
negative patients with respect to age group, sex, site of TB and bacilloscopy status. I also 
calculated the proportion of the different treatment outcomes in these patients, as well as 
the rates of defaulting and treatment success.  
       
  For univariate analysis, I used the Chi square test to compare group differences and I 
used the Fisher’s exact test when indicated. I also used the Chi square test to compare the 
treatment outcomes among the HIV positive and the HIV negative patients. I used simple 
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logistic regression to estimate odds ratios and confidence intervals.  I used the 
independent sample t test to compare differences between means. 
       
  I performed multiple logistic regression analysis to assess the relative impact of 
predictor variables on the outcome variables and I considered a P value of 0.05 as 
statistically significant. In the multivariate analysis, I chose those factors for which I 
found a P value of less than or equal to 0.25 on univariate analysis and also chose 
variables which I strongly suspected to have association.  
  
2.12. Qualitative data 
    2.12.1. Data collection 
       2.12.1.1. Interviews 
  I begun my interviews after I finished my record reviews, after doing a preliminary 
analysis of the quantitative data so as to see factors that needed to be further explored or 
clarified. For example, one of the findings from the quantitative data that I particularly 
found interesting was that, as opposed to my assumption/hypothesis, there did not seem 
to be a highly significant difference in the rate of default from TB treatment between co-
infected patients on concomitant treatment and HIV negative patients and I believed that 
I needed to explore the reason behind that further. In addition, while conducting the 
quantitative data collection, I managed to establish good contact with the health 
personnel at the health centers, and I also engaged in informal discussions with them, 
which was later important for my qualitative data collection. In addition, I managed to 
conduct some observation at that time, trying to observe factors such as patient- provider 
contacts, the duration of contacts, waiting times for patients…Although observation was 
not a major part of my study, it not only helped me familiarize with the setting, but 
mainly allowed me to formulate further discussion points and allowed me to see some 
points from a different angle than I initially did.   
        
   When I was ready for the interviews, I asked the health professionals to appoint patients 
for me, as per the criteria I discussed earlier. The patients were appointed at their time of 
convenience and I conducted the interviews in clinic offices which were empty at the 
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time of my interviews. Health professionals were also interviewed in their offices at their 
time of convenience. I used an interview guide, and I tried to formulate my questions in a 
way that they were simple and clear and not leading. I did not follow the interview guide 
strictly, and I added and/ or subtracted questions as more interviews were conducted 
since I wanted to discuss further issues that came about in one interview and leave points 
that I thought were already well explored. The interview guide was particularly important 
in helping me check whether I covered all my topics of interest. The interview guide was 
initially pre-tested on two patients, and questions that were poorly understood by patients 
were modified accordingly. 
    
   The interviews lasted mostly from 45 minutes to one hour and were tape recorded, 
except two occasions where patients were uncomfortable with the recording and I had to 
stop the recorder and take note of the interviews. In those cases, although the patients did 
not completely decline the recording, they were asking me questions about the need for 
being recorded, and although I explained again thoroughly about why I was using a tape 
recorder, I gathered that the patients were not completely comfortable with being 
recorded, which I thought would also affect the information they would give me. So, I 
asked them whether it would be better if I did not use the recorder which they said yes to 
and instead, I took a note of the interviews in these cases.  
 
   2.12.1.2. Focus group discussions 
  The two focus groups were conducted towards the end of the data collection, after the 
interviews were completed. While going through individual interviews, I noted points/ 
themes that I thought needed to be further explored or clarified in the focus group 
discussions. I then formulated a set of questions based on that. Those questions were 
brought up for discussion in the focus groups. The focus group discussions lasted 1.5 
hours on average and were tape recorded.   
 
   I chose two health centers, to conduct one focus group in each. That because I believed 
that patients would want to be interviewed in a setting they’re familiar with, that’s the 
health center they’re attending; in addition, since the health centers are located relatively 
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close to the patients’ residence, it would be more convenient to the patients to come there 
than going to another health center; thus, I couldn’t mix and interview patients from all 
three health centers. We fixed a date with the health professionals, and willing patients 
were invited for participation. The focus groups were also conducted in an office in the 
respective health centers which was empty at the time.  
 
  2.12.2. Analysis 
   After conducting the interviews, I transcribed the data as early as possible, so as to be 
able to remember the general context in which the interview was conducted and to make 
use of small notes that I took during the interviews such as for example notes concerning 
patients’ emotions etc. I then translated the interviews from Amharic to English. Focus 
groups were similarly transcribed and translated to English.  
        
   All transcriptions were manually coded. Material about participants’ perceptions about 
TB/HIV, perceived barriers and facilitators of TB treatment adherence were identified 
and coded according to Giorgi’s phenomenological analysis, modified by Malterud (91). 
The analysis followed four steps: reading the entire material to get a sense in the whole; 
identifying units of meaning that represent different aspects of participants’ perceived 
barriers and facilitators to adherence, and coding for these; condensing and summarizing 
the content of each of the coded groups; synthesizing and integrating the insight from the 
condensed meaning units into generalized descriptions and concepts concerning barriers 
and facilitators to TB treatment. 
 
   2.12.3. Inspirations for the study 
 According to my literature review on adherence in general and on adherence to TB 
treatment in particular, and also according to my own pre-understanding, adherence is a 
complex phenomenon, and is influenced by many factors such as patient related factors, 
provider related factors, regimen related factors, socioeconomic factors, cultural factors, 
structural factors. And once we commit into studying adherence, all these factors should 
be looked into, unless one wants to focus on a specific aspect of adherence. 
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  In search of theoretical inspiration for my study, I came across health behavior 
theories/models, and in particular those used in relation to adherence e.g. health belief 
model, theory of reasoned action, health decision model and others (92, 93). These 
theories/models display their own strengths and weaknesses in terms of predicting 
adherence in different contexts, but, as Becker notes, there are many similarities between 
the different theories/models. Based on this, Cummings and his colleagues abstracted 109 
variables from 14 existing models which were given to the major developers of these 
models, to arrange those into conceptually similar categories and six summary categories 
eventually emerged:  
     1. Items pertaining to accessibility of health services, such as the individual’s ability to 
pay for health care and awareness of health services, and availability of health services 
    2. Items dealing with the individual’s attitude toward health care, such as beliefs in the 
benefit of treatment and beliefs about the quality of medical care provided 
    3. Items concerning the threat of illness, such as the individual’s perception of 
symptoms and beliefs about susceptibility to, and consequences of, disease 
    4. Items pertaining to knowledge about disease 
    5. Items dealing with the individual’s social interactions and with social norms and 
social structure 
    6. Items on demographic characteristics (social status, income and education)  
According to Becker, the different categories assume different importance depending on 
the situation (or disease, or regimen) in terms of their effect on adherence (92).    
 
   I have been further inspired by Kleinman, who points out that, in all societies, health 
care activities (illness, the responses to it, individuals experiencing it and treating it, and 
the social institutions relating to it) are more or less interrelated, and need to be studied as 
socially organized responses to disease that constitute a special cultural system: the health 
care system. The health care system includes people’s beliefs and behavior, which are 
governed by cultural rules, and are influenced by particular social institutions (e.g. clinics, 
hospitals, professional associations), social roles (e.g. sick role, healing role), 
interpersonal relationships (doctor-patient, patient-family), interaction settings (e.g. home, 
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doctor’s office), economic and political constraints, and other factors, most notably 
available treatment interventions and type of health problem (94). 
    
  According to Kleinman, health care is defined as a local cultural system which consists 
of three overlapping parts: the popular, professional and folk sectors. The popular sector, 
the largest part of the system, is a matrix containing individual, family, social networks, 
and community beliefs and activities. It is where illness is first defined and health care 
activities initiated. The cognitive and value orientations of the popular culture determine 
when people resort to folk or professional practitioners. After receiving treatment, 
patients go back to the popular sector to evaluate it and decide what to do next. The 
professional sector is comprised of the organized healing professions, that is modern 
scientific medicine and professionalized indigenous medical systems. The folk sector or 
non professional, non bureaucratic sector involves folk medicine which is divided into 
sacred and secular parts. The three sectors interact because patients pass through them. 
The importance that the three parts play differ in different set ups, based on people’s 
beliefs as well as the availability of the professional/folk sector. Kleinman further points 
put that the professional sector usually ignores the presence of the other two sectors as 
elements of health care, resulting for instance in patient physician relationships 
characterized by the physician being thought as being the most knowledgeable and the 
patient being a passive recipient of whatever he is told by the provider(94).  
    
  Knowledge of these different components of the health care system is important with 
regard to adherence because the patient’s medication intake and his adherence to 
treatment will be affected by what happens in these different parts of the health care 
system, the importance that the patient gives to these parts of the health system, the time 
spent within those systems….    
  2.12.4. Reflexivity 
   In her account of challenges associated with qualitative research, Malterud states that: 
“A researcher’s background and position will affect what they choose to investigate, the 
angle of investigation, the methods judged most adequate for this purpose, the findings 
 68
considered most appropriate, and the framing and communication of conclusions.” She 
further discusses that the effect of the researcher should be assessed and shared (95).  
    
   I would describe myself as both an insider and an outsider in this study. An insider, 
because I could understand local cultures and norms and communicate fluently with my 
participants since I’m from Addis-Abeba myself, and an outsider because I’m a public 
health student with background in medicine, which is not shared by my participants. I 
conducted this study as a public health researcher interested in looking at the experiences 
of treatment in patients with co-infection on concomitant treatment, and particularly their 
adherence to TB treatment while receiving concomitant therapy. My background is being 
a medical doctor, with some short previous experience working with HIV patients in 
Addis-Abeba. When I initially presented myself to the staff at the health centers, I 
introduced myself as a master student doing research as part of my thesis, but often times, 
they would ask me what my background is either at the beginning or some time after 
during my data collection. I had prepared an invitation for patients where I explain that I 
am a master student doing research, but, in almost all the cases, I would find out that the 
heath professionals have informed the patients that I’m also a doctor. 
 
  The main reason why I wanted to present myself just as a researcher, and not a medical 
doctor, especially for patients, was that I did not want them to think that I’m a health 
professional trying to assess their medication intake; or that I was in some way part of the 
health system they were being treated in. I believed that would make them doubt the 
confidentiality of the discussions as well as its purpose and would affect the information 
they would be willing to give. That is why I emphasized on my role in the study, 
explained that I was in no way part of the clinics they were treated in and explained that 
their information will be treated with confidentiality and that it would not affect further 
treatment in any way. Often times, patients would ask me questions such as: “Can you 
tell me about the relationship between TB and HIV?”, in which case I would tell them to 
discuss the issue further with their treatment provider and tell them that we can discuss 
the issue a bit at the end of our discussion, which we often did. How the fact that I am a 
doctor affected my results is difficult to tell, but I believe that it can have both a positive 
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and a negative impact: the “normal” patient-doctor relationship that we have in Ethiopia 
is limited in terms of discussions and time spent with patients. Hence, patients are usually 
not used to having detailed conversations with health professionals and hence might find 
it difficult to open up and discuss matters in depth; in addition, patients might withhold 
some information regarding health professionals and the health system due to a belief that 
I might be part of the health system as mentioned above ; on the other hand, it is also 
possible that patients find it motivating that, being a medical doctor, I was interested in 
discussing matters other than their medical conditions. In some instances, I noted some 
comfort unfold in the process of interviews with patients calling me “my daughter”, 
instead of “doctor”, which they said at the beginning.  
    
   Similarly, I tried to establish a good relationship with the health professionals in the 
health centers, during my quantitative data collection as well as afterwards. We had 
informal discussions which were quite informative but also allowed me to explain the 
aim of my study in depth, and familiarize them with the fact that I was there as a 
researcher and not as a health professional, since I had at times the impression that they 
were treating me more as a colleague than as a researcher that was there for the purpose 
of the study. Being from the same profession, I believe, allowed us to easily bond and 
communicate, but, in few instances, I felt that health professionals were trying to give a 
medical perspective to many issues, probably hypothesizing that it is my perspective of 
interest.  
 
   I believe that the fact that I am a female might also have had some impact on the 
relationship I tried to establish with patients, mainly in that it probably allowed the 
female participants to talk more freely than if they had been talking to a male researcher. 
I also felt that my gender did not affect my discussion with male participants, probably 
because my gender was masked by my profession.  
    
   I also came in this study with my own pre-understandings/ perceptions. That was 
largely a result of the literature review that I made on my topic and partly a result of my 
experience working with HIV patients in the past. I therefore started this study with the 
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assumption that several factors would act as barriers to TB treatment in co-infected 
patients on concomitant treatment, more so than what has been found in patients without 
co-infection, because of additional factors such as high pill burden, double stigma…but I 
also believed that many of the factors acting as barriers and facilitators of treatment 
adherence would be similar in all patients. In addition, I also had the assumption that 
there might be misunderstandings about co-infection, and possibly concomitant treatment, 
and was interested in seeing how these affected patients’ treatment. This might have had 
an impact on the way I formulated my questions and the way I perceived patients’ 
responses, but I tried to be aware of the presence of my pre-understandings and not let 
that bias me.    
 
     2.13. Data quality 
Data quality was assured through:  
  1. Thorough review of charts with consultation of the health professionals for unclear 
matters: when I came across points on patient charts I was not clear with, I discussed 
those points with the health professionals in the respective clinics, and they clarified them 
for me. I also told my data collector to do the same.  
  2. Proper training and supervision of my data collector: my data collector and I went 
through few records together at the beginning of the data collection so that he understood 
clearly the points I wanted him to retrieve. I randomly checked few patient charts at the 
end of his data collection to see if the data gathering was done the way I wanted it to be 
done.  
   3. Pre testing of the interview guide: I pretested my interview guide and modified it 
accordingly before using it to interview my patients.   
 
   2.14. Communication of results   
  The results of the study will be presented at the Institute of General Practice and 
Community Medicine, University of Oslo. The results, together with my 
recommendations, will also be submitted to the Addis-Abeba Health Bureau as well as to 
the respective health centers I worked in. An article will also be written and submitted to 
a journal.  
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  Through informal discussions with health professionals in the health centers, I tried to 
point out some facts from my data collection such as the misunderstandings about co-
infection and modes of TB transmission, because I believed that it might create some 
awareness among the health professionals who can act upon it for instance through better 
health education of the patients. 
  
2.15. Ethical considerations 
  Ethical clearance for the study was obtained from the Norwegian Ethics Committee and 
the Ethical Committee of Addis Ababa health bureau.  
      
  Standard coding procedures were applied for the record review so that no patient record 
can be traced back at a later time. 
       
  Patients were recruited through health professionals who provided them with an 
invitation on my behalf. I contacted those who agreed to participate at their time of 
convenience and provided them with all necessary information. That is, I explained again 
that participation is voluntary and that it will not affect treatment, that confidentiality will 
be assured, and I further explained the objectives of the study and I conducted the 
interview/focus group discussion upon their consent. 
      
  Patients who were very sick were excluded from the interviews/focus groups. The 
interviews lasted from 45 minutes to 1 hour and were conducted at the time of 
convenience of the patient, in a room where only I and the participant/s were present. All 
patients were refunded for their transportation costs; all received the same amount of 
money.  
        
   I discussed with patients who had defaulted treatment or who were contemplating it 
about the consequences of defaulting treatment and I tried to convince the defaulters to 
go back to treatment. This was done with confidentiality, and was not discussed with the 
health professionals.  
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Chapter three: Results 
           
We will first present the results of the quantitative component of the study, and then the 
results of the qualitative study. 
 
  3.1. Results of the quantitative study 
 This section will be divided in two parts. In the first part, we will discuss the results of 
the HIV positive cohort. We will then discuss the results of the HIV negative group and 
present the comparisons. 
 
  3.1.1. Results of the HIV positive cohort 
  In this section, we will present the socio-demographic as well as clinical characteristics 
of the study population, and present the TB treatment outcomes. We will then present the 
different factors associated with defaulting from TB treatment, presenting results of both 
univariate and multivariate analysis.  
     
   3.1.1.1. Socio-demographic characteristics of the study population 
  There were a total of 248 TB/HIV co-infected patients who were initiated on TB 
treatment in the inclusion period (July 2006- September 2007) and received concomitant 
treatment .The socio-demographic and clinical characteristics of the study population are 
summarized in table 1. The proportion of females was slightly higher than those of males, 
with a female to male ratio of 1.2:1. The mean age was 34.9± 8.8 SD, with a median age 
of 34.The mean age for females was 32.6 and that for males 37.7.Figure 1 shows the age 
distribution of the cohort.    
     
  We found that 33% of patients were single, 35.5% were married, and 31.5% were either 
divorced or widowed. Sex related significant difference in marital status was observed (p 
= 0.006, see table 2), with 54 out of 136 females(39.7%) being either divorced or 
widowed as compared to 24 out of 112 males(21.4%); and with 40 out of 136 
females(29.4%) being married as compared to 48(42.9%) of males. The rest, that is 
42(30.9%) females and 40(35.7%) males were single. 
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   We found that 20.6% of patients were illiterate (had no education, could not write and 
read). There was a sex related difference in illiteracy status (p= 0.026, see table 2), with 
16 out of 112 males (14.3%) being illiterate versus 35 of 136 females (25.7%).  
     
Table 1.Socio-demographic characteristics of the study population  
 
Characteristic 
 
Group   n (%) 
Sex 
 
 
Male 
Female 
112 (45.2%) 
136 (54.8%) 
Age group 
 
 
16-24 
25-34 
35-44 
45+ 
 
18(7.3%) 
110 (44.3%) 
83 (33.5%) 
37(14.9%) 
Marital status 
 
 
 
Single 
Married 
Divorced or widowed 
82 (33 %) 
88(35.5%) 
78 (31.5%) 
Level of education 
 
 
Illiterate 
Read and write 
Primary 
Secondary 
Higher education 
47(19%) 
4(1.6%) 
77(31%) 
99(39.9%) 
21(8.5%) 
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Figure 1. Age distribution of the study population 
 
Table 2 Comparison of males and females with regard to marital status and 
education 
Variable Male Female Total P value 
Marital status 
    Single 
    Married 
    Divorced and 
widowed 
 
40(35.7%) 
48(42.9%) 
24(21.4%) 
 
42(30.9%) 
40(29.4%) 
54(39.7%) 
 
82(33.1%) 
88(35.5%) 
78(31.5%) 
0.006 
Education 
    Illiterate 
    Literate 
 
16(14.3%) 
96(85.7%) 
 
35(25.7%) 
101(74.3%) 
 
51(20.6%) 
197(79.4%) 
0.026 
 
 
age in years
706050403020 10
Frequency
50 
40 
30 
20 
10 
0
 
 
Mean =34,93
Std. Dev. =8,845
N =248
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3.1.1.2. Clinical characteristics of the study population 
 
  We found that 162 (65.3%) patients had pulmonary TB, the rest having extra pulmonary 
disease. Of those who had pulmonary TB, 106(65.5%) were cases of smear negative TB.  
 
  We also retrieved data on the WHO stage of HIV at time of TB diagnosis. We found 
that 148(59.7%) of patients were in WHO stage III, with the rest (100 patients) falling in 
WHO stage IV of disease. This means that of the 162 patients with pulmonary TB, 14 
had or have had a stage IV defining illness.  
        
  We also recorded the CD4 count at the time of TB treatment initiation and we found that 
151(60.9%) patients had CD4 count between 50 and 200.Those with CD4 less then 50 
were 44(17.7%) and those with CD4 greater than 200 were 53(21.4%). We did not record 
the absolute CD4 number of the patients; hence we were not able to calculate the mean 
CD4 count. 
 
  The continuation phase of anti-TB treatment was the most common time for initiation of 
ART in these patients, with 110(44.4%)  patients started on ART in this phase; followed 
by the intensive phase, with 94(37.9%)  patients initiated on ART in this phase. Forty 
four (17.7%) patients were already on ART when they were diagnosed with TB and 
started on anti-TB treatment. 
 
   Four ART regimens were used in the treatment of these patients. The regimen 
containing stavudine, lamivudine and efavirenz was used in 138(55.6%) patients, 
whereas the regimen containing stavudine, lamivudine, nevirapine and that containing 
combivir, efavirenz were similarly used in 46(18.5%) patients. The rest of the patients, 
18(7.3%) received the regimen containing combivir and nevirapine.  
 
   Concomitant illness (other than TB and HIV) was documented in 119(48%) of patients. 
The three most commonly recorded concomitant illnesses were: diarrhea, candidiasis and 
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upper respiratory tract infection, 18% of the patients had more than one concomitant 
illness. Table 3 summarizes the clinical characteristics of the patients. 
 
   All patients received co-trimoxazole as PCP prophylaxis during anti-TB treatment, with 
three patients who were discontinued from treatment due to drug induced allergy.   
 
   3.1.1.3. Tuberculosis treatment outcomes of the study population 
   The TB treatment outcomes for the 248 patients included were as follows: 148(59.7%) 
completed treatment, 32(12.9%) were cured, 31(12.5%) died, 3(1.2%) failed (all three 
were recorded as being cases of MDR TB); twenty six patients (10.5%) defaulted 
treatment, and 8 patients (3.2%) were transferred out. Fig.3 illustrates the flow of the 
study participants.  
 
   A total of 180 (72.5%) patients either achieved cure or successfully completed 
treatment and the default rate was 10.5%, and it was 10.7% in smear positive cases. Table 
3 summarizes the treatment outcomes.  
 
  Of the 26 patients who defaulted treatment, 19 did so in the continuation phase of TB 
treatment, 7 defaulted in the intensive phase. 
Table 3 Clinical characteristics of the study population  
Characteristic 
 
Group   n (%) 
WHO stage 
 
 
III 
IV 
148(59.7%) 
100 (40.3%) 
Site of illness Pulmonary 
Extra-pulmonary 
 
162(65.3%) 
86(34.7%) 
Bacilloscopy status 
for pulmonary TB 
cases 
 
Positive 
Negative 
56(34.5%) 
106(65.5 %) 
CD4 count 
 
 
 
<50 
50-200 
>200 
44(17.7%) 
151(60.9%) 
53 (21.4%) 
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Time of ART 
initiation  
 
 
Before start of anti-TB 
In intensive phase 
In continuation phase 
44(17.7%) 
94(37.9%) 
110(44.4%) 
ART regimen used Stavudine/lamivudine/nevirapine 
Stavudine/lamivudine/efavirenz 
Combivir/Nevirapine 
Combivir/Efavirenz 
 
46(18.5%) 
138(55.6%) 
18(7.3%) 
46(18.5%) 
Concomitant illness 
 
 
Yes 
No 
119(48%) 
129(52%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Flow chart of study participants 
 
 
 
 
 
 
 
248 patients with TB/HIV co-infection 
treated within the inclusion period 
31 died 
3 failed treatment 
8 were transferred out 
26 defaulted from treatment 180 successfully completed treatment 
(cured + completed) 
 78
Table 3.  Tuberculosis treatment outcomes of the study population   
 
 
Characteristic 
 
Group   n (%) 
Treatment outcomes 
as per WHO criteria 
 
 
Cured 
Completed 
Died 
Failed 
Defaulted 
Transferred out 
32(12.9%) 
148(59.7%) 
31(12.5%) 
3 (1.2%) 
26(10.5%) 
8(3.2%) 
 
Timing of default 
 
Intensive phase 
Continuation phase 
7(26.9%) 
19(73.1%) 
 
 
 
3.1.1.4. Factors associated with defaulting from TB treatment 
  We compared the defaulters against patients who successfully completed treatment 
(taken as proxy of adherence according to the WHO recommendations).Age, sex, 
education, marital status, health facility used, WHO stage of disease, site of illness, 
bacilloscopy status, CD4 count, concomitant illness, time of ART initiation were all 
assessed for association with default using univariate analysis. The analysis showed that 
sex, education and time of ART initiation were associated with defaulting from TB 
treatment; the other variables did not show significant association. Accordingly, male sex 
was significantly associated with defaulting (p= 0.046, OR= 2.36 (95%CI: 0.99-5.57)). 
Education level of primary and below was also found to be significantly associated with 
defaulting (p=0.041,OR=2.45(95%CI:1.01- 5.94)).Similarly, timing of ART initiation 
was also found to be significantly associated with defaulting from treatment (p=0.001). 
The results of the univariate analysis are summarized in table 4. 
 
 
 
 
 
 79
Table 4 Univariate analysis to assess association between socio-economic and clinical 
characteristics and defaulting 
Group Default (%) Successful 
treatment (%) 
OR (C.I) p-value 
Sex  
      Male 
      Female 
 
17(17.5%) 
9 (8.3%) 
 
80 (82.5%) 
100 (91.7%) 
 
2.36 (0.99-5.57) 
 
0.046 
Age 
   16-34 
    35+ 
 
16(14.5%) 
10 (10.4% 
 
94 (85.5%) 
86 (89.6%) 
 
1.46(0.63-3.39) 
 
0.373 
Marital status 
   Married 
   Non married 
 
7(9.1%) 
19(14.7%) 
 
70(9.9%) 
110(85.3%) 
 
0.579(0.231- 1.44) 
0.238 
Health facil. 
    Bole       
    Arada 
    Woreda7 
 
9 (10.7%) 
11 (16.4%) 
6 (10.9%) 
 
75 (89.3%) 
56 (83.6%) 
49 (89.1%) 
 
0.98 (0.32- 2.92) 
1.60 (0.55-4.65) 
 
0.522 
Education 
    Primary and 
below 
    Secondary and 
above 
 
18(17.3%) 
 
8(7.8%) 
 
86(82.7%) 
 
94(92.2%) 
 
2.45(1.01- 5.94) 
0.041 
WHO stage 
     III 
     IV 
 
15 (11.5%) 
11(14.5%) 
 
115 (88.5%) 
65 (85.5%) 
 
0.77(0.33-1.77) 
0.543 
Site of illness 
     Pulmonary 
     Extrapulm. 
 
18(13.3%) 
8 (11.3%) 
 
117(86.7%) 
66(88.7%) 
 
1.21(0.49-2.94) 
 
0.671 
Bacillos. status 
Positive 
Negative 
 
 
6(12%) 
12(13.8% 
 
 
44(88%) 
75(86.2%) 
 
 
0.85(0.29-2.43) 
 
0.765 
 
CD4 count 
  <50 
50-200 
>200 
 
6 (18.8%) 
12(9.7%) 
8(16%) 
 
26(81.3%) 
112(90.3%) 
42(84%) 
 
1.21(0.37-3.88) 
0.56(0.21-1.47) 
 
0.275 
Conc. Illness 
    Yes 
     No 
 
13 (13.1%) 
13 (12.1%) 
 
86 (86.9%) 
94 (87.9%) 
 
1.09(0.48-2.48) 
0.832 
Time of ART init.  
  Before anti-TB 
  Intensive phase 
  Contin. phase 
 
6 (16.7%) 
16(21.6%) 
4 (4.2%) 
 
30(83.3%) 
58(78.4%) 
92(95.8%) 
 
4.60(1.21-17.40) 
6.34(2.02-19.91) 
 
0.001** 
**Fisher’s exact test 
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  We performed multiple regression analysis to assess the possible association of different 
socio-economic and clinical variables with defaulting from treatment. The independent 
variables included in the multiple regression analysis were: sex, level of education, 
marital status, CD4 count, time of ART initiation.  
       
   In multivariate analysis, after simultaneously controlling for potential predictor 
variables, sex, education and timing of ART initiation remained independent factors 
associated with defaulting from treatment.  Table 5 shows the results of the multivariate 
analysis. Males were 2.6 times more likely to default than females AOR= 2.66(95%CI: 
1.05- 6.71), P=0.038. Similarly, initiation of ART in the intensive phase was significantly 
associated with defaulting as compared to ART initiated in the continuation phase, AOR= 
9.68(95%CI: 2.71- 34.57), P= <0.001; the same was true for ART initiated before the 
start of anti-TB as compared to ART started in the continuation phase, AOR= 4.83(95% 
CI:1.19- 19.83), P= 0.025. Education also remained significantly associated with 
defaulting, with those with education level of primary and below having 3.81 times the 
chance of defaulting than those with secondary and above education. AOR= 3.81(95% 
CI:1.38- 10.52), P= 0.009. 
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Table 5 Multivariate analysis of factors associated with defaulting 
 
Variable AOR (CI) P value 
Sex  
     Male 
     Female 
 
2.66(1.05- 6.71) 
 
0.038 
 
Marital status 
   Married 
   Non married 
 
0.51(0.18-1.41) 
 
0.195 
 
 
Level of education 
    Primary and below 
    Secondary and above 
     
 
3.81(1.38- 10.52) 
 
0.009 
CD4 count 
    <50 
     50-200 
     > 200 
 
0.99(0.25-3.81) 
0.33(0.10-1.06) 
 
 
0.993 
0.063 
 
T of ART initiation 
   Before anti-TB  
   Intens. phase 
   Cont. phase 
 
4.83(1.19- 19.83) 
9.68(2.71- 34.57) 
 
 
0.027 
< 0.001 
 
 
3.1.2. Results of the HIV negative group 
 3.1.2.1. Socio-demographic and clinical characteristics of the HIV negative patients 
  Age and sex were the socio-demographic characteristics that were recorded at the time 
of anti-TB initiation in the TB clinics. Of the 248 patients included, 127 (51.2%) were 
females. The ratio of females to males was 1.04/1.00.  
 
  The mean age was 31.83 (+/_14.3) and the median age was 26. The mean age of 
females was 30.53 and that of males was 33.19.  
       
   Pulmonary TB was documented in 144(62.5%) patients, whereas 93 patients (37.5%) 
had extra pulmonary disease. Of those with pulmonary disease, 78(50.3%) were smear 
negative. Table 6 summarizes the baseline characteristics of the patients. 
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 3.1.2.2. TB treatment outcomes 
   We found that 57(23%) of patients achieved cure, 141(56.9%) successfully completed 
treatment, 10(4%) died, 1 patient failed treatment, 20(8.1%) defaulted, 19(7.7%) were 
transferred out. 
 
   Therefore the treatment success rate was 79.9%. Of the 20 patients who defaulted from 
treatment, 3 did so in the intensive phase and 17 in the continuation phase of TB 
treatment. Table 7 summarizes the treatment outcome of the patients. 
 
   We performed univariate analysis to assess factors associated with defaulting and we 
found that sex, age, site of illness and bacilloscopy status were not significantly 
associated with defaulting. Table 8 shows the results of the univariate analysis. 
Table 6 Baseline characteristics of the HIV negative patients  
Characteristic 
 
Group n (%) 
Sex Male  
Female 
121(48.8%) 
127 (51.2%) 
Age group 
 
16-24 
25-34 
35-44 
45+ 
96 (38.7%) 
80 (32.3%) 
27 (10.9%) 
45 (18.1%) 
Site of disease 
 
Pulmonary 
Extra pulmonary 
155 (62.5%) 
93 (37.5%) 
Bacilloscopy status 
 
Positive 
Negative 
77 (49.7%) 
78 (50.3%) 
 
Table 7 Treatment outcomes of the HIV negative  patients 
Treatment outcome 
 
Group   n (%) 
Treatment outcomes 
as per WHO criteria 
 
 
Cured 
Completed 
Died 
Failed 
Defaulted 
Transferred out 
57(23%) 
141(56.9%) 
10(4%) 
1 (0.4%) 
20(8.1%) 
19(7.7%) 
 
Timing of default 
 
Intensive phase 
Continuation phase 
3(15%) 
17(85%) 
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Table 8. Univariate analysis of factors associated with defaulting in the HIV 
negative group 
 
Group Default Successful 
treatment 
   OR (C.I)   P value 
Sex  
      Male 
      Female 
 
11(10.9%) 
9 (7.8%) 
 
90 (89.1%) 
107 (92.2%) 
 
1.45(0.57-3.66) 
 
0.426 
Age 
   16-34 
    35+ 
 
15(9.5%) 
5 (8.5%) 
 
143 (90.5%) 
54 (91.5%) 
 
1.13(0.39-3.26) 
 
0.817 
Site of illn. 
     Pulmonary 
     Extrapulmonary 
 
16(11.2% 
4 (5.4%) 
 
127(88.8%) 
70 (94.6%) 
 
1.21(0.49-2.94) 
 
0.218*
 
Bacillos. status 
Positive 
Negative 
 
9(12.7%) 
7 (9.6%) 
 
62 (87.3%) 
66 (90.4%) 
 
1.36(0.48-3.89) 
 
0.556 
 
* Fisher’s exact test 
 
  3.1.3. Comparison of the HIV positive and HIV negative groups  
       3.1.3.1. Comparison of demographic and clinical characteristics 
   We found that there is a significant difference in the mean age (p=0.004) between the 
two groups. The mean age was 34.9± 8.8 SD in the HIV positive group and 31.83+/_ 
14.3 SD in the HIV negatives with a mean difference of 3.1.  
 
   We performed univariate analysis to compare the HIV positive and the HIV negative 
groups with regard to sex, site of illness and bacilloscopy status. We found that there was 
no significant difference in sex between the two groups (p=0.418). There was also no 
significant difference between the two groups in terms of site of disease (p=0.513). There 
was a significant difference in bacilloscopy status (p=0.009), with 106 out of 162(65.5%) 
patients being smear negative in the HIV positive group versus 78 out of 155(50.3%) 
patients in the HIV negative group. Table 9 summarizes the comparison. 
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Table 9 Comparison of characteristics of HIV positive and negative groups 
Group HIV positive HIV negative OR (C.I) p-value 
Sex  
      Male 
      Female 
 
112(48.1%) 
136(51.7%) 
 
121(51.9%) 
127(48.3%) 
 
0.86(0.60-1.23) 
0.418 
Age(mean) 
 
34.9± 8.8 SD 31.83±14.3SD 0.97(0.96-0.99) 0.004* 
Site of illness 
     Pulmonary 
     Extrapulm 
 
162(51.1%) 
86(48%) 
 
155(48.9%) 
93 (52%) 
 
1.13(0.78-1.63) 
 
0.513 
Bacilloscopy 
     Positive  
     Negative 
 
56(42.1%) 
106(57.6%) 
 
77(57.8%) 
78(42.4%) 
 
0.55(0.35-0.86) 
 
0.009 
* Independent sample t test 
 
    3.1.3.2. Comparison of treatment outcomes between the two groups 
 On univariate analysis, we found that there was no significant difference between the 
two groups (p= 0.261) in TB treatment outcome (default versus treatment success). Table 
10 presents the comparison. 
 
Table 10 Comparison of default between HIV positive and negative groups  
Characteristics HIV positive HIV negative OR(CI)                 P value 
Outcome. 
      Default  
      Successful 
treatment 
 
26 (56.5%) 
180 (47.7%) 
 
 
20 (43.5%) 
197(52.3%) 
 
1.42(0.76-2.63) 
 
0.261 
 
 We performed multiple regression analysis, and, after controlling for age and sex, we 
found that HIV status was not associated with defaulting from TB treatment, AOR= 1.56 
(95% CI: 0.78-3.13), p= 0.201. Table 11 summarizes the results. 
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Table 11. Multivariate analysis to assess factors associated with defaulting 
Variable AOR (CI) P value 
Sex  
     Male 
     Female 
 
1.98(1.04- 3.77) 
 
0.037 
 
Age 
   16-25 
   25-34 
   35-44 
    45+ 
 
1.15 (0.39- 3.39) 
1.26 (0.49- 3.21) 
0.69 (0.23- 2.08) 
 
0.792 
0.622 
0.518 
HIV status 
    Positive 
    Negative 
     
 
1.56(0.78- 3.13) 
 
0.201 
 
3.2. Results of the qualitative study 
   This section presents the results of the qualitative study, which consisted mainly of in-
depth interviews and focus group discussions as previously discussed. But the results 
have also been informed by informal discussions, mainly with health professionals as 
well as observations made during data collection.  
   
  3.2.1. Understandings/ perception about TB, TB/HIV co-infection and concomitant 
treatment 
  Participants conveyed beliefs about various causes for TB. The most common factor 
thought to lead to TB by the majority of patients was bird which literally means cold. 
Someone is thought to be “hit” by bird upon exposure to cold air and mainly blowing 
wind, but also upon exposure to cold water such as being exposed to heavy rain. Bird is 
believed to be a cause of illness, mainly the cause of cough but also frequently the cause 
of any form of muscular pain. Many patients recalled being hit by bird some time before 
they started coughing. A 36 years old male patient explained: 
       
 “I have been in Italy, and there is a lot of snow there, and that is what 
predisposed me to TB. It is very cold there, and we wear a lot of clothes, but 
sometimes, mainly when you are working, you forget to wear good clothes, and 
the bird hits you. That is why I had TB. Bird had gone into my body.” 
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  In addition, when heat and cold “collide”, the effect is thought to be worse than when 
one is “hit” just by cold; and also when the wind blows through an open window or door, 
mainly when those are partially open, since it increases the “force” of the wind. In this 
case, people would say: “draft metagn”, which means I was hit by draft. A 35 years old 
female patient said: 
“The main reason for TB is bird. Bird that diagonally goes into your body, from 
your sides and back, predisposes to TB, which is known. If some people are in the 
car and they are exposed to bird, and also sometimes because of the rain, that also 
gets into the body. Also, when cold and heat collide, that leads to TB also.”   
 
  My personal illustrative example related to the phenomenon of bird is the experiences I 
frequently encounter while trying to open the windows of taxis which are a common 
means of transportation in Addis-Abeba. Many times, that would upset most of the 
people in the taxi who would close the windows immediately, claiming that they do not 
want to be hit by bird, no matter how warm it is or how many people are in the taxi. This 
is a reflection of how bird as a cause of illness is deep rooted in people’s mind in Ethiopia.  
 
  All health professionals are aware of this belief and some even refer to it as “the bird 
theory.” They explain that cough and chest conditions such as pneumonia and TB are 
believed to be due to bird by many patients. A clinical nurse shared his experience at the 
TB clinic: 
 
“Over 90% of people, including educated people, are saying it is bird, and then 
they say I started coughing, and it changed into TB. Even educated people say 
that. When we tell them, cover your mouth, they get confused. And they say, but 
we have been closing all windows, so then should our brother, our mother, get 
tested? And it is even a problem here where we work. They go and close the door, 
and we explain, we leave it open because of this reason.” 
  
  Other factors mentioned by patients as being potential causes of TB included: 
excessive sun exposure, exposure to mud, smoking, alcohol, khat, and inadequate food 
intake. Excessive sun exposure is also believed to predispose to illness in Ethiopia, 
although to a lesser extent than bird. In that case, people would say “mitch metagn”, 
meaning I was hit by mitch. Some patients had a belief that smoking, alcohol, and khat 
 87
are causes of TB from what they hear in the community and for some, this was reinforced 
by health professionals’ prohibition of intake of these substances upon diagnosis of TB 
and initiation of treatment. Hence, these were perceived by some patients as being 
causative factors for TB, as well as aggravating factors, with patients mentioning that 
smoking, chewing khat and drinking alcohol would lead a patient to get TB but that they 
would also result in a delay in getting cured once the patient is started on treatment. The 
lung was thought of as a fragile organ, through which these substances pass, a “recipient 
of everything going into the body” as described by one patient. Lack of food or 
consumption of poor quality food was also thought to lead to TB by many, who believed 
that it was the reason for them to get TB. A 46 years old male patient said:  
             
             “Q. Do you know what causes TB? 
 Bird, sun, excess mud. That is what predisposed me to TB. In addition, you know, 
there is the problem of food. If you do not eat good food, you get TB. And for me, 
my life is from hand to mouth, so, sometimes, you have to eat beans and sleep.” 
 
 Hence, TB was perceived by many as being a disease of poverty, resulting from a lack of 
food or consumption of poor quality food; and a body harmed by lack of food as well as 
hard work was thought to be more easily predisposed to bird. In addition, work that starts 
very early in the morning and work that results in excessive exposure to sun were thought 
to be particularly responsible for the development of TB.  
 
  Few patients mentioned bacteria as a cause of TB .Some patients mentioned 
transmission from another person through breathing. Sharing eating and drinking objects 
was also mentioned by some as a mode of transmission of TB, and patients or their 
families had separated their eating utensils after the diagnosis of TB. Two patients said 
that TB could be sexually transmitted since health professionals were telling them not to 
have sex during treatment. Health professionals who were asked why they were 
prohibiting sex during TB treatment said that it was because of the fear that patients 
would lose too much energy. A clinical nurse explained:  
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“Yes, we tell them to stop having sex. You know, you lose energy with sex, and 
for a sick person, it is not good. If you don’t tell them, they just do it without 
limits; you have to be strict with that.”   
      
  Other patients also believed that different origins and modes of transmission exist for 
TB, some getting it from bird, others from other people, that being the reason why some 
patients are told to cover their mouth at the clinic, and others not, and said that the drugs 
were also different depending on which type of TB one has.  
 
 A large majority of patients was aware that there is a relationship between TB and HIV. 
A common belief was that TB could change into HIV, if TB had been left untreated for 
long. Therefore, bird was most frequently thought to be the cause of TB which, due to 
delay in treatment, could transform into HIV. Some patients said that they had heard 
about this in the media. A 36 years old male patient explains how the TB changed into 
HIV in his case:  
 
 “Sometimes, when we sit and wait for the nurse to give us the drugs, we talk with     
the other patients. And they also have HIV, many have.” 
            Q. Why do you think many people with TB also have HIV? 
I think it is because we do not come to the clinic early. Me, I was at home 
thinking I will get better. The cough, for me, started more than two months back. 
But I was drinking hot drinks at home; I thought I will get better. So I came to the 
clinic here late. I think that is why I got the HIV. The samba (TB) changed to HIV. 
If I came to the clinic earlier, maybe it would not have changed on me.” 
 
  Health professionals are aware of this belief among patients. A clinical nurse shared her 
experience while doing provider induced counseling and treatment (PICT). 
 
 “When I was doing PICT, I had patients who thought that you would have HIV if 
you have TB, they thought of the two diseases as being similar. At the beginning, 
when you tell them that a person with HIV would get TB because of the 
immunity…, they say, Ah! It’s like that? Because they thought HIV follows TB, 
that they will get it after the TB. There is a patient who recently told me that the 
TB changed on him.”  
 
  For the majority of these patients, two types of TB exist: the TB that is related to HIV 
(or can change to HIV), and the one that is not related to HIV. Most knew patients who 
had had TB even before HIV came to be known, or know patients with TB who got 
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treated and cured and did not have HIV even in the HIV era. The most common type of 
TB was believed to be the HIV related TB. Some estimated the HIV related TB to 
constitute as high as 90% of TB.  
     
 Other patients explained the relationship between the two illnesses as being a result of a 
weakness in the body due to HIV, which leads to a susceptibility to other diseases such as 
TB, but also diarrhea, skin lesions…  
   
 According to some health professionals, many patients who came to the TB clinic 
usually assumed that they could have HIV infection, before getting the test. Families 
accompanying patients were also strongly suspicious of the possibility of the patient 
having HIV when diagnosed with TB. A clinical nurse explained his experience: 
 
 “Even their (patients’) families, when you ask them, what is the problem, they 
would say: it is the new disease (HIV).And sometimes, you ask them, did he get 
tested? And they say, well, he has TB, so he has HIV. Sometimes even when we 
tell them they are negative, they do not trust us.” 
     
 Some health professionals associated the high acceptability of HIV counseling and 
testing (which some quantified as being between 70-90%) in the TB clinics to the fact 
that there was a widespread belief among patients that TB and HIV were associated, 
hence patients usually were prepared for the possibility of an HIV diagnosis. A clinical 
nurse said: 
     
 “What they (patients) say when we ask them to get tested for HIV is that, 
normally, they come here thinking that they have HIV. There is this thinking 
among people. They conclude that, if you have TB, you have HIV. When you ask 
them to get tested, they do not take it as a problem, I am positive, so it is no 
problem, is their attitude.”  
 
  Some patients also said that, if TB comes back (relapses), then that can be an indication 
of HIV infection. One of these patients was told by her relatives that, if her TB came 
back, then she might have the “new disease”, and was advised by them to get tested.  
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  In contrast to the knowledge about TB, all of the patients in the study knew that HIV 
could be transmitted sexually and through blood containing sharp objects, such as needles. 
Most had gotten the information from mass media, such as radio and TV. But, when 
asked about the relationship between TB and HIV, many, as mentioned above would 
respond that TB could change into HIV; hence classifying HIV into two, the one that is 
transmitted from others through sexual intercourse and exposure to sharp objects, and the 
other that had followed TB. A 50 years old female patient said: 
 
“It is from TB that I got this disease (HIV). They go side to side. The samba (TB) 
went into HIV. Initially, I was saying, can it be from sharp objects, but it is not. It 
is the samba that changed. I am a menekussie (equivalent to a nun in the orthodox 
religion); I did not go to a man.” 
 
3.2.2. Perception of the effect of HIV on TB and its treatment  
   One of my interests was to see how treatment and prognosis are perceived by patients 
with co-infection, how they see the impact of HIV on their TB treatment. Most patients 
agreed that TB could be cured, even in the presence of HIV infection; but a majority 
thought that it was more difficult to be cured when one was an HIV infected TB patient 
as compared to an HIV negative person. “Weakening” of the body by HIV was a reason 
mentioned by some, who explained that the two diseases support each other to weaken 
the body. Hence, the body was thought to need more time to heal. For others, if TB has 
turned into HIV, it was thought to be very difficult to treat. A 20 years old female patient 
explains the prognosis:   
 
 “If you have HIV, TB can be strong, because they can collide. If you do not have 
HIV, TB will disappear soon. Like any person who has TB, you take your drug, 
and it disappears, but if you have HIV, it will not disappear fast.” 
 
 Two patients also mentioned that the reason why TB treatment was given for 8 months is 
because it is more difficult to achieve cure in an HIV positive person, and said that 
treatment is shorter for HIV negative patients. 
 
  Patients had a divided opinion on which disease they thought was the most severe 
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when comparing TB and HIV. Some mentioned HIV as being the most serious illness 
that they feared more, while others thought that TB was more dangerous. Some patients 
also mentioned being told by health professionals that TB would kill them before HIV 
does if they don’t take their TB treatment properly; which motivated them take their TB 
treatment properly. This perception of severity affected partially the decision about which 
drug to discontinue for those patients who decided to take one of the drugs and stop the 
other. A 36 years old male defaulter explains the reason why he decided to discontinue 
his anti-TB drugs and continue with the ART after experiencing side effects aggravated 
by lack of food: 
 
“I said: I have to take at least one of the drugs. I wanted to survive. I said, I will 
take the HIV drugs only. 
Q. Why the HIV drugs and not the TB drugs? 
The HIV, it will kill you, it will kill you fast. Samba (TB) will not kill me if I take 
these drugs (ARV drugs) properly.” 
 
   Many patients tended to classify patients with TB as having HIV or not based on their 
weight status and their strength. Particular emphasis was put on weight, with thin patients 
classified as being HIV positive; but patients who came to the clinics looking weak or 
supported by others were also considered as being HIV positive by the patients. 
Darkening of the skin was also commonly mentioned by patients as a sign of HIV 
infection. A 46 years old male patient explains: 
 
 “When I see other patients in the TB clinic who do not have HIV, they are 
stronger than me.  
 Q. How do you know they are HIV negative? 
 I told you, they are strong. They are not like me. The two illnesses, they support 
each other to weaken you. Oh! Your body, your mind, they all get weak!” 
 
 
  3.2.3. Hope and survival 
  
    A word that almost every patient used when I asked about how they felt upon 
diagnosis of co-infection is hope. Loss of hope was a common feeling that patients had 
upon diagnosis of TB followed by HIV or vice versa, despite many being suspicious of a 
possibility of being co-infected, when first diagnosed with TB. For many, the initial 
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period of diagnosis of co-infection was therefore a very tough period. Many also feared 
not being able to survive two illnesses. For some, it also meant that their illness had 
progressed and had changed into HIV, which was associated with a worse prognosis.           
    
  Two patients had also contemplated committing suicide. A 30 years old male defaulter 
explains: 
 
“When they told me I had TB, I started waiting for my death. When you already 
have HIV, it is the worst illness you can have. You don’t want it to happen to 
anyone. And, if, together, they tell you that you have TB, what can you do? You 
lose hope. I was waiting for my death. Two diseases, it is the work of Satan! I did 
not think I will live after that. I was upset. That is why, after some time, I stopped 
the drugs and I was told I have to take them again.” 
 
 
  For some patients, counseling received from health professionals played a critical role in 
managing this difficult period. These patients explained how health professionals gave 
them hope by informing them that there is treatment and that they can be cured if they 
take their treatment properly. Those who had told to their families about their illness 
similarly received support and encouragement from them, which was of critical 
importance at this stage. A 46 years old male patient explained: 
 
“It gives you hope to talk to the staff at the clinic. They tell you that you can live, 
that the drugs will help you. They say that we can come if there is a problem, this 
gives you hope.” 
 
  Another factor that most health professionals believed helped patients gain hope was the 
change that they saw on other patients, who were initially critically ill and later showed 
improvement. According to health professionals, that helped patients believe in the 
efficacy of treatment and hence gave them hope for themselves. A medical doctor states: 
 
 “I think many patients are encouraged to come because they see critically ill 
patients with co-infection who have improved. That gives them a lot of hope.” 
 
  Many patients indeed explained that seeing very sick patients who were coming 
supported improve and come to the clinic by themselves gave them hope, and encouraged 
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them with their treatments. After this initial period of loss of hope, most patients 
explained how an eagerness to survive was the driving force for their medication intake. 
Since prognosis was adversely perceived by patients in the presence of concomitant 
illness, many patients believed in the necessity to take drugs properly, in order to survive. 
A 50 years old female patient explained:  
 
“You have to take what the doctors give you, you can not stop that. You can only 
survive if you take the drugs. Two diseases, it will kill you at once, your body can 
not support that. We are different from those who have TB only.” 
 
   All health professionals interviewed in this study believed that adherence to TB 
treatment in co-infected patients on concomitant treatment is not poorer than the 
adherence in HIV negative patients, as might be expected. These health professionals 
explained that, despite a pill burden that many patients are afraid of and other factors 
such as higher occurrence of side effects in these patients, their adhere to TB treatment 
was similar to HIV negative patients, in general. The most common reason given by 
health professionals was the eagerness by patients to survive, mainly a result of adverse 
perception of prognosis and severity of illness. They explained that many patients 
believed that TB might be very severe and might be lethal in their case because of the 
HIV infection, and hence usually adhere well to TB treatment, even after subjective 
symptomatic improvement.  
 
  Some health professionals also explained that most patients with TB co-infected with 
HIV had more severe symptoms at the beginning of treatment than the HIV negative ones, 
hence showed more eagerness to take drugs and see improvement. Health professionals 
also explained that, unlike some HIV negative patients, most co-infected patients did not 
tend to discontinue treatment once they improve because of fear of getting the initial 
severe symptoms again.  
     
   Another factor that both patients and health professionals pointed to was the importance 
to take TB treatment and show improvement, mainly improvement in weight, in order to 
avoid the suspicion of HIV infection by others. Some patients explained how weight gain 
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after few weeks of treatment for TB had helped them avoid the risk of being suspected of 
having HIV. One health professional, a clinical nurse, shared his experience: 
 
“HIV positive patients, as compared to the HIV negatives, I think have a better 
adherence. Unless they have things that are out of control, for example 
economically, those who can not have food; they have an eagerness to survive. 
Even the feedbacks we get from them are pleasant. They tell us: I got better, I 
gained weight. Because they think that if you are positive, you will not get cured, 
you will not gain weight. When they gain weight, they are very happy. That is a 
good thing. The negatives, some of them, once they finish the intensive phase, 
they say: what if I stop now? The positives, once they start improving, they gain 
hope.” 
      
   Another factor also believed to encourage TB treatment intake was the fact that TB is 
known to be a curable disease, unlike HIV, as it has been known in the community for 
long, as illustrated in a quote from a medical doctor: 
 
“Patients respect TB treatment, usually they default because of lack of supporter, 
or because they are forced to come every day. When you tell a patient that he has 
TB, he wants to start treatment, when you ask them to start ART, they want to 
wait. They have seen many patients get treated and survive TB in the community, 
but for the HIV, they are told that they will not be cured, so they say, why should 
I? You need more extensive counseling for the ART.”    
 
3.2.4. Perceived impacts of concomitant treatment 
  Pill burden: 
   Most patients mentioned pill burden as being one of the major challenges of 
concomitant treatment. In addition to anti-TB drugs and ARV drugs, patients were also 
taking co-trimoxazole for PCP prophylaxis; and some in addition had to take drugs for 
other illnesses that they had. For many, the higher the number of pills, the bigger the 
damage it could cause to the body, and the higher the difficulty to tolerate the drugs. The 
amount and quality of food needed and the degree of possible side effects were also 
believed to be proportional to the drugs taken. Many worried, especially initially, about 
whether they would be able to tolerate so many pills. Patients used expressions such as 
“becoming a drug bag”, and “becoming a pharmacy” to describe the pill burden. A 36 
years old male patient said: 
 95
 
“Swallowing so many drugs, it was very difficult. I was scared that it would harm 
my body. Drugs can harm you if they are too many, but I wanted to survive.”  
 
   According to some patients, the burden was also bringing mix up of drugs and also 
resulted in drugs being forgotten. The majority of health professionals also agree that the 
most important factor affecting patients during concomitant treatment is the pill burden, 
and think of it as the most important potential challenge against adherence. They explain 
that a frequent fear among patients when asked to take concomitant treatment is the pill 
burden. A medical doctor shared her experience:  
  
 “When they think about pill burden, they day, can I tolerate this, won’t this kill 
me? Taking many pills is perceived as lethal by some. Patients worry a lot about 
whether their body will be able to handle so many pills every day.” 
 
  Some patients also said that decreasing the number of drugs to be taken would facilitate 
medication intake. 
    
  In addition, patients also found it difficult to comply with the daily schedules of drug 
intake, which included swallowing TB drugs, followed by HIV drugs, and then 
cotrimoxazole, since it resulted in forgetfulness, as well as inconvenience with the daily 
routines. A female focus group participant explained: 
 
“I had to take the TB drugs at 2 (8 a.m), the HIV drugs at 3 (9 a.m), and the 
bactrim at 7 (1 p.m.). Sometimes, there were other pills that they were giving me 
for other illnesses I had. That was very difficult, especially when you are 
working.”  
 
Side effects:  
  Side effects were experienced by many patients, mainly at the beginning of anti-TB 
treatment or upon initiation of concomitant treatment. Examples of side effects 
experienced by patients included: generalized body weakness, burning of the stomach, 
turning of the head, headache, bad dreams, rash, vomiting…The most common side 
effect patients had was burning of the stomach or gastritis. For many, stomach burning 
was believed to be due to excessive pills, aggravated with intake of inadequate or poor 
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quality meal. Generalized body weakness was also mentioned as a side effect by many 
patients, at times with inability to perform daily tasks.  
A 46 years old male patient explains:  
 
           Q. Tell me about your experience taking the TB drugs and the HIV drugs? 
It was very difficult. Very difficult. My body was weak; I could not keep my  
balance. Sometimes, everything was blurred, I lost my balance. It is a lot of drugs. 
It burns your stomach. Oh god! You burn! My stomach was out of use. The 
suffering! Don’t think it is easy! It is not!”  
              
  Two of the patients interviewed had temporarily discontinued anti-TB drugs because of 
hepatotoxicity, and were subsequently reinitiated on treatment. 
      
   In addition to the actually experienced side effects, patients were also worried about 
side effects they hear about in the community. Some patients relied on the information 
circulating in the community about drug side effects. The commonest belief being that 
drugs can be dangerous and cause severe side effects if one is HIV positive, because the 
body is too weak to support drugs. Some had heard about relatives or neighbors who died 
due to drug side effects because their body was too weak due to HIV. ARV drugs in 
particular were thought of as being very toxic.  
 
  Many patients also believed that the drugs can “collide” (collision is what is referred to 
as drug-drug interaction in the biomedical term), and that they were worried about that 
when they started treatment. Some attributed their symptoms to the “collision” of the 
drugs. Drug collision is a common worry for patients in Ethiopia, and people usually ask 
about collision of drugs whenever offered two or more drugs together. Collision could be 
between drugs or between drugs and food.     
     
  One patient said he would prefer injections to drugs because it will not burn the stomach. 
Another person recommended the use of one pill including all drugs (fixed dose 
combination of ART were recently introduced, were not used by the patients in the study 
at the time).  
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  Another common “side effect” mentioned by patients was a gain of appetite/excessive 
hunger, as discussed earlier, which was creating problems for those who could not afford 
to buy food. 
    
  Health professionals said that patients hear stories about side effects from other patients 
and also from the community at large and tend to get scared. A clinical nurse explains: 
 
 “…the problem that I also commonly hear, they (patients) hear people’s stories, 
like the side effects that other people treated had, and what if it turns my head, 
what if I vomit etc, they say. And some people also say that if a TB patient who is 
weak is started on ART, then he might die. There is a fear of death.”  
 
  According to many patients, health professionals had not warned them about potential 
side effects of TB drugs; nor did they know that these could be managed.  
 
  Worsening of symptoms was also one factor that was frustrating to some patients, 
mainly in the initial period of treatment. These patients recall feeling better before 
initiation of treatment than after starting the drugs. An example is a 40 years old female 
defaulter who discontinued her TB drugs and continued with the ARV drugs. She said 
she is happy and made the right decision because her symptoms (weakness, loss of 
appetite, turning of the head) were worse than before treatment and that they improved 
after she stopped the TB drugs and that she was now able to work. 
 
Lack of food: 
   Lack of food was a common problem that patients mentioned. The majority of patients 
in the study believed that high protein diet such as milk, eggs, were needed while on TB 
treatment, and, for some even more so while on concomitant ART treatment. Many had 
been informed by health professionals to consume such diets upon initiation of treatment, 
but many also knew about the need for such diet from before, from what they heard in the 
community, where it is believed that milk, eggs…are important for someone with TB. 
Not being able to afford good food therefore created a problem for some patients who 
believed that the drugs would harm their body because of this. Others also mentioned that 
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it would be better not to take the drugs than to take them on an empty stomach. A 36 
years old male patient explains: 
 
 “When you have two diseases, you need good food. Otherwise, it will harm your 
body. It is better not to take the drugs. The drugs alone, it might kill you.”  
 
  Many patients also experienced a gain in appetite some time after initiation of TB 
treatment, and were unable to get food to satisfy their appetite. That resulted in a fear of 
having the body harmed because food was believed to be important to avoid damage to 
the stomach when one uses so many pills; and the lack of food was also thought to affect 
the healing process, the cure from the TB. 
      
   Health professionals recognized the problem of food as being common, especially with 
the gain in appetite related to improvement. A 32 years old clinical nurse explained: 
  
            “Q. How about the problem of food among patients? 
That is a very serious problem for many of our patients. They almost want to kill 
us wanting help. They come here asking for help from NGOs. They say that 
especially TB drugs increase appetite. They feel hungry after they start feeling 
well a bit, and food becomes a problem.” 
 
  Dietary advises regarding consumption of high protein diet were very often given by 
health professionals; patients being told to consume foods such as milk and eggs. In 
addition, some health professionals also explained that the media also emphasizes the use 
of adequate food in the presence of HIV infection, which makes patients give excessive 
attention to the problem of lack of food, and also to the quality of food consumed. For 
two of the defaulters in this study, lack of food was a major factor in their decision to 
stop treatment.  
 
   Patients who had dietary restrictions because of the ART drugs that they take such as 
for example efavirenz with which consumption of high fat diet is contraindicated faced 
even more dilemmas. A 36 years old patient who also had to temporarily discontinue 
treatment because of hepatotoxicity explains the challenges he faced. 
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“TB needs food with fat, and liver does not want that, it is a tragedy for us, 
because you do not know what to do. Even the life prolonging drug does not want 
fatty food. That is if you can afford fatty meals anyways. ” 
 
  Many patients said that provision of food by the health center or NGOs would facilitate 
medication intake, when asked about what could be done to facilitate medication intake 
for patients in their situation. 
 
3.2.5. The role of the health personnel  
  The majority of patients in the study were happy about the way the health professionals 
received them at the health centers, many were grateful for the affection that they 
received from health professionals. Many were encouraged to come for treatment because 
health professionals were receiving them with a “good face”, and were encouraging them 
to finish their treatment. A 20 years old female patient said: 
 
 “They (health professionals) were very good to me. They are like friends, did you 
not see? Since my head was not good, they were giving me the drugs in a certain 
way, in a bag, so that I know which drug to take when, they translated it in 
Amharic for me. They gave me a watch, they helped me a lot. They were like 
relatives. I have no words to thank them. I am standing today because of them. 
They told me what drugs to take at what time.” 
 
  The support was mainly important in the initial months of treatment, when loss of hope 
and difficulties to tolerate drugs made medication intake difficult for patients. For many, 
support from health professionals and counseling they received were major factors that 
assisted them with their decision to embark on treatment. 
 
 But, when asked about whether they received information about their illnesses, or about 
the drugs and potential side effects, many patients replied that they did not get any 
information; except the few who had asked the health professionals the information they 
needed. Those who asked questions tended to be more educated in general. A male focus 
group participant said: 
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 “Someone might be kind, that is not because they always give me drugs, they 
should also ask me what did it cause on you, is it good, did it cause any harm, 
what can we do for you? They have to say this. I come, they see my card, I get my 
drugs, and I go. That’s all. Someone might be good naturally, but when I see from 
profession, it is less than I expected.” 
 
 Some felt the need to ask questions about their treatment and the drug but did not do so 
because they believed the health professionals did not have the time to reply to 
everyone’s question.  
  
 Most patients explained that they were given information about factors such as the need 
to consume high protein diet, the need to abstain from sex, alcohol and smoking; they 
were also told that it is important to finish treatment. But many patients were not told 
about the relationship between TB and HIV, about why they needed TB treatment for 
eight months, about the side effects that the drugs can have, and about concomitant 
therapy since many were worried about “drug collision” during concomitant treatment. 
The information received had at times been misunderstood by some patients, whom, for 
instance, were taking sex as a route of transmission of TB because all they were told by 
the health professional was that they should abstain from sex while on treatment. In 
addition, not knowing about possible drug side effects and the fact that they could be 
managed adversely affected treatment of patients who thought that stopping treatment 
would be the solution to their problem. Some patients were also taking drugs for eight 
months without understanding the need for this long treatment. Much of the knowledge 
that patients have came from the community, from other patients at the health centers and 
mainly from the media.   
     
  Health professionals agree that patient-provider relationship is very important in the 
treatment of patients. They also explain that lack of time with high burden at the clinics 
has made it difficult for them to spend adequate time with their patients and provide all 
the necessary information. Most also believe that adherence counseling is critical for 
patients, mainly for co-infected patients on concomitant treatment because of dual long 
term treatment, and that patients should be evaluated for their drug intake every time they 
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come for a visit, but that it has been difficult to do so because of the time constraints. A 
clinical nurse said: 
 
“What we do is not enough. The counseling should be done every time they come 
for treatment. Sometimes, we just give them their drug and send them home. You 
do not even know if they are taking the drugs the right way.” 
     
   During my interviews, I found patients who told me that health professionals informed 
them they had bird and initiated them on TB treatment. I raised the issue to health 
professionals and I found two kinds of explanations. Some said that some health 
professionals were telling to patients that they have bird because they themselves 
believed it could be a cause of illness or because it is easy for patients to understand. 
Another health professional, a medical doctor from one of the clinics, had another 
opinion: 
 
 “You know what happens? When patients talk about bird to physicians, 
physicians do not respond. They simply say, ok, we will give you drugs, and you 
will improve. Then, they think you agree with the bird theory. That is because 
there is no time to explain.” 
 
  Many health professionals also mentioned the media as a good channel of 
communication for patients that can be used to give health education on TB as well as on 
co-infection. All said that TB has been neglected in general in health education 
campaigns and in the media as compared to the increased attention that HIV has received. 
One of the observations I myself made during my fieldwork was that many of the posters 
used in the clinics were posters about HIV, even the ones posted outside the TB offices. 
Information pamphlets were also available in the HIV clinics, with information both 
about the illness and about ARV treatment, but were non existent in the TB clinics. The 
knowledge that participants in the study had about TB as compared to HIV was also 
reflective of this; many patients having had the chance to learn about HIV from the media, 
but also from the community, where awareness about HIV, I believe, is higher than that 
of TB, in view of the information available.  
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  Health professionals gave examples such as the media’s role in promoting bed nets for 
malaria, after which a high use of bed nets and a decrease in malaria incidence were 
noted. But many health professionals also said that the information provided on the media 
should be made clear, understandable by the general population and more sensitive; and 
explained that information provided by the media has at times been the source of 
misunderstandings and that the media is partly responsible for the stigma that is present 
against HIV. 
  
3.2.6. Coming to the clinic every day: the challenges of DOT 
  The absolute majority of the patients found DOT with daily supervision of treatment for 
the first two months a very difficult task to accomplish, as well as an expensive routine. 
The initial phase of treatment during which daily supervision is made was the phase when 
many patients were ill and weak, which meant that they often had to come to the clinic 
accompanied by their families. That made patients feel guilty because they were putting 
pressure on their close ones who were already struggling to make their living.  In addition 
to physical weakness, transport costs were also a problem for many patients. In addition 
to the daily visits to the TB clinic, patient also had to attend the HIV clinics on a twice 
monthly or on a monthly basis and at times more frequently. A 35 years old female 
patient shared her experience with DOT. 
 
 “Q.What was it like coming to the clinic every day? 
 It is very difficult. TB, you know, it is a very difficult disease. You have no 
energy; even your dreams are bad. The transport money, it is too much, I finished 
a lot of money. People helped me, thanks god. I had to come every day for 
injections. I tell you the truth, there was a time when I had to sell my jewellery: 
my rings, my necklace, everything. I had to run here without even eating 
breakfast.” 
 
  Few patients also explained that they were taking the drugs for their own good, and 
therefore needed to be given the drugs. A male focus group participant said: 
 
 “I come for treatment for myself. As long as it is for myself, I do not have to 
come every day. I am the one who will be harmed; I am the one trying to survive, 
they can give me my drugs.”  
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  A health professional shared his experience with patients who felt that they were treated 
like kids and were thought of as being non- knowledgeable by being given the drugs 
daily at the health centers:  
     
“There are some (patients) who say: swallow, don’t swallow, do you think I am a 
kid? I know for myself. Do you think you are the only ones with knowledge? 
Some even throw the drugs at us and leave.”  
 
  Another concern for some patients was that coming to the clinic every morning was 
exposing them to the cold and aggravating their cough.  
    All health professionals agreed that DOT with daily supervision is a difficult task for 
most of their patients. Most believed that DOT is too rigid, and some stated that 
something has to be done to modify the daily schedule into a better schedule for patients, 
like a once weekly or twice monthly schedule. Some were giving drugs for patients for 3-
4 days when these reported a strong argument for not being able to come to the clinic 
every day. A medical doctor explained: 
 
“I know there is a problem with individualizing treatment, but, if there is a 
committed health worker, it can be good. As long as the reason for DOT is 
properly told and as long as side effects etc. are properly monitored every time the 
patient comes, and if they assess what happened when the patient did not come, 
then I think it is ok to have some flexibility. We are doing this with ART where 
they say adherence should be more than 95%, right? Why not trust them with 
anti-TB as well? Asking a patient to come every day, it is a punishment.”   
       
 Others were very strict with DOT and said that the patient has to come every day if he is 
to achieve cure, and said that they were worried about drug resistance. They expressed 
past experiences where flexibility had resulted in improper drug intake. A clinical nurse 
explained: 
 
 “I have some bad experience. I gave a patient drug for a few days because he was   
telling me he can not come. He divided the drugs and started swallowing them 
BID (twice a day). I had that experience.”  
 
  It was many patients’ opinion that drugs need to be given to families at least when the 
patient is too ill to come. Health professionals had a divided opinion on this issue as well. 
Some said that they would give drugs to relatives if the patient is very sick. Others said it 
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is very important as well as a guideline from the NTLCP that the drugs have to be 
swallowed in front of the health professional and showed more rigidity in this regard. 
     
   Another challenge faced by some patients in the health center was the necessity to bring 
one person responsible for their treatment. The national guideline says that, before 
starting anti-TB treatment, every patient has to bring one person who will be responsible 
for his/her treatment and who might be contacted by the health system if the patient does 
not come for treatment. Some patients chose not to reveal their diagnosis of TB for 
anyone for fear of being stigmatized, and hence found it difficult to find someone 
responsible for their treatment. In addition, according to some health professionals, the 
necessity of being treated within the health centers in their neighborhood was a problem 
for some patients, who did not want to be seen by people from their neighborhood. A 
clinical nurse shared her experience:  
 
 “I also had a patient who was cyanosed, critical, and he survived by miracle. He 
said: Let me die if you give me treatment in my sub city, because he did not want 
to be seen by neighbors.” 
 
  Health professionals also faced the dilemma of accepting patients without I.D. cards, 
since the rule is that all patients coming to the health centers for TB treatment should 
have an ID card. A health officer shared her experience: 
 
“Once I accepted two patients with no ID card because they said they could not 
get one. One finished, the other disappeared. I didn’t have anything to find him. 
The reason for the ID card is to have an address to trace them when they default. 
It is such patients on the street with no address who are the reasons for increasing 
default.”  
 
   Another major challenge associated with DOT was the impact on patients’ income 
because of the obligation to attend the clinic every day; which was either not suitable 
with their working schedule, mainly for those who had no fixed jobs and had to go out 
early in the morning and look for a job; or was creating problem with employers for those 
with fixed jobs, mainly those who did not want to convey their diagnosis. That created a 
major stress on some patients, for whom TB treatment for the first two months equated 
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with loss of income. Most patients thought that the waiting time at the TB clinics is 
reasonable, although some patients reported long waiting hours after being told that they 
had to wait for drugs to arrive or because the health professionals were not there.  
 
3.2.7. Collaboration between TB and HIV clinics 
    One of the recommendations in the WHO’s policy for collaborative TB/HIV activities 
is that “TB and HIV programs should ensure a continuum of care and support for people 
living with HIV, during and after TB treatment” (6).  
       
    In two of the health centers I worked in, TB and HIV clinics were co-located. In the 
third clinic, construction of co-located TB and HIV clinics was finished as I was about to 
complete my field work and work was initiated there.  But, although physically co-
located, the two clinics were operating independently. A patient was managed as a TB 
patient in the TB clinics and as an HIV patient in the HIV clinics. In the TB clinics, the 
health workers were often times not aware of which patients are co-infected and on 
concomitant treatment, unless they see the patients and remember their HIV status since 
they were the ones who screened most of them; or unless they referred to the PICT 
register. In one of the health centers, information on HIV status and on whether the 
patient was on ART or not was filled out in the remarks column of the TB register. Again, 
two weeks before I was about to finish my field work, a new TB register was introduced, 
and in this new register, in addition to the information present on the old register, other 
columns were added which show whether the patient was tested for HIV, his HIV status, 
and whether s/he was initiated on ART or not, and when the ART was initiated.     
      
  Most of the health professionals also underlined the fact that collaboration has been 
poor. Some said that the staff in both clinics should be trained in both TB and HIV 
management to be able to respond to patients’ needs. In addition, health professionals 
also worried that the information provided at the two clinics might sometimes conflict, 
and create confusion among patients. A clinical nurse explained:  
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 “The problem is, there is TB, there is HIV, and those of us at the TB and at the 
ART clinic, we are not getting along well. We might have a common patient, and 
if the information we give is different, for example if we have a patient with low 
CD4, with extra pulmonary TB, and if I say he should start ART in two weeks 
and if they tell him to come back in two months, whom should he trust?” 
 
 
 Some health professionals also expressed concern that patients might get lost from either 
clinic without health professionals in the other clinic knowing about it. A clinical nurse in 
the TB clinic said: 
 
“Sometimes, the patient comes from the ART clinic, when I ask him here if he is 
having a follow up, he might say yes without going there, so patients might get 
lost like that. The collaboration is not good.” 
 
   In addition to provision of training in both TB and HIV management for staff in the TB 
and HIV clinics, health professionals also suggested that regular joint meetings should be 
arranged to discuss matters related to common patients. 
 
  One health professional expressed concern that, although the collaboration is important, 
it could also potentially increase the stigma against TB because of the association with 
HIV. She explained that it could adversely affect mainly those patients who only have TB 
and come for treatment at the TB clinics, and explained that collaboration should be done 
with caution.  
 
   Some patients similarly felt that the collaboration between the two clinics is weak, and 
said that more should be done to arrange patient appointments on similar days at the two 
clinics, to avoid repeated visits at the clinic to take anti-TB and ART medications. A 
male focus group participant shared his experience whereby a drug that should have been 
changed because of his anti-TB treatment was not changed at the HIV clinic since his 
intake of anti-TB was temporarily forgotten at the HIV clinic.  
 
3.2.8. The influence of stigma  
  The majority of patients said that TB would predispose to stigma. For most, stigma was 
mainly due to the fact that people associated TB with HIV. This resulted in many patients 
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hiding their diagnosis of TB or only disclosing it to selected people, mostly close families. 
A male focus group participant told: 
 
 “Before, I knew a lot of people with TB who did not have HIV. But now, if you 
say you have TB, people will take it to HIV. Me, even when I take these TB drugs, 
I don’t tell to anyone.”  
      
   Fear of stigma not only lead to patients not telling about their illnesses but also made 
seeking TB treatment in their catchments areas difficult as mentioned earlier, for fear of 
being identified by neighbors there. Many health professionals had experienced that with 
their patients. Since the regulations of the NTLCP are that a patient should be treated for 
TB within his/her catchment area, health professionals face problems with patients 
wanting to be treated in their clinics without belonging to the catchment area( recently, 
similar problems have lead the HIV clinics to accept patients coming from any area to be 
started on ART).  A 36 years old male patient told: 
 
“I don’t want neighbors to see me here (TB clinic). So, if I have an appointment 
in the morning, I hide and I come late, and I lie to the nurses here; I tell them that 
I had something else to do. Everyone comes early in the morning, so I come at 
around 5 hour (11 a.m.). One day, I saw this girl from my neighborhood here; I 
was sitting outside and waiting. I wished the earth would open and swallow me. I 
know she would spread the gossip. I tried to hide behind the man sitting next to 
me. I don’t think she saw me.” 
 
   Patients said that HIV associated stigma is what they feared the most. Many had seen 
other HIV patients suffering from stigma in their communities, and said the same might 
happen to them. Some shared their personal experiences of HIV related stigma which 
included being pointed at in their neighborhoods, neighbors gossiping about their illness 
behind their backs, exclusion from social events, and mainly events that needed their 
active participation such as group meal preparations for funerals. Many patients believed 
that, although both TB and HIV are stigmatized, there is more stigma attached to HIV. 
Many also said that HIV related stigma has improved from before; an opinion also shared 
by all health professionals, many of whom believed that is mainly because of the 
introduction of ART making the community believe of HIV as a chronic manageable 
illness, and not a lethal untreatable illness like before. Some patients said that they were 
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hiding the HIV, and not the TB. A health officer shared her experience telling that some 
patients had asked her to mention only the TB and not the HIV on their medical 
certificates, which they usually bring to their employers.   
    
  Many patients said that, in addition to the cough, losing weight was the factor that made 
them vulnerable to stigma the most, because that indicated that they also have HIV; many 
patients themselves believed that a patient with TB only has a higher weight and is 
“stronger” than them. Gaining weight quickly was therefore important; to avoid suspicion 
of HIV, and patients who managed to gain weight early would be very satisfied and 
encouraged to continue treatment, according to many health professionals. In Ethiopia, 
weight gain is seen as a sign of health, and someone who has gained weight would be 
complimented and would be told that he looks healthy. Weight loss is often perceived as 
a sign of illness, and excessive weight loss in a patient who is sick is frequently 
associated with HIV infection, since the advent of the HIV epidemic.   
 
  Some patients said that the media was responsible for the fact that people were 
automatically associating TB and HIV. Health professionals also share this opinion. 
A clinical nurse explained:  
 
“You know, the people they interview on the media usually say: I had TB and I 
was told I am (HIV) positive. So for those who listen to it that would mean: ok, if 
there is TB, there is HIV.”  
 
 
  Those patients who knew that TB was transmitted to others through the respiratory route 
also said that people were staying away from them because they were afraid they would 
catch TB from them. One patient reported leaving her sister’s house and moving out of 
Addis-Abeba because the people who were renting the house to her sister were afraid of 
her cough and told her sister that they were afraid to get diseased as well. Another patient 
explained that she had lost her business and gone into absolute poverty after customers 
buying tella (traditional alcoholic drink) that she sold to make her living stopped coming 
for fear of catching her illness, since she had been coughing for long. Some patients also 
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had experiences with families isolating their eating and drinking utensils, as well as not 
allowing them to do works at home, such as cooking. Others reported not being invited 
by neighbors for coffee, people not visiting them anymore, and people “changing” on 
them. 
  
 3.2.9. Social support  
  Social support was a very important factor affecting many patients’ treatment. In this 
study, as mentioned earlier, most of the participants told about their illnesses, both TB 
and HIV, only to close families. Few had informed others about their diagnosis of TB but 
had hidden their HIV status, for fear of being stigmatized. The support of close families 
was therefore the only available support for most patients; and was found to be critically 
important for many. Many had been seriously ill when initiated on treatment and had 
been in need of someone to accompany them for treatment. Families also provided food 
and transportation money for patients, since some had no income and others had to stop 
working for some time. Families were also a source of encouragement and comfort when 
patients had lost hope. Many said that they were able to take their drugs and survive 
because of the support that they received from their families. A female focus group 
participant explained:  
 
“My family members supported me a lot. They encouraged me. After the TB, 
when they found the HIV, I wanted to die. I did not want to live. But my families, 
especially my brothers and sisters, they said: you are not the only one. Look, 
many people have this. And we are in a good period, you can get treated for your 
TB and your HIV and live a life like anyone else. It is because of them that I am 
alive today.” 
        
  Health professionals also believed that patients who had family support and come to the 
clinics accompanied are usually the ones who successfully complete their treatment, and 
explained that having some form of social support was vital for adherence.  
     
  But getting support, mainly financial, made some patients think about themselves as a 
“burden” to their family; one of the defaulters in the study said that one of the reasons 
why he discontinued treatment was that he did not want to be a burden to his families 
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who had to provide transportation money during DOT as well as the food he needed to 
tolerate treatment. A 20 years old female patient who had to give up her work as a 
commercial sex worker after being diagnosed with TB then HIV similarly explained: 
 
 “There are many problems in one person’s life. You do not have transport money. 
A sick person has many expenses. You do not have any money on you. They 
should give you (TB drugs) for one month. To ask money from your family, it is a 
burden. I feel sad, because I was the one giving money to my families. Now, I ask 
for money, even for transport money. That damages you.”  
 
  Some patients appreciated the help of local NGOs providing them with cereals, and at 
times transport money, while others complained about not receiving enough support from 
these NGOs or that the support had been delayed. According to health professionals, 
local NGOs have been providing food and also transport money for treatment for HIV 
patients. Some also provided home treatment supporters for patients who had no family 
support; others provided money for patients to start small scale businesses to support 
themselves. Although the support was found to be important by health professionals, it 
had also resulted in high expectations from patients who needed health professionals to 
refer them to such NGOs, even when no specific contact existed with the NGOs and the 
health centers.   
 
 3.2.10. The economic burden 
  This has been already discussed in large in the previous sections, and will be briefly 
presented here. Costs related to the illnesses, both TB and HIV were both direct and 
indirect. Many patients had had long periods of illness and had consulted different health 
facilities, mainly private, before the start of their treatment. Many had been supported 
financially by their families starting from this initial phase. A 50 years old female patient 
who had been ill repeatedly before getting diagnosed with TB and HIV explained: 
 
“I used to rent a place and work, and when I was working, I got sick. I finished all 
the money I had saved on the hospitals. I was going to private clinics and getting 
treated and treated and treated.”  
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  In addition to costs related to treatment, some patients had to stop working because of 
severe illness. That meant that they needed financial support from families for their 
treatment costs as well as daily costs. Although TB and HIV treatments are provided for 
free for these patients, transport costs, especially during daily treatment, were too 
expensive for many patients. A 30 years old male patient explained:  
 
“It is difficult. You have to come every day. We come here in the morning and 
take our drugs. And you also have to come for the life prolonging drugs. The 
transportation money, it is not easy for some of us. Sometimes, I walk, if it is not 
too much sun. But sometimes, you get tired, so you have to take the taxi. It is not 
little money.”  
     As discussed earlier, the routines of DOT had cost some patients their jobs and 
compromised others’ because of the necessity to be present to the clinic every day for 
two months. This made patients require support from others which in turn resulted in a 
feeling of guilt; because of the burden they felt they imposed on their families.  
  
   In addition, the need for high protein food also imposed problem for some of those who 
could not afford it, since they believed that they needed that type of food to improve from 
the TB and since many also believed in the importance of gaining weight as a sign of 
improvement and as a protection against suspicion of HIV and resultant stigmatization.   
      
3.2.11. Right timing of ART treatment 
  In general, the recommendation is that, in a co-infected patient, the priority is given to 
the treatment of TB no matter how advanced the HIV is and to start ART according to 
clinical conditions and CD4 counts; and WHO’s recommendation on the initiation of 
ART in co-infected patients is what is used in the clinics. There is room for 
individualization in this case. Those patients already on ART upon diagnosis of TB are 
continued with their ART and initiated on anti-TB treatment.  
 
  Many patients in this study had been initiated on ART upon completion of the intensive 
phase, some were initiated in the intensive phase, and few were already on ART when 
anti-TB was initiated. In general, patients faced a dilemma when confronted with the 
possibility of starting concomitant treatment versus delaying ART. Many were worried 
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about pill burden and about whether their body was ready to tolerate the drugs, in 
addition, for some, other problems such as the lack of food…existed; but patients were 
also concerned about the risks of delaying ART. But most who were told by health 
professionals that ART will be delayed until the end of the intensive phase said they took 
the recommendation positively, since their fear and doubts of starting concomitant 
treatment immediately were for them confirmed by health professionals usually telling 
them that it is better to delay the ART. Some also believed that their body would “adapt” 
to the TB drugs with time, and it will make it easier for them to tolerate the ART.     
    
   According to health professionals, some patients are eager to start their ART after 
initiation of anti-TB but that many also fear factors such as pill burden…and want to 
delay treatment. A medical doctor explained: 
 
“Some patients do not agree to start the ART before they finish the anti-TB, for 
fear of pill burden, and you can not force them, even when you know that they 
need it. I’m talking about patients with very low CD4 counts, stage IV patients.” 
    
  Health professionals said that adherence counseling is provided and the patient’s 
readiness to start concomitant treatment assessed before initiating the ART. Some health 
professionals also said that they were able to see the adherence to cotrimoxazole 
preventive therapy during this time and have some assessment of what the adherence 
would be like in these patients.  
     
 Three of the patients who defaulted treatment in this study said that initiation of ART in 
the intensive phase of their TB treatment had been too difficult, and that they were unable 
to tolerate treatment, and claimed that delaying the ART would have been better in their 
cases. A 36 years old male defaulter who had discontinued both anti-TB and ART drugs 
explained: 
 
 “It is better to take one drug and then the other drug. Your stomach can tolerate it. 
Your body can tolerate it. Together, it is too much. That is why I stopped my 
drugs.” 
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 3.2.12. The impact of gender 
    It was quite difficult to assess the impact of gender on treatment in patients because 
questions regarding this subject were usually poorly understood by patients, most 
probably because they did not think of gender as a factor that affects treatment.  
    
   Some health professionals said that, in general, women tend to adhere better to TB 
treatment than males, although females usually tend to be more delayed in seeking 
treatment than males. The reasons given included the ability of women to tolerate stress 
more, an opinion shared by two health professionals. A clinical nurse explained: 
           “Females follow treatment better. 
Q. Why do you think that is the case? 
I think females feel more responsible. And they tolerate problems more. Often, 
men do not want much stress. Even when there is discordant (HIV) result, if the 
man is negative, they usually disappear. When the female is negative, she is with 
him till the end. I think females have the ability to go face to face with problems.” 
   
   One difference that was apparent in my data was that there was a difference in what 
worried males and females more when it came to consequences associated with TB 
treatment, together with ART. For men, what was worrisome was the fact that either the 
illness or the necessity to constantly attend treatment would affect their jobs, and hence 
would affect their income; and this affects them as well as families who were usually 
dependent on them. For females, the biggest worry was what would happen to their 
siblings if they were not able to survive their illness. Females also worried more about 
what the community or neighbors thought about their illnesses, and reported incidences 
like not being invited by neighbors for coffee as being a serious problem associated with 
their illness; whereas males tended to be less worried about such incidences, and usually 
did not tell their illnesses and claimed that they decided to live their own life. Hence, it 
would seem like males usually confronted the challenge of having to make a choice 
between treatment and their income; and might be forced to discontinue treatment if the 
loss of income would appear to have more immediate consequences than the illness itself, 
mainly once they get some symptomatic relief. Females also have big burdens on their 
shoulders, and, even though more females were unemployed than men, the daily routines 
at home were also very demanding. But it seemed like females managed to make time for 
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their treatment while at the same time managing their daily routines. Showing quick 
improvement might also be very important to women in order to be able to have their 
place in their social sphere and avoid stigma, since socializing with neighbors and 
attending ceremonies such as coffee ceremonies were very important to women.  
   
 3.2.13. Alternative treatments:  
  Use of traditional medicine was not a common practice among participants in this study. 
Many patients simply preferred modern treatment over traditional medicine, and others 
explained that the reason for not consulting traditional healers was related to the fact that 
they did not trust traditional healers present currently; they believed that “good” 
traditional healers were not here anymore, and doubted that the now available traditional 
healers had the right plants for treatment. A real traditional healer would be an old man 
who has inherited the practice from his father and would in turn train his male siblings to 
do so. Thus, according to some participants, there was a belief that those elder traditional 
healers are no longer present and now, some people are just trying to call themselves 
traditional healers, and thus, they were unable to trust them. A 36 years old male patient 
said:  
 
“These days, who will go to the traditional healers? Who will trust them? How do 
you know what plants they give you? I do not go to the traditional healers.” 
 
  Other patients said that traditional medicine is good for some illnesses such as almaz 
balechira (local term for herpes zoster), for which they had consulted a traditional healer 
but said that modern treatment is better in the case of TB. Health professionals also 
believed that the use of traditional medicine for TB was not a common practice among 
their patients from their experience, but said that patients consulted traditional healers for 
illnesses like almaz balechira, as was also mentioned by patients. Almaz balechira 
(herpes zoster) is a common illness in HIV positive individuals and is due to reactivation 
of the varicella zoster virus secondary to immunosuppression. There is a very common 
belief in the community that it is due to an insect bite and the best treatment is believed to 
be traditional medicine, and a famous traditional healer in Addis-Abeba, Ato Mammo, is 
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particularly known for treating this illness; in recent times, the association between 
herpes zoster and HIV is becoming known to the community, which many patients in this 
study were also aware of.  
 
  Many patients had used home remedies such as warm drinks and at times herbs, hoping 
that the cough, which was frequently thought to be due to bird, would subside. Patients 
eventually consulted health services, at times visiting several private clinics before being 
diagnosed with TB and coming to the health centers or coming to the health centers 
because they could not afford the private clinics any more.  
   
   Some patients had also taken tsebel, which is holy water that is commonly used by 
followers of the Orthodox Church, sometimes also by people who are not followers of the 
orthodox religion. Holy water can be collected from the churches and taken at home but 
can also be used in the churches and given by priests, with different durations of 
“healing”, most frequently 7, 14 or 21 days. All of the patients who used holy water in 
this study used it together with their anti-TB and ARV drugs; except one defaulter who 
had given up all his treatments and gone for holy water, hoping to get cure. Another 
patient was contemplating giving up her ART and go for holy water. In the past, it used 
to be more common that one either takes drugs or tsebel and not both. With the advent of 
the HIV epidemic, and the introduction of ART, priests in the Orthodox Church are 
preaching concomitant intake of tsebel and drugs, since many patients were abandoning 
their ART treatment and going for holy water. 
 
   Health professional also confirmed that, although few patients abandon treatment to go 
for holy water, more and more patients are now using tsebel and drugs together. They 
also explain that more patients abandon tsebel over ART than those who abandon it over 
anti-TB. That can be explained by how the disease causations are understood by patients. 
In this study, some patients referred to HIV as being a disease of Satan that can not be 
cured, even with drug intake. Others thought of HIV as a punishment from god for sinful 
behavior. Hence, religious healing such as the use of tsebel might be considered more 
important for HIV than for TB for some patients. Few patients also thought of having 
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both TB and HIV as being a punishment from god, and took both their drugs and tsebel 
together. A 46 years old male patient said: 
 
“Two diseases at the same time! I felt cursed! I said: God, why? Why two 
diseases for me? (He stops conversation for a while) But you can’t change God’s 
will, so I had to accept it. What was expected from me was to take my drugs 
properly; the rest is up to god.” 
 
  Another patient, 30 years old male, similarly said: 
“I said, why do two diseases come on me? I am sad that I am like a bad person. 
Given two diseases. I am not a bad person; you can ask anyone about me, they 
will not tell you I am a bad person.”    
    
   Few patients also said that tsebel is not good for TB because it is cold and can worsen 
the cough, but said that it is good for HIV.  
 “…samba (TB) doesn’t like cold. Tsebel is cold. You should use warm things. 
You can’t use tsebel when your lung is diseased.”  
 
3.2.14. Cases  
  Next are two cases I selected because I believed they show the interplay of factors 
involved in the experiences of drug intake of patients. The first case involves a patient 
who defaulted treatment, whereas the second case involves a patient with successful 
treatment completion. 
 
Case 1   
  This is a story of a 57 year old ex- soldier currently earning his living by repairing 
umbrellas. He has an irregular income, which he can not estimate, and he says that he just 
waits for work and for people to come. He can write and read, but has no formal 
education. He is divorced, and has two children who live in a neighboring country with 
their mother. When he starts coughing, he ignores his symptoms for a while and 
continues to work, until people who noticed his non stopping cough tell him to consult a 
treatment center. He does so after a while, and is provided free treatment at the health 
center, where, after chest x-ray and sputum exams are conducted, he got diagnosed with 
TB. At the same time, the health professionals ask him whether he would volunteer to 
have an HIV test, which he agrees to, and he is told that he also has HIV. He was then 
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started on anti-TB and, few days later (he does not remember exactly how many days), he 
was told that he needs to start ARV drugs, and is started on those.  
 
 When I ask him about what he thinks causes TB, he tells me that it comes from another 
person through respiration, because the health professionals had told him to cover his 
mouth not to transmit the disease to others. He says that HIV can be transmitted sexually, 
as well as through razors and through blood. But he also believes that TB turns into HIV, 
and insisted he heard that information on the radio. 
 
  He takes his medications for some time, but starts experiencing very unusual feelings, 
such as hallucinations, feelings of upset, and he was unable to sleep at night. (Efavirenz, 
an ARV drug that is used in the health centers, and which he also received has central 
nervous system side effects such as confusion, abnormal thinking, impaired concentration, 
abnormal dreams, insomnia, and hallucinations). In addition, he experiences hunger, but 
was not able to afford the food he needs. He recalls his experience at the time by telling 
me that the medications made him very upset; that he would ask himself what type of 
drug it is that would give such symptoms; and that, although he was getting hungry, life 
was too expensive for him to get the food he needed. He decides to continue with his 
drugs, thinking about the situation and his health; “I wanted to live, so I continued the 
drugs”, he says. He receives support from health professionals who encourage him to 
take his drugs and even provide him with left over foods. His families are not around and 
he chose not to tell about his illnesses to anyone, so health professionals are the major 
source of support for him; he sometimes gets left over food from people on the street. He 
says that health professionals were more supportive than he expected.  
 
  When I ask him about whether he believed TB is curable, and how the presence of HIV 
affects that, he tells me that if the TB had changed into HIV, then the body is weaker, and 
because of his age and because of his “bad life” also, it might be difficult for him to get 
cured but not impossible; but says that he has seen people who came supported by others 
improve and come for treatment by themselves. 
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  Despite the difficulties with side effects and lack of food, he continues his treatments for 
three months until he decides to abandon all treatments. He elaborates on his experience 
and his decision to stop treatment by telling me that he started the drugs with few days 
difference hoping to save himself from suffering but that he was unable to know which 
drug gave him the problems and that he lost energy, and was unable to get food although 
health professionals had advised him not to take medications without taking food. He 
tells me he was eating beans soaked in water until he abandoned his medications. He says 
that the nightmares were frequent and that he had an urge to run away at night and that, 
since he had no one beside him, he got scared and stopped all drugs. 
   
  Although very grateful for the support he received from health professionals, he 
expresses his frustration about being compared to other patients by them. He tells me that 
it is not right to compare him with someone with good life and give him the same advises. 
He says that, if his life was full, he would also have taken the drugs properly. He says 
that he does not want to be a burden to anyone, and that he has made his decision to stop 
his treatments. 
 
   He also tells me that, provision of food would facilitate medication intake for people in 
his situation, and also says that taking one drug followed by another can lead to 
forgetfulness and thinks that health professionals should do something about that. The 
other comment he gave was that he believed that in his case, he should have been given 
the TB drugs first, since those are only taken for some time only, and then the HIV drugs, 
and not both together, like he was offered. When I ask him whether the health 
professionals had explained the need for ART and asked his opinion on starting ART, he 
tells me that he was told that the illness had harmed his inside and that he needed the 
drugs and agreed to it because he wanted to survive. 
 
Case 2 
   This case involves a 36 years old male patient, single, with secondary education. He 
works as a broker, a private job that is flexible in terms of time schedule, and which 
provides him with a fair income.  
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    He has been treated for TB before; and relapsed shortly after completing his TB 
treatment. He had taken six weeks of anti-TB treatment for the second time when I 
interviewed him. The first time, he was started on ART two months after he started his 
anti-TB treatment. He recalls being sick for a long time, with body weakness, pain at 
multiple joints and swelling of the legs followed by cough. He then went to a private 
clinic where he was told that he needed to be tested for HIV, and, in addition, sputum 
exam and x-ray were taken. The HIV test became positive, and he was also diagnosed 
with TB and was told that his lungs were damaged and that he also had water around the 
lungs. He explains that this period was very difficult for him and that he even 
contemplated committing suicide, he says that life was dark at the time.  
     
   He says that he had been exposed to bird and that it was the reason why he got TB, but 
says that, after he came to the clinic, he was informed that HIV predisposed him to TB 
even more. When I ask him why HIV predisposes to TB, he explains that getting one 
disease harms the body and makes one more liable to get another disease. 
 
  He shares his experience of concomitant drug intake the first time he received TB 
treatment by telling me that the pills were burning his stomach and were too many and 
that he decided to discontinue the bactrim (co-trimoxazole).When I ask him why he chose 
to stop bactrim, he tells me that some patients stop bactrim and nothing happens and says 
that even the doctors are not so strict with that drug. When I ask him: How about the anti-
TB? He replies that he was told by the nurse that TB will kill him before HIV does if he 
does not take the drugs properly. 
 
   He also tells me that he was receiving injections (streptomycin) for the first two months 
which were painful because his body was harmed by the cold. He is then diagnosed with 
a problem on the liver after blood tests are conducted, and he temporarily discontinues 
his drugs which are subsequently restarted. He explains that his illnesses (TB and HIV) 
need good food, and that he tried to consume those during treatment, although the 
restrictions of fat because of his ART drug and also because of his liver problems made it 
difficult to take high fat foods. He explains the importance of gaining weight and 
 120
showing improvement in order to avoid stigma by telling me that these days, when 
someone starts losing weight and his face starts to change, everyone suspects that he has 
HIV. He says that he only told about his illnesses to his close families, and says that, if he 
tells to others, everyone will be pointing fingers at him. He says that he was lucky 
because he quickly gained weight after starting his anti-TB treatment, and that people 
thought “he was ok”.  
 
  He also tells me, even though he was afraid that the pills will harm his body because 
they were too many, and even though he was experiencing side effects, he continued his 
drugs because he wanted to live; and that he was told by the health professional that with 
HIV, TB will kill him if he doesn’t take his drugs. 
 
  When I ask him what else encouraged him to finish treatment, he explains that the help 
from health professionals was very important, and says that if it wasn’t for them, he 
might have been dead by now; and he appreciates that they were giving him answers to 
his questions. He also says that it is difficult to come to the clinic every day for the first 
two months. He says that it is mainly difficult for patients who are very sick, because the 
bird is forceful in the morning and can harm them. He also believes that it might be 
difficult for those who have regular work, because they might be late for work, but, in his 
case, his work schedule is flexible. He also says that the waiting time is not so long in the 
clinics. 
    
   When I ask him why he thinks he got TB again, he tells me that, the last time, he has 
taken his medications properly, that he did not skip even a single dose, and says that he 
thinks he got TB again because he was hit by bird again. He believes that TB is curable, 
even in the presence of HIV, although it might be more difficult. He says that mainly for 
those who are weak, who come supported by relatives, it might be more difficult to get 
cured and says he is lucky, because he is not like the others, because his body is “full”. 
  
   When I ask him to compare his TB medication intake this time and the first time, he 
tells me that, since his body has now adapted to the HIV treatment, it is easier for him to 
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tolerate the drugs this time but he says that drugs always collide and fears that he might 
have problems like the first time (liver problem).  
   These cases shows how a number of factors act as barriers and facilitators of treatment 
adherence in one patient and how the end result is just a matter of which factors 
predominate and are given importance by the patient to tilt the decision in a certain 
direction. 
    
  Fig .2 presents a summary of the findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Summary of factors influencing Tuberculosis treatment adherence in TB/HIV co-
infected patients on concomitant treatment in Addis-Abeba, Ethiopia 
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                             Chapter four: Discussion and recommendations 
We will hereunder present the discussion of important findings. We will divide the 
discussion into discussion of qualitative and quantitative findings to point out the 
important results emerging from the two components of our study and to allow for a clear 
flow in the discussion that would make it easier for the reader to follow; but this division 
does not represent a strict demarcation, since the discussions in many instances are 
complimentary. Fig.2 presents a summary of the findings. We will first discuss the 
strengths, weaknesses and limitations of our study, which are to be taken into account 
when looking at our results.  
4.1. Strengths, weaknesses and limitations of the study 
Weaknesses 
  1. The quantitative study adopted a retrospective design, and hence, was subject to 
weaknesses inherent to retrospective studies namely that some important information 
such as for e.g. occupation, side effects was not available in the charts we reviewed 
  2. Since the default rate was lower than what we initially anticipated, we had a small 
number of cases (defaulters), hence making the power of the quantitative study weak, 
which has to be taken into consideration when looking at the results of the quantitative 
study 
  3. One point that can be considered as a weakness in qualitative studies is the effect of 
our pre-understanding, background and position which can make us ask leading questions 
as well as make us put emphasis on the parts that we think are important, and our study is 
not devoid of this weakness; but we tried to at least partially account for that through the 
discussion of reflexivity 
 
Strengths 
  1. A major strength of our study is the fact that we used a combination of both  
quantitative and qualitative methods and we also combined in depth interviews and focus 
group discussions in our qualitative study, with triangulation that made the understanding 
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of adherence, which is a complex phenomenon, better. The triangulation in our study also 
allowed us to validate our results. 
  2. We had both patients’ and health workers’ perspectives of treatment barriers and 
facilitators 
   
Limitations 
  We conducted our study in Addis-Abeba, in three Health Centers providing both free 
anti-TB and ART. Our results can therefore be generalized only to patients attending 
treatment in similar treatment centers in Addis-Abeba. Our findings can not be 
generalized to other patients, for example those receiving ART treatment in hospitals or 
private clinics and getting TB treatment in the Health Centers, since these may have their 
specific barriers and facilitators, for example those related to attending two treatment 
centers located at different places and linked by cross-referrals. Although we only 
included a total of 29 patients and 9 health professionals in our qualitative study, we 
believe that we have, through our sampling, achieved adequate diversity among 
participants; in addition, the results we found were largely similar and repeatable among 
participants and therefore we believe that our results are transferable to similar contexts, 
that is Health Centers providing free anti-TB and ARV treatment in Addis-Abeba, as 
mentioned above.  
4.2. Discussion of quantitative findings 
  The discussion in this section is that of the HIV positive patients, who are our major 
group of interest, but a discussion of the differences in treatment outcomes with the HIV 
negative patients will be presented. 
4.2.1. Distribution of the patients with TB/HIV co-infection  
  In these patients, the proportion of females exceeded that of males (1.2/1.00). The mean 
age for females was 5 years lower than that of males. These findings go in parallel with 
the data on HIV from Ethiopia which shows that HIV prevalence among females is 
higher than that of males, with 55% of PLWHA being females in 2005; and which also 
shows that in the age group between 15-29, there are more females living with 
HIV/AIDS than males, whereas in the age group 30 and above, there are more males 
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living with HIV/AIDS than females (18). One of the reasons thought to be fuelling the 
HIV epidemic in Africa is actually the fact that the disease spreads in different age 
groups, mainly because of old males having sexual contacts with young females, 
vulnerable because of socio-economic and cultural reasons; as well as with females of 
their own age groups. Studies have found that the notification rates of TB among males 
are usually higher than those among females, in particular in developing countries, 
mainly due to socio-economic and cultural factors limiting women’s access to treatment 
(96,97).Although we found more females than males in this study, it does not necessarily 
reflect an adequate access to health care by females, but might be a reflection of the fact 
that females are affected more than males by HIV; although it is also possible that the 
gender differences in accessing treatment do not exist in this set up( and that seems to be 
supported by the fact that we also found slightly more females than males among the HIV 
negative patients(F/M: 1.04/1.00)).  
 
  The mean age was 34.9 years; both HIV and TB affect largely the economically 
productive age groups, with 75% of cases of TB occurring in the economically 
productive age group (15-54 years) (13). More females were illiterate as compared to 
males and this follows the national and regional trends (6). 
 4.2.2. Clinical characteristics of the TB/HIV co-infected patients 
  We found that 65.3% of patients had pulmonary TB, the rest having extra pulmonary 
disease. Of those who had pulmonary TB, a high proportion (65.5%) were cases of smear 
negative TB. This is expected since HIV is known to result in higher rates of smear 
negative TB (8, 10). There is a high rate of smear negative TB because, due to the 
alteration of the normal host immune response to MTB in persons with HIV, cavitations 
and transfer of bacilli into respiratory secretions is markedly reduced (98). This also 
explains why we found a statistically significant difference in bacilloscopy status 
between the HIV positive and negative cohort. In addition, according to the WHO 
definition, a patient with TB involving extra pulmonary sites is classified as a case of 
pulmonary TB if there is pulmonary involvement and the smear is positive. Hence, it is 
very likely that a significant proportion of patients in this study classified as having 
pulmonary TB are cases of disseminated TB involving the lungs.  
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  We also found that 151(60.9%) patients had CD4 count between 50 and 200 and that 
44(17.7%) had a CD4 count of less than 200. Only 53(21.4%) of patients had a CD4 
count greater than 200. TB accelerates the course of HIV-induced disease by activating 
viral replication and accentuating the decline in CD4 T cell counts (11).  We also found 
that 44 patients were already on ART when diagnosed with TB. This shows that many 
patients had reached advanced stage of HIV disease without starting ART (and largely 
without knowing their HIV status). TB clinics had thus been the entry points for 
diagnosis and HIV care for many patients. Tuberculosis is an aggressive opportunistic 
infection that arises at higher median CD4 counts than most other opportunistic infections 
(23). The fact that we did not have many patients with CD4 counts of 200 and above 
might partially be due to the fact that health professionals delay ART in these patients 
until after the completion of TB treatment, based on their clinical judgment as well as 
patient request, since the patients included in our study were only those who had received 
ART during TB treatment.  
 
   It is worrisome that patients come very late for HIV treatment, after severe immune 
deterioration, and that necessitates raising awareness among the population about early 
diagnosis of HIV treatment and initiation of therapy, since ART is now freely available in 
governmental treatment centers. 
 
   Efavirenz containing regimens were used in the large majority (74%) of patients. The 
regimens available in the health centers are either efavirenz or nevirapine containing 
regimens. Nevirapine is not used when the patient receives rifampicin because rifampicin 
is an inducer of an isoenzyme which leads to increased metabolism and decreased 
concentration of nevirapine (39); therefore, in addition to patients already on efavirenz, 
patients taking ART in the intensive phase of anti-TB are started on or shifted to an 
efavirenz containing regimen; this explains why a large majority of patients were on an 
efavirenz containing regimen.  
   We also found that 48% of patients had another concomitant illness other than TB and 
HIV during TB treatment. This is expected in view of the low CD4 counts of the patients. 
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But it is also possible that some patients are referred to hospitals by the health centers for 
better evaluation and management and these cases might sometimes not be noted on the 
charts of the patients or the diagnosis put might not be the right ones; and patients 
themselves might go to hospitals or private clinics when very sick; so these factors should 
be put into consideration when looking at the results on concomitant illness that we 
recorded from the health centers, and this might also explain why we did not find any 
association between defaulting from treatment and concomitant illness, as we would have 
expected; since another illness would mean that the patient would need to take more pills, 
and pill burden was a major factor that patients and health professionals said would affect 
TB treatment adherence from our qualitative findings and it also means that the patient 
might have more difficulty attending treatment… 
  
 4.2.3. The magnitude of default from TB treatment 
   We found that there was no statistically significant difference in default rate between 
the co-infected patients and a comparative group of HIV negative patients treated in the 
same set ups, among whom default rate was 8.1%; although more patients defaulted in 
the HIV positive group than in the HIV negative one (26 vs. 20 defaulters). We should 
first point out here that there might have been a selection bias, although we tried to 
minimize this by including consecutive HIV negative patients going from the period of 
inclusion onwards.  We were only able to control for the difference in age that was 
existent between the two groups but it is possible that other differences exist between the 
two groups of patients that could have affected our results, for instance differences in 
socio-economic status which we were not able to account for due to lack of data. 
Although published studies comparing socio-demographic characteristics of HIV positive 
and negative TB patients in Ethiopia are not to my knowledge available, an analysis of 
data from 34,512 VCT clients in Ethiopia showed that HIV prevalence decreased 
significantly with each increase in education level in both men and women (99), and 
another study indicated that lower income among women is also a risk factor for HIV 
infection (100), so such socio-demographic differences between the HIV positive and the 
HIV negative patients in our study might have impacted the comparison, hence, the 
results should be seen more as indicators of the fact that, in general, there does not seem 
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to be a significant difference in defaulting from TB treatment between co-infected 
patients on concomitant treatment and HIV negative TB patients in our set up (although 
default was higher in HIV positive patients), despite the former having a double burden 
of disease as well as being on concomitant treatment, and this needs to be confirmed with 
further studies. The interviews with health professionals nevertheless reinforced this 
finding, since all of them reported that, from their experience, there does not seem to be a 
major difference in adherence to TB treatment between HIV negative and positive 
patients, including those on concomitant treatment. As we shall discuss later, although 
co-infection with HIV and concomitant treatment with ART have their own negative 
impacts on adherence to TB treatment, such as through increased pill burden, side 
effects…other factors such as adverse perception of prognosis seem to positively 
influence adherence in co-infected patients, many of whom manage to complete 
treatment, although they face many difficulties. We also found out that many of the 
barriers and facilitators to TB treatment that patients reported are actually those that have 
been reported by TB patients without HIV in different contexts, as we will come to in 
later discussions.  
  
  Very few studies have assessed the effect of HIV on TB treatment adherence; and to my 
knowledge, there is no published study looking at the effect of concomitant TB/HIV 
treatment on TB treatment adherence. Two studies conducted in Nigeria did not find any 
association between HIV status and defaulting from TB treatment (45, 47). A study from 
Ethiopia also showed that HIV positive patients were more defaulters than HIV negative 
patients but that the difference was not significant (78). In these studies, patients were not 
on ART treatment; hence what was assessed was only the effect of the illness on 
adherence to TB treatment.  WHO’s Global Report also indicated that lower treatment 
success rates were found in HIV positive patients as compared to HIV negative ones, 
from reports gathered from over 40 countries (who were actually almost exclusively from 
the Americas and the European region) in 2005, mainly due to higher death rates, and, to 
a lesser extent, due to a higher default rate in HIV positive patients (15).  
   It is also important to see the default rate we found in comparison to other studies 
conducted in TB patients, both in Ethiopia and outside Ethiopia. The default rate of 
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10.5% in the co-infected patients is lower than the rates found in other studies in Ethiopia, 
in patients with TB only, including in Addis-Abeba where a study conducted in 1989/90 
showed a default rate of 82%. The default rate we found was also lower than the rates 
found in the Southern region (20%) (28) and in Hadiya (18%) (32); and it was similar to 
the default rates found in the Northwest region where defaulters were found in 10% of 
the households (77) and in Oromia where a default rate of 11.3% was found. The default 
rate in our study was higher than that found in Jimma (6.7%) (30) and in a retrospective 
trend analysis in the Southern region(6%)(33). Similarly, the default rate in this study 
was lower than that found in Zambia (58), Nigeria (59), and Malaysia (57); higher than 
the default found in Uganda (56). The default rate was also lower than that found in TB 
patients with HIV in Nigeria (47) and Portugal (43).  
 
   Many reasons can explain the differences noted. One of the reasons is the criteria used 
for default; for example, although most of the studies from Ethiopia used the WHO 
criteria of default, in the first study from Addis-Abeba where default rate was found to be 
82%, default was defined as three or more consecutive days absence in the intensive 
phase and/or two months absence in the continuation phase, which was a stricter 
definition than the WHO definition we used. WHO’s definition of default actually 
excludes patients who might have been on treatment for less than one month and 
abandoned treatment, and also excludes patients who have irregular attendances in the 
clinics, and thus might inflate adherence. Another factor that could explain the 
differences, at least in terms of improvements in default rates across time and across 
regions within Ethiopia is, among other things, the decentralization of DOTS making the 
services available closer to patients which has improved through time; and which still has 
variable distribution across regions since the health service coverage in Ethiopia is 
variable, aggravated by poor transportation means (1). Two studies from Ethiopia have 
indicated that the introduction and expansion of DOTS resulted in significant 
improvements in treatment success rate as well as default rates in the Southern regions of 
the country (32,33). Similarly, a study from Uganda showed a high completion rate of TB 
treatment (92%), and that was found to be due to the way services were organized, their 
geographic proximity to patient’s homes and the progressive use of short course 
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chemotherapy (56).In addition, other reasons specific to this group of TB patients, who 
are also HIV positive and received concomitant ARV treatment, might explain the 
differences noted, as well as socio-economic and cultural factors specific to different set 
ups. But the results in general indicate that the default rate to TB treatment that we found 
in this group is among the lowest found in studies from Ethiopia so far.  
     
   4.2.4. Timing of default   
  Most of the defaults in this study occurred in the continuation phase of treatment, and 
consistent evidence exists in the literature that most defaults from anti-TB occur in the 
continuation phase of treatment, with studies both from Ethiopia and outside Ethiopia 
showing that majority of patients default in the continuation phase of treatment (28, 29, 
59, 69, 75).The most common reason given in the literature is a feeling of improvement 
that patients may get after having been on treatment for a while that would encourage 
them to stop treatment, mainly in areas where improvement is equated to cure. A 
qualitative study from Addis-Ababa where the effect of time was assessed indicated that 
patients usually lost support from families and community as treatment progresses, and 
hence are forced to discontinue treatment in the later stages of treatment (31). Our 
qualitative data also suggests that patients usually struggle to continue treatment as much 
as their resources allow; despite medical and socio-economic problems that they face, 
and the decision to stop treatment usually happens after the patient feels that all means 
have been exhausted, or when they feel that the pressure they are exerting on their 
families is too much. Thus, although it is the intensive phase with daily clinic attendance, 
severe clinical symptoms and severe side effects(mainly in those started early on ART) 
that patients describe as being the most challenging, patients usually manage to go 
through it and exhaust all their means while doing so; forcing them to quit treatment in 
the continuation phase. For those patients whose jobs are compromised because of the 
requirements of treatment, subjective improvement might also lead to the patients 
wanting to return to their daily works. Many patients interviewed pointed to the fact that 
improvement in weight and strength is very important to avoid stigma related to HIV; 
hence, once the patients regain weight and strength after being on TB treatment for a 
while, they might stop treatment over more pressing issues. It is important to mention 
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here that WHO’s definition excludes patients who leave treatment within the first month 
of treatment, and that patients might actually leave treatment in that period because of 
factors such as immune reconstitution etc.   
    
  Nevertheless, the continuation phase is a critical phase for adherence. Health 
professionals should be aware of this fact, and adherence counseling which is usually 
given only in the beginning of treatment should be repeated at later stages, when patients 
come for drug refills.  
 4.2.5. The impact of timing of ART initiation on TB treatment 
adherence 
  We found in our quantitative study a significant association between timing of ART 
treatment and defaulting from TB treatment. Patients initiated on ART in the intensive 
phase of anti-TB treatment were found to have a 9 times higher chance of defaulting 
than those started in the continuation phase. These results confirm the concerns on the 
side of many about the possibility of adherence being potentially affected if ART is 
started early in the treatment of TB (23, 39, 101), a concern that has also been taken into 
consideration when setting guidelines regarding timing of ART initiation in the course of 
TB treatment. Many reasons could explain this finding. First, patients are usually 
diagnosed with HIV when coming for TB treatment and the initial phase is usually 
difficult in terms of coping with the diagnosis of two illnesses, as was also revealed by 
the patients we interviewed. Many patients described a loss of hope in the initial phase, 
which they usually overcame, but after some time. Therefore, patients’ readiness for 
treatment might be compromised initially. On top of that, drug intolerance might be 
worse for these patients since multiple treatments are initiated at close times. Some 
patients interviewed had a belief that their body would adapt to the TB drugs after some 
time and get ready for the ART if they are provided ART at a later time. Patients started 
on ART drugs early in their TB treatment can also be predisposed to immune 
reconstitution inflammatory syndrome, presenting as transient worsening or appearance 
of new signs and symptoms of TB (23) and due to the restoration of pathogen specific 
immune reactivity against pre-existing pathogens leading to inflammatory reactions in 
infected tissues (39); and that can also potentially affect adherence in these patients. A 
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study from Malawi had indicated that adherence to ART was better in those initiated on 
ART in the continuation phase of TB treatment as compared to those immediately started 
on it, due to better readiness (46). Although health professionals said that patients’ 
readiness was assessed before the initiation of ARV, some patients interviewed said that 
they started treatment because health professionals told them that they need it. Hence, 
despite fear of concomitant treatment and stress related to the diagnosis of two chronic 
illnesses, patients might agree to initiate ART without being ready for it and subsequently 
default from either or both treatments. 
 
  There is strong evidence that ART improves mortality of patients with TB, which is 
highest in the first two months of treatment; mainly when introduced early (11, 23, 39, 44, 
45) .Therefore, delaying ART might not be a good option for this group of patients, 
weighing against the possibility of mortality, although adherence might be compromised. 
Rather, such patients for whom ART is introduced early in the course of TB treatment 
need further adherence counseling and assistance from health professionals; and should 
be followed thoroughly for occurrence of side effects or immune reconstitution syndrome 
and managed accordingly. Patients need to have a say in their treatment and should be 
thoroughly counseled and informed about risks and benefits of starting ART early, and 
should be allowed to make decisions themselves.  
 
  Patients started on ART before the initiation of anti-TB also had a higher default than 
those started in the continuation phase. That might be due to the fact that patients give up 
hope on treatment when developing TB after taking ART for some time. The overall 
period of concomitant treatment is also longer for these patients meaning that they have a 
longer period of exposure to problems associated to concomitant treatment.  
    4.2.6. The impact of gender on TB treatment adherence 
  We found in the quantitative study that male sex is associated with defaulting from 
treatment; although the difference was not statistically significant in the HIV negative 
patients, which might be due to a lack of power in the study. Studies from Ethiopia (32), 
Pakistan (102), Thailand (50), Madagascar (55), Nigeria (59), India (103), have also 
indicated that male sex is associated with defaulting from TB treatment, whereas other 
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studies from Ethiopia (28), Portugal (43), Zambia (58), did not find any relationship 
between sex and defaulting. 
    
   The reason why more males than females default from treatment in our set up might be 
related to the fact that more men than women are employed, therefore find it difficult to 
adjust their working schedules with attendances at the clinic. In our interviews, we also 
found that a major concern of males was the impact of treatment on their jobs and 
consequently on their income and that of their family as a whole because they were 
providing for their families as well. Similar reasons were given for why more males 
default in Madagascar (55) and Nigeria (59). Some health professionals interviewed said 
that females are more responsible than males and that their experience is that females 
adhere better to treatment than males. Females are indeed responsible, and raised worry 
about what would happen to their siblings if they did not recover from their illness, and 
hence seemed motivated to take their treatment and get cured. But what might appear as 
irresponsible on males’ side by discontinuing treatment might actually reflect a 
responsibility they assume by continuing their works and providing incomes for 
themselves and families at the expense of their treatment.  
    
  As discussed earlier, females might have more problems in accessing health care and in 
being notified to treatment facilities because of socio-economic factors and gender 
inequalities; so there is an argument that barriers to diagnosis of TB in women screen out 
those women most likely to default and that those who overcome diagnostic barriers are 
likely to be highly motivated, hence most likely to adhere to treatment (97), and this 
possibility can not be ruled out in our set up as well. 
   
  What might help in this case is addressing the factors that make males particularly 
vulnerable to defaulting. The daily routines of DOT and additional attendances at the 
ART clinics do not fit working schedules for many as we will discuss later and 
addressing that issue might solve the problem. Health professionals should be aware of 
this potential gender difference in default and its potential causes and they should assist 
patients accordingly. 
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   4.2.7. The impact of education on TB treatment adherence 
  We found a significant association between defaulting from treatment and education, 
with patients with primary and below education having a higher chance of defaulting than 
patients with secondary and above education. It is first important to explain that in our 
record review, we were not able to retrieve data on income or occupation of the patients, 
since, although occupation should have been filled out in the ART charts, it was not the 
case in many instances, and hence, we had to take it out from our analysis. Hence, it is 
possible that in our study, level of education was confounded by the economic status of 
the patient, since it is likely that patients with higher education would have a better 
chance of getting a job and having a better income than those with no education, although 
it is difficult to know to what extent the confounding was. And income/economic status 
 of the patient could potentially affect adherence as will be discussed in later sections. 
     
   Nevertheless, education can impact on adherence to treatment because it might be 
related with knowledge about the disease, the drugs, their side effects, and the necessity 
for adherence and for taking treatment for eight months. Adequate knowledge about the 
illness and its treatment have been shown to be associated with better adherence in many 
studies, both from Ethiopia and outside Ethiopia (40, 52, 53, 54, 75, 82). From our 
interviews, it also appears like patients who ask for information from health professionals 
about their illness and the treatment were those who were more educated; and therefore 
these might get the necessary information from health professionals, which might also 
explain why more educated patients adhere to treatment better. A similar tendency was 
noted by Sagbakken in her study conducted among TB patients in Addis-Abeba in 2001/2, 
with less educated patients being more hesitant to approach health professionals as well 
as being the ones receiving less information from health professionals (104). Studies 
from Ethiopia (28, 29), Malaysia (57), and Zambia (58) did not show an association 
between education and defaulting. One of the reasons might be the fact that there is better 
awareness about TB and its treatment in the community secondary to health 
education/communication about TB provided for the community at large in some set ups. 
These studies are also conducted in patients with TB only, and our patients were co-
infected patients taking complex treatment and might face more complex issues such as 
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understanding the effect of pill burden, concomitant illness, side effects…As we will 
discuss in the following section, many misperceptions exist with regard to the illnesses 
and their treatment, and that can have an impact on adherence to TB treatment. 
4.3. Discussion of qualitative findings 
  4.3.1. Understanding about TB, HIV, co-infection and the impact on TB 
treatment 
  We found that there were misperceptions about the origins of TB, which included its 
association with bird, as well as other factors such as excessive sun, mud, smoking, 
alcohol, sexual contact. Patients also believed that lack of food would predispose to TB. 
Misperceptions about TB have been found in other studies from Ethiopia where, in 
addition to the factors mentioned above, other factors such as evil spirit and consumption 
of contaminated food and water were incriminated in the causation of TB (76, 77, 81). 
Similarly, a study from South Africa showed that mine work, malnutrition, infected food, 
disobeying traditional rules were thought of as causes for TB, in addition to smoking, 
alcohol, and sex (67). In Kenya, a study found that the origins of TB were thought to be: 
alcohol, smoking, exposure to cold, hard work, hereditary (68). The importance of bird as 
a causative agent for TB is particularly significant, and it seems like that belief has at 
times been supported or reinforced by health professionals, because some felt like it is 
too difficult for patients to understand the medical explanations for TB, or there was no 
sufficient time to discuss with patients. The belief in bird as a causative agent for TB 
adversely affected treatment because patients first tried home remedies such as warm 
drinks and avoidance of further exposure to cold and therefore were delayed in seeking 
medical advice. This is particularly dangerous in this group of patients co-infected with 
HIV since it also means that the untreated TB infection causes further deterioration in the 
immune status of the patient; which can also potentially affect adherence because patients 
come at a late stage for treatment when their symptoms have progressed, which makes 
clinic attendances difficult, tolerability of drugs worse, worsen the economic situation of 
both the patient and/or families because of inability to work, … . In addition, it resulted 
in some patients ascribing their HIV diagnosis to their delay in seeking treatment.  A 
previous study from Ethiopia had indicated that self treatment was associated with 
treatment delay in the Amhara region (27); another study in the Southern region also 
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showed that 70% of patients initially thought that the symptoms would disappear without 
clinical treatment (26). The reason for delayed treatment in these studies might be due to 
similar believes about TB in those areas as well. Sagbakken similarly indicates that the 
belief in bird as a causative agent of TB guides different beliefs and activities in TB 
patients, starting from the time of symptom recognition, to when treatment is initiated; 
subsequently leading to delay in diagnosis, and indirectly affecting treatment adherence 
(104). 
    
  In this study, the absolute majority of patients interviewed knew that there is a 
relationship between TB and HIV. Even in 1997 when the epidemic did not reach its 
current dimension, a study from the rural area had indicated that 20% of patients knew 
there is an association between TB and HIV (77). But misperceptions as to the 
relationship between the two illnesses existed. The most common one being that TB 
turned into HIV. A previous study from Addis-Ababa had indicated that such a belief 
exists among patients, with AIDS perceived as a second stage of TB (81). Few 
understood the relationship between the two illnesses as being due to the effect of HIV on 
their body. For some patients, the knowledge about the association between TB and HIV 
came from what they heard in the community and others claimed they heard that on the 
media. It is thus evident, as also explained by health professionals, that information 
disseminated by the media was misunderstood by patients.  
    
   Patients also explained that not all patients with TB have HIV, although they believed 
the most common type of TB was the HIV associated one, and said that a patient with TB 
only and a patient with TB and HIV can be differentiated based on their weight and 
strength, in addition to darkening of the skin, which is due to HIV. It was found in a 
study from Thailand that half of the patients interviewed believed that AIDS patients 
were different from TB patients because AIDS patients were too weak to walk while TB 
patients could walk, hence reflecting the picture of an HIV patient that they had (72). 
Most patients believed that this belief is shared by the community and hence feared 
stigma, especially when they lost weight, became weak and developed skin changes. This 
in turn affected their treatment (the effect of stigma on adherence to treatment will be 
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discussed later).These believes might be due to the fact that ART was only introduced in 
recent years in Ethiopia, and many in the community have seen terminally ill patients in 
the pre-ART era, many of whom they lost, and the popular image of a patient with HIV 
infection is a patient who has lost weight, has skin lesions, and coughs. And this image 
has probably been supported by the media’s portrayal of HIV patients. Being from Addis-
Abeba myself, I have also experienced seeing many people being suspected of having 
HIV if they have been ill for a while, have lost weight, and appear weak. 
  
  We also found that the difference in knowledge between TB and HIV is significant, 
many knowing the major routes of transmission of HIV. This might be a reflection of the 
media’s coverage of the illness, and many indeed explained that they heard about HIV in 
the media. HIV has also been well covered in different health education campaigns that 
have involved schools, communities, work places …. But TB seems to have been 
neglected by the media and by health education campaigns, and if education was given 
about TB, it has most often been in relation to HIV. A study from Thailand also found 
that the community had a higher awareness about HIV as compared to TB, and that an 
increase in awareness about AIDS had not been accompanied by a rise in understanding 
of TB control (72).  The HIV epidemic has been followed by unprecedented funding 
from international donors, which has made it possible to make media advertisements, 
dramas, health education campaigns, with involvement of multiple NGOs. But TB has 
not gotten the same attention or the same amount of donor involvement that HIV has had, 
despite the heavy burden of disease that TB imposes in many areas of the world. Whether 
TB will receive better attention now because of the tight association with HIV which is 
becoming apparent in many countries and whether better collaboration between TB and 
HIV programs will include raising awareness about TB as well remains to be seen. One 
of the aspects of collaboration should be raising awareness about the relationship between 
the two diseases.    
 
  One finding that was interesting was that many patients believed in the curability of TB, 
as well as in the efficacy of TB treatment, although some thought it might be more 
difficult and might take more time for them, because they also had HIV infection. Even 
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those who believed that TB had changed into HIV still thought that they could take drugs 
and get cured from the TB, but that the HIV would persist. This, as also mentioned by 
some health professionals, might be a result of the fact that patients have seen people 
with TB in their community cured after receiving treatment(also shown in a study from 
Pakistan(65)), and were also encouraged by the changes that they see in patients at the 
clinic. Studies have shown that belief in the efficacy of treatment facilitates adherence to 
TB treatment (52, 53, 54); while other studies have shown that patients’ adherence was 
adversely affected because of the belief that TB is incurable or the treatment inefficient, 
or that alternative treatment such as traditional medicine is better (51, 52, 53, 67, 68). 
Although some authors had raised concern about the possibility of the relation between 
TB and HIV enhancing the questioning of the curability of TB (68), there was no strong 
evidence of it in this study.   
 
  But, for many patients, prognosis of TB treatment in the presence of HIV infection was 
believed to be poorer as compared to HIV negative patients, and that had at times been 
reinforced by warnings from health professionals about the danger of TB linked with 
HIV. That seemed to positively influence adherence because patients believed in the 
importance of taking treatment in order to survive, and many health professionals also 
said that it encouraged patients to take treatment. That might mean more motivation for 
this group of patients as compared to HIV negative patients, some of whom might 
discontinue treatment, mainly when they feel better. In addition, health professionals also 
argued that these patients had severe symptoms and were eager to take drugs to improve 
and not to get these symptoms again. Other studies have also suggested that patients 
experiencing more severe symptoms were more likely to adhere, possibly because of a 
fear of becoming more ill (52). These believes actually correlate to the threat of illness 
and the consequences of diseases which are believed to influence adherence behavior 
(92).  
 
   Use of traditional medicine for TB treatment was not reported by participants in our 
study. Traditional medicine was commonly used in the past in Ethiopia, with as high as 
80% of people estimated to be relying on it in 1991 (3), mainly due to lack of access to 
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modern treatment but also due to persisting believes in its efficacy, mainly in rural areas. 
But participants in our study said that traditional medicine is not a good option for TB, 
reinforcing their belief in the efficacy of anti-TB treatment. In addition, some seem to 
have lost confidence in traditional medicine in general. The fact that the health service 
coverage is high, that patients see people in their communities getting treated and cured 
from TB by using modern anti-TB drugs can also explain why traditional medicine is not 
used for TB.  
  
  The issue of use of tsebel or holy water had raised concerns in recent years because of 
many abandoning ART treatment over it; but we found in our study that patients now are 
taking tsebel together with both anti-TB and ART, and this follows the preaching of 
concomitant use by priests in the orthodox church, as explained by health professionals, 
after the orthodox church was approached by health professionals.  This is a reflection 
that the health system and religious leaders can work together to make changes, since 
religious leaders are quite influential in the community.  
 
  So what we found in summary is that misperceptions exist with regard to TB and 
TB/HIV co-infection. Many patients relied on information that they got from the 
community, as well as the media; hence what was evident was the role that the popular 
sector was playing in terms of defining the illnesses, their causations, whether treatment 
will be beneficial, as well as when to consult the professional sector. The patients we 
interviewed have passed through the professional sector, many having been there for 
many months, but still many of their beliefs were those defined within the popular sector, 
a reflection that the professional sector has not been a major source of information for the 
patients; at times, the beliefs in the popular sector have even been reinforced by the 
professional sector such as for instance the effect of bird as a causative agent for TB, 
further reinforcing the misperceptions. The folk sector seems to have gradually lost 
importance in the setting, at least in relation to TB treatment, although the sacred part 
retains its importance, as exemplified by the high use of holy water together with TB 
treatment in patients. The use of holy water together with modern treatments is a result of 
the cooperation between the professional and the folk sectors, which yielded fruitful 
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results by encouraging concomitant intake of holy water and drugs instead of abandoning 
treatment over tsebel, which had been the case in the past.  
 
   What we largely discussed is what Cummings et al abstracted in two of their categories 
as factors affecting treatment adherence, that is items dealing with the individual’s 
attitude toward health care, such as beliefs in the benefit of treatment and beliefs about 
the quality of medical care provided, and items concerning the threat of illness, such as 
the individual’s perception of symptoms and beliefs about susceptibility to, and 
consequences of, disease (92). We found that these factors largely influenced patients’ 
treatment adherence; mainly that the beliefs in the benefits of treatment and the belief in 
the severity of TB treatment when related to HIV infection and its potential consequence, 
that is death, positively influenced adherence in these patients despite many difficulties 
that they reported. 
 
   Our recommendation with this regard is that much needs to be done to raise awareness 
about TB/HIV for patients and for the community at large. The MOH calls for Advocacy, 
Communication and Social Mobilization (ACSM), as one of the components of TB/HIV 
collaborative activities, with the aim of raising awareness about TB/HIV among the 
community in general and those at risk of TB/HIV in particular and to mobilize them 
ultimately to, among other things, enhance comprehensive patient care (18). This is 
indeed very important and collaborative communication and social mobilization 
strategies need to be set, that ensure that coherent messages about TB, HIV, and TB/HIV 
are passed along. Health education and communication should be delivered in health 
facilities, households, schools, traditional social meetings and in religious institutions 
whenever possible. The messages should be made culturally sensitive, and adjusted to the 
audience that is to be addressed. Religious leaders and community leaders are influential 
and their participation is very critical in order to reach the community at large. 
Experience from the southern region has shown that organization of patients into DOTS 
clubs, together with involvement of other influential community members such as priests 
and Muslim religious leaders and community elders has yielded remarkable results in 
improving knowledge about TB as well as improving adherence to treatment and 
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increasing awareness about TB and its treatment (79,80). Lessons should be derived from 
this and adopted to the context in Addis-Abeba. 
  
  The media is also a channel that reaches many people at once and should be used to give 
health education, and it seems that patients listen frequently to messages on the media, 
with many referring to knowledge gained from the media in our study but the messages 
conveyed should be made simple and sensitive to avoid misunderstandings as well as 
further stigmatization as will be discussed later.  
  
4.3.2. Regimen related factors and their impact on adherence 
   4.3.2.1. Pill burden 
  Pill burden was one of the most important problems that both patients and health 
professionals interviewed said affected treatment in co-infected patients on concomitant 
treatment. Patients not only ascribed some of their symptoms to pill burden but also 
feared that their “weakened” body might not be able to tolerate so many pills. In this 
study, pill burden was seen as a major problem by patients because patients believed that 
the number of pills swallowed determined the degree of “harm” that the drugs could 
potentially cause to the body but also because they believed that the amount and quality 
of food needed is proportional to the number of drugs swallowed. Studies have 
previously indicated that pill burden adversely affects adherence to treatment (36, 40, 73, 
105). In addition, some found the dosing schedule difficult since they had to swallow 
anti-TB, ART and cotrimoxazole, with ARV drugs twice a day; which resulted in 
forgetfulness as well as difficulty to adjust drugs with working routines. The effect of 
dosing frequency has also been discussed in the literature and frequent dosing has been 
found to be associated with poorer adherence to treatment, whereas decreased frequency 
was associated with better adherence (40, 41, 42, 73). 
    
  Recently, fixed dose combination ARV drugs have been introduced and this will assist 
patients in terms of alleviating the problem of pill burden. Introduction of once daily 
doses of ART in the future would further assist patients. In addition, health workers 
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should thoroughly discuss and plan together with individual patients the schedule that fits 
the most with their daily routines instead of setting similar schedules for all patients. The 
fear of patients about the effect of many pills on the body should also be addressed 
through health communication as well as the issue of necessity of food proportional to 
pills swallowed, as we will discuss later. 
  4.3.2.2. The impact of side effects 
  Multiple side effects were reported by patients and this is expected because both anti-
TB and ARV drugs are known to have side effects, some of which are overlapping. In 
addition, patients feared side effects that they heard about in the community. Beliefs such 
as the weak body of an HIV positive patient not tolerating drugs were described. Health 
professionals were also aware of these believes among patients. Worsening of symptoms 
after start of treatment was also reported, and patients ascribed that to the drugs. Most 
patients interviewed also said that they were not informed about side effects, and were 
unable to know whether it was the TB drugs or the ART drugs that gave them the side 
effects, and had to rely on their own believes about side effects. One patient discontinued 
all treatments, not able to know which drug gave him the side effect, while another 
believed it was due to TB drugs and discontinued those. Side effects, both experienced 
and perceived, have been known to affect adherence in many studies on adherence to 
anti-TB, in both HIV positive and HIV negative patients (29, 43, 50, 52, 54, 58, 74) and 
side effects were also found to affect adherence to ART (73, 82), often because patients 
were not warned about those. 
    
  Some of these side effects might be transient or otherwise could be managed but some 
patients were unaware of it and believed discontinuing treatment is the solution, and did 
not seek treatment for it. Health professionals should inform patients about potential side 
effects. Early detection and management of side effects would also help patients. Health 
communication should include educating patients and the community about anti-TB and 
ART drugs and dealing with beliefs that exist about side effects, since what patients 
relate to is largely the perceived side effects of anti-TB and HIV drugs in the popular 
sector, although many have actually experienced side effects while on treatment. 
 
 142
   It is worth noting here that the impact of side effects and pill burden are affected by 
popular beliefs about drugs and side effects and how patients and the community 
perceive those; these therefore also become part of factors related to patients’ beliefs, as 
well as actual experienced regimen related factors associated with patient treatment. 
Therefore the same solution to address popular misperceptions should also address side 
effects and pill burden, giving patients and the community a better understanding of these. 
4.3.3. Health service related factors and their impact on adherence 
   4.3.3.1. The impact of DOT 
  DOT was difficult for many because of the economic constraints related to 
transportation costs as well as its clash with job routines, threatening the jobs of some; 
and patients in addition were also attending HIV clinics. In addition, it was physically 
demanding for those who were very sick, and those had to be accompanied by their 
families, every day for the first two months. In those cases, the income of family 
members was also compromised, with patients feeling guilty for imposing a burden on 
their family. A previous study from Addis-Abeba also showed that DOT was physically 
demanding for patients, mainly for those who were ill, and showed that it incurred 
transportation and opportunity costs for patients, many of whom were unable to hold on 
to their jobs (31). For a few, it was also the lack of autonomy that they were finding 
difficult to accept and that was also reflected by health professionals’ comments as well. 
Therefore patients might usually face the dilemma of choosing between their incomes 
versus daily attendances at the clinic and discontinue treatment if the loss of income is 
beyond what they can tolerate. In addition, it might be difficult for a patient to comply 
with a routine he/she doesn’t believe in. Other studies have also indicated that patients 
face difficulties with the daily routines of DOT (31, 52, 53, 64).  
     
   Although health professionals raised concern about the improper intake of drugs 
without DOT, many also agree that the routine is difficult for patients. There was also 
variable degree of flexibility among them, some being strict in terms of following 
guidelines, others being more flexible. The guideline indeed says that patients should be 
supervised while swallowing pills the first two months but some personal judgment might 
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be necessary, mainly when very ill patients are involved, or if patients have very pressing 
issues that make it difficult for them to attend treatment. TB treatment approach was set 
up mainly from a public health perspective, according to which infectious cases should be 
treated to cut the chain of transmission to others and treatment supervised in order to 
protect rifampicin from the occurrence of drug resistance. What is taken into account less 
is how this affects individual patients, both socio-economically, but also in terms of 
autonomy. 
    
  The possibility of community based DOT, in conjunction with local NGOs already 
working with HIV patients should be considered, after proper training of community 
workers, although there might be limitations due to HIV related stigma. The ministry of 
health also reported the following barriers to the implementation of community TB and 
TB/HIV care: poverty and basic needs requirement that hinder community members from 
participation in the care of their own sick, a difficulty to maintain motivation and 
awareness, and financial constraints faced by community organization (15). Use of 
already established NGOs working with patients at community level might help alleviate 
some of these problems. This might not only provide support with treatment but also 
emotional and social support for patients since some, as found in our qualitative study, 
were not telling about their illnesses to their families or neighbors and lacked the 
necessary social support. A review of trials conducted in low, middle and high income 
countries showed no evidence of superiority of DOT versus self supervision in terms of 
cure and treatment completion. Supervision by health professionals, lay health worker, 
and family/community member was similar in terms of treatment completion (71). In set 
ups like ours where economic constraints and unstable daily jobs are common, DOT at 
health facilities might not be the right option for management for all. Encouraging results 
have already been obtained in a community based DOTS programme in the Oromia 
region of the country (13).  
 
   It is also important to change the daily routines of DOT into encounters with patients 
from which they benefit more in terms of getting information and support from health 
professionals, and that might be more motivating for patients. Flexibility at least in terms 
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of appointment hours for patients would assist some patients like students who can come 
and collect their drugs as per their class schedules.  The necessity for daily supervision of 
treatment should be clearly explained to patients, who should know that supervision 
when it comes to TB treatment is a universal phenomenon, and not something imposed in 
that particular set up. 
    
   Another concern for many patients was that receiving treatment in nearby health 
centers would predispose them to stigma. Although some patients prefer being treated in 
distant health centers, health professionals could not accept those because the guideline is 
that patients should be treated within their catchments area. The regulations have recently 
changed for HIV patients who can now be treated in the health center of their choice, and 
the same solution might be necessary for TB treatment as well, although this might result 
in unequal distribution of patients within health centers with overburdening of some of 
them. 
  4.3.3.2. TB/HIV collaboration 
   The HIV epidemic has challenged DOTS as a sole tuberculosis control strategy for 
Africa, since even strong programs can not adequately compensate for the rising 
susceptibility to tuberculosis at the population level that occurs as HIV prevalence 
increases (23). The need for TB/HIV collaboration is therefore important in many aspects. 
 
   One barrier to collaboration has been the difference in how HIV/AIDS and tuberculosis 
surveillance, diagnosis and treatment have traditionally been approached. TB control 
programs have adopted a public-health approach, with major aims of controlling TB 
transmission and avoidance of drug resistance whereas HIV/AIDS programs have 
adopted a patient centered approach (23). In addition, separate administration and 
funding have also played their role (106). 
 
   Most health professionals (one being the exception) we interviewed said that the 
collaboration is very weak. There was a fear that different information might be given or 
patients lost in between. Although TB clinics were serving as points of entry into HIV 
clinics for many patients, after referral to the HIV clinics, those were treated as any TB 
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patient, and no link exists between the two clinics concerning the management of 
individual patients, and HIV clinics were leaving the whole responsibility of TB 
treatment to the TB clinics, hence, the traditional way of working is persisting in the 
clinics. Joint trainings or meetings were not organized. Unless health professionals are 
trained in the management of both illnesses and have a common recording system for 
common patients and regular occasions to meet and discuss their patients and their 
collaborative activity, the traditional way of working will persist, and health professionals 
will only feel responsible for the management of either illness. 
 
   Patients also felt that the two clinics were not working together in terms of arranging 
their schedules and managing their treatment. This can adversely affect patients’ 
treatment because they get treated by different health professionals who manage their 
illnesses separately, and patients might be discouraged by repeated queuing at the heath 
centers on different days which might compromise their jobs, increase transportation 
costs, and some patients pointed this fact in the interviews. 
      
   Provision of training in both HIV and TB management for health professionals in both 
clinics and establishment of a system of recording whereby common patients are easily 
identified should be set. That would facilitate the management of side effects as well, and 
would allow health professionals to notify each other when a patient initiates or 
terminates or changes treatment or when he disappears from either clinic. The new 
registers in the TB clinics that were recently introduced are important.  Arranging 
convenient schedules at the two clinics so that patients are spared from repeated visits at 
the health center would also assist patients. Successful integration of TB/HIV treatment 
has resulted in excellent adherence and TB and HIV outcomes in a rural setting in South 
Africa (104), and three case studies from Malawi and South Africa of TB/HIV 
collaboration and integration also gave successful results (107).  
 4.3.3.3. The role of the health personnel 
  This has to some extent been discussed earlier in relation to the routines of DOT and 
information provided. What we found in this study in general is that patients felt satisfied 
by the health personnel in both TB and HIV clinics and appreciated the degree of 
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compassion from their side. Many were satisfied with the counseling they initially 
received upon diagnosis of HIV or concomitant illnesses. That encouraged many patients 
to regain hope and continue treatment, some saying that they would not have been able to 
take their treatments and finish it without the support from health professionals. 
      
   However, what was notable as well is that, after 8 months of treatment, most patients 
knew little about their illnesses (in particular TB and co-infection), the medications, their 
side effects…, reasons which have led to discontinuation of treatment for e.g. through 
lack of knowledge about side effects, screening of which drug should be discontinued… 
Most health professionals are aware of the lack of health education / communication 
provided to the patients, and said that lack of time was a major barrier. The problem was 
aggravated by the fact that patients themselves do not ask questions to health 
professionals, and some replied that it is because they believe health professionals do not 
have time to reply to their questions.  What was apparent was that many of these patients 
accepted the fact that they did not receive information as something “normal”, most 
probably because of the cultural gap that exists between patients and health professionals; 
with a hierarchy that places health professionals far above and makes it difficult for 
patients to ask questions. This can also partly be due to the fact that many have been 
through similar encounters with health professionals previously, and had similar 
expectations when coming to the clinics. Few health professionals also felt that some 
detailed explanations might confuse patients more. What was apparent was also the fact 
that more educated patients felt more comfortable asking questions and discussing their 
illnesses with health professionals. This is probably because one potential barrier between 
the patient and the health professional is broken, that is the level of education, making 
patients less scared to ask questions. Health professionals might also feel that providing 
further information for such patients would not lead to “confusion”, because they are 
educated. 
   
   Whatever the reason is, the information gap was therefore wide. Some information 
regarding what to consume and what to avoid, and not to stop treatment was told to most 
patients, in what seems like a routine kind of information provision, in which patients 
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passively received information, at times not even understanding the logic behind it, or 
misunderstanding the information. Sagbakken also noted in her study in Addis-Abeba 
that there was a lack of dialogue between patients and health professionals, with 
consequent lack of information and knowledge provided to patients (104).  
 
   Previous studies have shown that patient-provider communication affects adherence. 
Good relationships such as those in which trust was established, a supportive clinic 
environment, adequate time spent explaining the disease facilitating adherence in the 
consecutive studies (40, 51, 63), whereas poor patient provider relationships, including 
those with lack of information from health professionals adversely affected adherence (53, 
64).  In addition, the fact that there is little flexibility in DOT routines on the side of some 
health professionals who at times refuse to give drugs to relatives of very sick patients, 
affects the patient-provider relationship and threatens adherence, and a previous study 
from Addis-Abeba described similar results (31). 
    
   It is encouraging that health professionals are showing compassion to patients and 
assisting them with their treatment. Although there is usually a lack of time in the clinics 
because of a high number of patients coming to the clinics, health professionals should 
make it a routine to give at least the most important information to patients, in a simple 
and understandable manner. In addition, patient education materials such as the 
pamphlets available in the HIV clinics should also be prepared for TB patients. Patients 
should be empowered and encouraged to have discussions with health professionals, and 
have a say in their treatments as well. This will need a commitment from the side of 
health professionals as well, who are the “sources” of the information, because one 
important aspect of health communication is the fact that among other things, the receiver 
should feel close to the source, believe in its trustworthiness (108).Similarly, 
communication is more accepted when the person perceives the source to be similar to 
him/her (108).  Hence, use of ex-TB patients to give health education to patients might be 
a good option because patients might relate to them more, in addition to information 
provided by health professionals; this is actually being practiced in the HIV clinics with 
relation to HIV where expert patients (trained HIV positive patients) give health 
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education to patients. Persisting beliefs about TB among some health professionals such 
as the effect of bird and sexuality on TB treatment should also be addressed, since it 
affects both patients’ belief and it also leads them to bring such information back to the 
community as information supported by health professionals. Patients will actually serve 
as sources of information to their families and to the community at large, since they 
might be considered as having good knowledge about the disease because they have 
experienced it and attended treatment facilities, and patients developing illness in 
particular might consult these patients subsequently, hence educating patients means 
allowing them to disseminate adequate information further.  
 
  What is interesting is that health professionals seem to be largely aware of the factors 
that influence treatment in their patients, as we found that their perceived barriers and 
facilitators of treatment are very similar to those reported by patients, including the 
impact of health service related factors, such as the information provided to patients. 
Hence, that should create a solid ground for interventions involving health personnel. 
Adherence counseling is very much emphasized upon in the treatment of HIV where it is 
provided to all patients prior to initiation of treatment. Adherence counseling is also 
needed for TB treatment, and potential factors affecting treatment should be addressed, 
with family involvement whenever possible. Since adherence is a dynamic process, 
adherence counseling should be done throughout the course of the eight month treatment, 
as much as possible.   
4.3.4. The social influence 
  The importance of society surrounding the individual on adherence to treatment has 
been indicated in the abstraction from Cummings et al, where it was categorized as 
“items dealing with the individual’s social interactions and with social norms and social 
structure”, and this is what we will discuss next through the discussion of stigma and 
social support.   
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    4.3.4.1. Stigma 
   Several definitions have been given to stigma along the years. One definition is: “a 
social process or related personal experience characterized by exclusion, rejection, blame 
or devaluation that result from experience or reasonable anticipation of an adverse social 
judgment about a person or group. In health related stigma, this judgment is based on an 
enduring feature of identity conferred by a health problem or health related condition” 
(Weiss and Ramakrishna, 2001) (109).  
    
   What we found in this study is that patients believed that both TB and HIV could lead 
to stigma; but feared more HIV related stigma. In many instances, when asked about TB 
related stigma, patients actually emphasized that it was HIV related stigma that was 
predominant. There was a high degree of felt stigma, which is different from enacted 
stigma. Felt stigma refers to the fear of being discriminated against, whereas enacted 
stigma refers to the actual experience of a prejudicial act (110). That was because many 
had seen patients with HIV suffer from stigma and discrimination in their communities, 
and feared the same will happen to them, and felt that TB will predispose them to HIV 
related stigma because of the association between the two diseases; that was particularly 
worrisome for those who had lost weight and experienced generalized weakness, because 
they believed that it would make people label them as having HIV as well. There were 
nevertheless experiences of enacted stigma due to TB among patients. Social isolation 
and interruption of visits by neighbors and relatives were reported by patients.    
    
    A mechanism that was adopted to fight against stigma among patients in our study was 
“covering”, which is a strategy whereby a person with multiple discreditable attributes 
covers a dominant stigma with one that is less dominant (Goffman, 1963) (110). Hence, 
some patients disclosed TB infection over HIV. HIV is associated with behavior that is 
thought of as inappropriate (many are aware that HIV is sexually transmitted, and it is 
therefore at large believed to be  related to behavior such as promiscuity) whereas TB is 
usually believed to be due to factors such as bird, hence it is expected that more stigma 
will be attached to HIV than TB alone. Sagbakken, in her study in Addis-Abeba, 
explained that people are exposed to different types of stigma related to TB, depending 
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on how the neighborhood behaves in relation to their illness, which follows a cognitive 
continuum which; on the one hand, contains a curable type of TB associated with bird, 
and on the other has the non curable type of TB or AIDS, associated with sinful behavior 
(102). A study from South Africa also found that co-infected patients hided their HIV 
status and only told about their TB diagnosis due to fear of stigma (110). A study from 
Thailand also showed that although both TB and HIV are stigmatized, more stigma was 
attached to HIV, and that patients got delayed in seeking treatment or defaulted from 
treatment of TB when they suspected they have HIV and feared for it to be detected (72). 
But other patients in the study did not tell about TB as well; even to close families, 
because they knew that there was a belief that one has most probably HIV if he has TB. 
For other patients, stigma was due to the fact that they were infectious, and reported 
incidences such as families separating their eating utensils.  
     
    Felt stigma and /or enacted stigma had negative impacts on the treatment of patients. 
Patients usually lost a support system, the social support, by not telling about their illness.  
These patients would have benefited from financial and moral support from families, 
relatives. It also made it difficult for patients to be treated in the health centers located in 
their neighborhoods, for fear of being seen by community members. That created 
additional stress for patients, some of whom were constantly hiding their medication 
intake, both anti-TB and ARV. TB related stigma was found to affect patient treatment 
and in particular adherence to treatment in many studies. TB related stigma was reported 
in a study from Ethiopia published in 1996, which showed that patients and family 
members were excluded from social and religious ceremonies for fear of contagion (76) 
Another study also showed that the majority of respondents were not attending social 
gathering and festivities with TB patients on treatment (77). Although contagion as a 
source of stigma was not stressed upon by patients in our study, it is most probably 
because it was overshadowed by a biggest fear of stigma associated with HIV. Other 
studies have similarly indicated that TB related stigma due to contagion, as well as 
attribution of the illness to breakage of cultural rules… had adversely affected patient 
treatment (52, 53, 63, 65, 67, 68). A study from Pakistan (65) indicated that the stigma 
might be worse for females who risked divorce and low chance of marriage. Low rates of 
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HIV testing acceptability in some regions of Ethiopia might also reflect a fear of stigma 
associated with the diagnosis of HIV (84). A study conducted in Nigeria indicated that 
one of the reasons from TB treatment default in HIV patients was the fact that stigma and 
discrimination forced some HIV positive patients to relocate (47). The impact of HIV 
related stigma on ART has also been reported from a study in Uganda, Tanzania and 
Botswana with patients having to hide their medication intake for fear of being 
stigmatized, which resulted irregular drug intakes and loss of social support (74). 
    
   An important intervention would therefore be combating TB and HIV related stigma, 
and both patients and health professionals noted an improvement in HIV related stigma 
along the years, which is encouraging. This can be done through raising awareness about 
TB, HIV and co-infection. In addition, the community should be informed that HIV has 
now become a chronic manageable disease with the introduction of HAART, since some 
of the stigma related to HIV might be the fact that it is seen as an incurable lethal illness. 
It is important to note here that the media has its share of responsibility in the stigma 
against HIV, and that was also noted by health professionals in our study. The media had 
adopted a mechanism that seemed like “teaching by scaring”, and this was also found to 
be the same in Thailand, where it was described that the popular image of AIDS is 
influenced by the media, which sometimes created fear and anxiety that resulted in 
stigmatization of infected persons (50). Hence, although the role of the media is 
undeniable in terms of the general awareness it created about HIV, extreme portrayals of 
the illness have created unnecessary stigmatization of patients, and these should be 
modified and the information/education provided made more sensitive, and it seems like 
more positive information is now being provided by the media. Using already established 
community based organizations, religious organizations will in addition assist in reaching 
the community. HIV patient organizations have also played a big role in terms of raising 
awareness and fighting against stigma and discrimination and establishment of TB patient 
organizations would also be helpful; with involvement of ex-TB patients, and the two 
organizations should be able to work together.  
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  4.3.4.2. Social support  
  As previously discussed, the social environment was at times a source of stigma, 
making treatment difficult for patients; and both felt and enacted stigma were making 
some patients reject social support. Non disclosure was common. Non disclosure is a 
cause of concern also because of possible transmission to others. But for those who 
disclosed their illness to families and at times relatives/neighbors, the support was very 
vital. From moral encouragement to financial assistance, to accompaniment for clinic 
visits as well as collection of drugs in some instances, families or others played an 
important role in ensuring that treatment was facilitated and adherence ensured. The 
importance of social support in enhancing TB treatment adherence has been described in 
studies from Ethiopia (29, 31), and outside Ethiopia (52, 53, 63). A study on adherence to 
ART in Ethiopia has also shown the important role of social support in adherence to ART 
treatment (82).   
 
   But for some patients, a sense of guilt developed when they felt the burden they exerted 
on their families was excessive, leading to discontinuation of treatment. Receiving 
support was most difficult for those who used to assume the role of being the ones 
providing for their family, when the role reversed and they were the ones receiving 
support. This was exemplified by the 20 years old female patient who used to support her 
parents (whose income only depended on the very small pension money that the father 
gets) and who had to depend on them for her costs including transport costs after being 
diagnosed with both TB and HIV. She described the role reversal as “damaging”, as 
quoted earlier.  
 
   In Ethiopia, extended families usually serve as a source of support for people, mainly in 
times of crisis. Patients’ screening out of some of this support because of fear of stigma 
makes the burden on close families worse, since it is not shared by others. Solving this 
problem will necessitate raising awareness about the TB as well as HIV, and will also 
involve devising mechanisms by which the costs related to treatment can be minimized, 
such as the provision of community based DOT as mentioned above, which can make 
patients less dependent on others. 
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4.3.5. Economic factors affecting adherence 
   4.3.5.1. Direct and indirect costs of treatment  
  The impact of the economic burden has been partly described above, and will be briefly 
discussed here. Although the direct costs are minimal since patients receive both anti-TB 
and ART for free, although they at times had to pay for investigations such as x-rays 
themselves, indirect costs were multiple, and included transportation costs, costs due to 
loss of job mainly for patients who wait for daily jobs to come such as daily laborers, and 
other costs such as those related to food. What is worth noting here is that the public 
health centers are not the first health facilities visited for some, who had been to private 
clinics before, at times repeatedly for repeated infections because of advanced HIV 
illness, and hence join the health center with an already compromised economic status.  
Sagbakken also found that a lack of trust in governmental health centers as well as the 
stigma attached with attending such centers forced people to attend private facilities, 
where they spent much of their money before joining governmental centers where TB 
treatment is provided (104). 
 
   The question is then what can be done to assist patients. Minimizing DOT related 
transportation costs through the provision of community based DOT and working 
together with already existing NGOS to provide food and financial assistance such as 
covering transport costs have been discussed earlier. The impact of incentives such as 
food and transport money on improving adherence to chronic treatment in general has 
been demonstrated (53). In addition, studies from the United States have also indicated 
that increasing preexisting incentives and providing financial incentives improved 
adherence to TB treatment (60-62). Farmer also showed that, in a poor Haitian plateau 
where treatment was offered for free, adherence was only related to whether patients had 
access to supplemental income and food (35).  
    
  The feasibility of provision of incentives in our set up might be questionable, but, as 
mentioned earlier, working with NGOs already providing financial assistance to patients 
might be one option.  
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    4.3.5.2. Lack of food 
  One factor threatening the belief in curability of TB by taking anti-TB treatment for 
some patients was the belief in the necessity to get good food, that is protein rich foods 
such as eggs and milk in order to achieve cure, and some thought of food as being as 
important as treatment. Patients believed that lack of food predisposed them to TB and 
that it will threaten their chance of getting cured. In addition, patients believed that, since 
they had two illnesses, and were taking many pills (anti-TB and ART); they had to take 
adequate food so that their body does not get harmed by the drugs; and some ascribed 
side effects such as gastritis to the lack of food. In addition, since patients believed in the 
importance of weight gain to avoid suspicion of HIV, getting food is also important for 
that purpose. The belief about the necessity of high protein foods while on TB treatment 
came from the community but also from health professionals who were informing 
patients on the need to consume such foods.  This again is a reflection of how beliefs, 
emerging and reinforced by the community, the popular sector of the health care system, 
impact on the treatment of patients; and information provided by health professionals was 
also supporting these beliefs. Sagbakken similarly explains in her study from Addis-
Abeba that the cultural conception, which puts emphasis on protein food, creates mental 
stress and hopelessness among patients, since many were actually chronically hungry, 
fighting to get their daily meals (104). Other studies on adherence to TB treatment and 
HIV treatment have similarly shown that lack of food is a barrier to treatment adherence 
in resource constrained set ups (51, 74, 83 ).  
 
   Health professionals should be aware that giving information about consumption of 
high protein diet in a set up where most of the patients can not afford such meals can be 
dangerous, and patients should rather be encouraged to consume whatever food is 
available for them, and advised to eat nutritious meals if and whenever possible. This 
information should also be disseminated to the community at large. One of the most 
common answers from patients when asked what could be done to facilitate medication 
intake for patients in their situation was provision of food. Many NGOs are working in 
Addis-Abeba to provide assistance for HIV patients. According to information I gathered 
from health professionals, some NGOs have criteria for deciding which patients they 
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would help such as the BMI of patients to provide food. In addition, patients with other 
chronic illness such as TB in addition to the HIV should be considered for assistance 
since that would facilitate their medication intake, and clinics should work in 
collaboration with NGOs to assist such patients.   
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                                                                                                                 Chapter five: conclusion 
   The default rate from TB treatment in this study was 10.5% (10.7% in smear positive 
cases); which, although still high, was less than we actually expected. WHO recommends 
that the rate should be less than 10% (15). The Stop TB Partnership’s target for TB 
control, which includes achieving cure in 85% of infectious TB cases, has not been 
reached.  Default was higher in the co-infected patients than in a comparative group of 
HIV negative patients that we took, but the difference was not statistically significant. 
We also found that many of those who manage to finish treatment do so with many 
challenges and struggles. We found that sex, education and timing of ART initiation were 
associated with defaulting from treatment from the quantitative study, and the qualitative 
study further showed that misperceptions existed about TB and TB/HIV, and that adverse 
perception of prognosis with a desire to get cured, and support from family and health 
professionals were assisting patients with their treatment whereas pill burden, side effects, 
lack of food, stigma and economic burden of treatment were making treatment difficult. 
We also found that proper health education/communication was not given to patients by 
health professionals and that TB/HIV collaborative activities were weak. Much needs to 
be done to make medication intake better and easier for this group of patients. Although 
some of the factors that make medication intake difficult in these patients are related to 
socio-economic factors such as poverty, which are difficult to deal with, other factors are 
amenable to change. We have pointed out the importance, among other things, of 
thorough health Information, Education and Communication to increase awareness about 
TB/HIV and their treatments and combat stigma, as well as the need to strengthen 
collaborative TB/HIV activities. We have suggested the importance of community based 
DOT, as well as provision of food and small financial incentives, in collaboration with 
existing NGOs. It is also important that health professionals be aware of facilitators and 
barriers to treatment in these patients and act accordingly, such as discussing thoroughly 
the timing of ART initiation with patients who should make informed decisions, and 
proper adherence counseling is mandatory. The continuation phase is a critical phase for 
adherence and health professionals should be aware of it and provide continuous support 
for patients. 
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   Although we focused in this study on adherence to TB treatment, we actually addressed 
ART treatment indirectly in co-infected patients, and it seems like many patients give up 
both their anti-TB and ART treatments in many cases; hence the implications also extend 
to ART treatment. Many of the challenges such as for e.g. pill burden, side effects are 
also faced by patients who need to take other long term treatments in addition to their 
ART, and thus the findings to some extent apply to them as well.  
                     
 Implications for further research 
1. We recommend that further prospective studies with larger sample size should be 
conducted, with recording of all factors potentially affecting adherence at the beginning 
of the study as well as the recording of factors during treatment (such as side effects) that 
can influence adherence in co-infected patients and follow patients subsequently  
 
2. Similar studies should be conducted in other regions, in particular rural regions where 
ART is now being scaled up, to look at context specific factors influencing adherence in 
co-infected patients on concomitant treatment 
 
3. Studies assessing the impact of community based DOT in regions where it is being 
implemented are necessary to be able to derive evidence based lessons from these areas 
 
4. Studies looking in depth at gender differences in TB/HIV treatment are needed, which 
address factors such as gender differences in accessing health care and in following 
treatment as well as gender differentials with regard to stigma related with TB/HIV  
 
5. Despite several reports of it, HIV related stigma in Ethiopia remains unexplored and 
studies addressing this issue are highly needed  
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7. ANNEX  
ANNEX I: Form for record review 
Age:               years 
Sex:    0. male 
1. female 
Marital status:  0.single 
                         1 .married 
                         2. Divorced 
                         3. Widowed 
Education:        0.illiterate 
1. can write and read 
2. primary 
3. secondary 
4. higher education 
Occupation: 
Monthly income:        ETB 
WHO stage: III 
                     IV 
Site:              0.pulmonary 
1. extra pulmonary 
Bacilloscopy:  0.positive 
1. Negative 
 
CD4:  0. <50 
1. 50-200 
2. >200 
ART initiated: 0.before start of anti TB 
1. in intensive phase of anti TB  
2. in continuation phase of anti TB 
ART regimen: 0.stavudine/lamivudine/nevirapine 
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1. stavudine/lamivudine/efavirenz 
2. combivir/nevirapine 
3. combivir/efavirenz 
4. other 
PCP prophylaxis: 0. yes 
1. No 
Other concomitant illness: 0.yes 
1. No 
                        If yes, specify 
Side effect to anti TB: 0.yes 
1. No 
                        If yes, specify 
Side effect to ART: 0.yes 
1. No 
                 If yes, specify 
Treatment outcome: 0.cured 
1. Completed treatment 
2. died 
3. failed 
4. defaulted 
5. transferred out 
6. lost to follow  
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ANNEX II: Interview guide for patients 
1. How old are you? 
2. What is your job? 
3. Are you married? 
4. Do you have children? 
5. Can you estimate your monthly income for me? 
6. When were you diagnosed with TB and with HIV? 
7. Tell me about your illnesses (HIV/TB)? 
        How did the illnesses first start? 
        What did you then do or whom did you consult? 
        How did you feel when you were told about the illnesses? 
8. Tell me what you know about TB? 
9. Tell me what you know about HIV? 
10. Do you think there is a relationship between TB and HIV? 
11. If yes, what do you think is the relationship between them? 
12. Tell me about your experience taking the TB medications? 
13. What is/was difficult for you taking the medications? 
     Probe on: costs, side effects, pill burden, stigma, attitude of health personnel, effects 
of drug intake on daily routines, DOT, waiting times at the clinic…  
14. What made it easier/assisted you with taking the medications? 
    Probe: belief on efficacy of treatment, social support, health professional support… 
15. What impact has being HIV positive had on your TB treatment? 
    Probe: perception of prognosis, efficacy of treatment, stigma… 
16. How about the concomitant intake of ART? 
  Probe on: Pill burden, perception of side effects… 
17. What was your experience like as a patient in the TB and in the ART clinics? 
   Probe: attitude of health personnel, communication with health personnel, information 
received from health personnel, attitude towards DOT, collaboration between the 
clinics… 
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18. What do you think can be done for patients to facilitate medication intake in this 
situation?  
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ANNEX III: Interview guide for health professionals 
          
         1.  How old are you? 
         2. What is your occupation? 
   3. What is your education? 
   4. How long is your work experience? 
         5. Tell me about TB/HIV co-infection in your set up? 
   6. What are the common problems you encounter in patients with co-infection? 
   7.  From your experience, is non-adherence to tuberculosis treatment in patients 
with co-infection a common problem?  
   8. What are barriers to adherence in these patients, from your experience? 
         9. What factors facilitate adherence in these patients, from your experience? 
        10. How do you assist patients with their adherence to treatment? 
        11. How is the collaboration between TB and HIV clinics? 
        12. How do you see the interaction between patients and health professionals here? 
        13. Do you believe patients are receiving necessary information about their illness 
and their treatment? 
        14. What strategies do you believe would assist patients with their adherence to 
treatment? 
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ANNEX IV: Request for participation  
Introduction 
My name is Mekdes Kebede. I’m doing a master in international health in Norway and 
this research is part of my study. I’m conducting interviews to find out issues related to 
tuberculosis medication adherence.  
 
I would like to have a discussion with you about your experiences taking tuberculosis 
medications. We may need to meet again to clarify issues that might arise from our 
discussion. Your identity will be treated with confidentiality and the information that you 
provide will be used solely for the purpose of the study. 
 
Your name will not be written on the interview note or anywhere else and will never be 
used in connection with any of the information you tell me. You don’t have to discuss 
issues that you do not want to and you may end the interview any time. If you want to 
withdraw from the study any time along the study process you will not be obliged to 
continue or give reasons for doing so. 
   
Refusing to participate or withdrawing from the study along the process will not have any 
consequences on you. However, the information that you provide during the discussions 
will help understand issues related to tuberculosis medication adherence and might help 
for future interventions.  
 
The findings of the interviews might get published and contribute to understanding of 
barriers and facilitators of tuberculosis medication adherence in Ethiopia. 
 
I would greatly appreciate your help in responding to the interview.  If you have any 
questions or any thing that is not clear please feel free to ask me when we meet for the 
interviews. 
If you are clear with the information provided and agree to participate, please inform the 
health professional and we shall meet at the time of your convenience for the interview. 
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ANNEX V :Consent Form 
 
I the undersigned has been informed that the purpose of this research is to find out issues 
related to tuberculosis medication adherence in Ethiopia.  
 
I have been informed that I am going to have discussions with the researcher about issues 
related to tuberculosis medication adherence and that the discussion might be repeated, if 
there is a need to clarify issues that might arise from the discussion. 
 
I have also been informed that the information that I give will solely be used for this 
study and the findings may get published, but that my identity will be treated with 
confidentiality and my name will not be used in connection with the information that I 
gave. 
 
I have also been informed that I can refuse to discuss issues that I don’t want to discuss 
and can stop the interview any time I want, and that I will not be obliged to continue to 
participate in the study or give reasons for doing so. 
 
I have also been informed that I can stop participating any time along the study process 
and that refusing to participate or withdrawing from the study will not have any 
consequences on me. 
 
I agree to participate in this research. 
  
 
Signature   ------------------------------------ 
 
Date -------------------------------- 
 
 
 174
 
 
 
 
 
       
 
 
 
     
 
 
 
    
                                                                                                                                                                               
 
 
 
 
 
  
 
 175
  
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
